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Abstract
Varicella-zoster virus (VZV) is an alphaherpesvirus that causes childhood
chickenpox, becomes latent in dorsal root ganglia (DRG) after primary infection and
subsequently may reactivate to cause shingles (zoster). It is essential to understand
the molecular mechanisms governing VZV latency and reactivation because
approximately 20% of the human population will develop zoster and possibly
experience post-herpetic neuralgia (PHN), a debilitating pain syndrome associated
with zoster. Little is known about the pathogenesis of PHN mainly due to a previous
lack of a good animal model and the cell-associated nature of VZV in vitro. An in
vivo model of latent VZV in the adult rat was adapted. Foot reflex withdrawal
responses has been shown to persist for longer than 60 days post infection similar to
changes seen in PHN patients. The aim of this study was to further characterise this
model so that it could provide a useful and unique opportunity to study the host-virus
interaction involved in the pathogenesis ofPHN. Nested PCR was able to detect viral
DNA in the different lumbar DRG but the low level of latent gene expression gave
no direct correlation of the observed behavioural changes with the pattern of gene
expression in the infected DRG. Real-time PCR was developed, a quantitative assay,
to investigate the low abundance of the latent genes. Viral DNA could also be
detected in microdissected cells, which provide an alternative for investigating the
gene expression in each subneuronal population in the DRG. Time course study
showed that viral DNA was present in the infected DRG as early as 24 h post
infection and viremia was not detected from 1 to 3 days post infection. This
suggested that the spread of the virus is mainly through axonal pathway. Viral DNA
could not be detected in other tissues like spleen, spinal cord and brain suggested that
the latent virus was limited to the peripheral nervous system. RT-PCR was able to
detect viral transcripts in infected cells but not in the latently infected DRG due to
the low abundance of viral genome copy and limitation in detection of the assay.
Therefore, a global approach was taken to look at the transcriptional activity in the
latently infected neurones by carrying out a microarray experiment. The Rat
Expression Set 230A GeneChip was used in this study. Of the 15,866 known rat
genes represented on the RAE 230A, 5295 probe sets were not detected (33%). 9556
genes detected on both samples, of which 332 with altered expression and 57 of them
has an increase in expression. Of the 57 increased in expression, 32 met the cut-off of
50 and only 5 had a fold change of greater than 2. Due to the tissue heterogeneity,
only a small fraction of cells in the DRG harbours latent VZV. A small difference in
expression might give rise to a large difference on a whole ganglion basis. Of the ten
genes which were significantly regulated, prostaglandin D2 synthase was validated
by real time PCR and showed an upregulation of 2.7 fold corroborate with the results
from microarray. PGDt was reported recently to have neuroprotective role in the
nervous system. This study is in effect a pilot study giving a general overview of the
changes within the DRG and thus provide a source of further characterisation of this
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1.1 Herpesviruses
Herpesviruses are ubiquitous in nature. Well over a hundred herpesviruses have
been identified, infecting a range of vertebrates from humans to fish (Roizman et al.
1992) and at least one invertebrate, the Pacific oyster, Crassostrea gigas is host to a
herpesvirus (Minson et al. 2000). In nature, each is closely associated with a single host
species, and the most extensively studied hosts are infected by several distinct
herpesviruses. The host-specific occurrence of herpesviruses indicates that they have
evolved with their hosts over long periods of time and are exquisitely well adapted to
them.
Herpesviruses are among the largest and most complex of viruses (Davison 2002).
The virions are 200-250 nm in diameter, and consist of a linear double stranded DNA
genome of 125-245 kbp, containing from around 70 to 200 genes. The DNA genome is
packaged within an icosahedral capsid approximately 125 nm in diameter, embedded in
a matrix known as the tegument which contains many virus-encoded proteins, wrapped
in a lipid membrane containing several viral glycoproteins.
Most herpesviruses share four significant biologic properties (Roizman and Pellett
2001):
i) They encode enzymes for nucleic acid metabolism, DNA synthesis and
processing of proteins.
ii) Viral DNA synthesis and capsid assembly occurs in the nucleus.
iii) The production of infectious progeny is invariably accompanied by cell death.
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iv) All herpesviruses have a tendency to remain latent in their hosts.
1.1.1 Herpesviruses Classification
All herpesviruses are included in the family Herpesviridae based on their virion
architecture. The members of the family Herpesviridae are classified into three
subfamilies, the Alphaherpesvirinae, Betaherpesvirinae and Gammaherpesvirinae. The
subfamilies are further classified into genera based on DNA sequence homology and
similarities in genome sequence arrangement (see Table 1.1).
1.1.2 Alphaherpesviruses
Alphaherpesviruses as a group have a wide but variable host range with short
reproductive cycles that cause rapid cytopathic effect and cell lysis (Roizman 1996).
They have the ability to establish latent infections primarily but not exclusively in
sensory ganglia. This subfamily contains the genera Simplexvirus, Varicellovirus,
Marek's disease-like virus, and infectious laryngotracheitis-like virus.
1.1.3 Betaherpesviruses
Betaherpesviruses have a restricted host range, a long reproductive cycle and
infection progresses slowly in culture (Pass 2001). Infected cells frequently become
enlarged (cytomegalia) and carrier cultures are readily established. The virus can be
3
maintained in a latent state in secretory glands, lymphoreticular cells, kidneys and other
tissues. This subfamily contains the genera Cytomegalovirus, Muromegalovirus and
Roseolovirus.
1.1.4 Gammaherpesviruses
Gammaherpesviruses have a narrow host range. They are distinguished by their
ability to establish latency in lymphocytes and are associated with malignancies, such as
various B-cell lymphomas (Cesarman et al. 1995) and Kaposi's sarcoma (Chang et al.
1994). This subfamily contains the genera Lymphocryptovirus and Rhadinovirus.
1.1.5 Herpesvirus Sequence Arrangements
Based on their genome structure, herpesviruses can be divided into six groups
arbitrarily classified A to F (Figure 1.1). In group A genomes, e.g. Channel catfish
herpesvirus, sequence from one terminus is directly repeated at the other terminus. In
group B genomes, such as herpesvirus saimiri, the terminal sequence is directly repeated
many times at both termini. For those herpesviruses which infect humans (group C,
group D and group E) unique structures are demonstratable. In the group C genomes, as
exemplified by Epstein-Barr virus and Kaposi's sarcoma herpesvirus, a number of
reiterations divide the genome into several well-delineated domains. The group D
genomes, such as Marek's disease virus, have sequences from one terminus repeated in
an inverted orientation internally. Thus, the DNA extracted from these virions consists
4
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of two equal molar populations. For group E viral genomes, such as herpes simplex
virus and cytomegalovirus, the genomes are divided into internal unique sequences
whereby both termini are repeated in an inverted orientation. Thus, the genomes can
form four equimolar populations, which differ in relative orientation of the two unique
segments. Repeat sequences have not been identified in group F exemplified by tupaia
herpesvirus.
5
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Figure 1.1 A schematic diagram of the sequence arrangements of Herpesviridae. The
genomes A, B, C, D, E and F are exemplified by the channel catfish herpesvirus, herpesvirus
siamiri, Epstein-Barr virus, Marek's disease virus, herpes simplex viruses, and tupaia
herpesvirus, respectively. The horizontal lines represent unique or quasi-unique regions. The
reiterated domains are shown as rectangles and are designated as left and right terminal
repeats (LTR and RTR) for group A, repeats R1 to R4 for internal repeats of group C, and
internal and terminal repeats (IR and TR) of group D. The termini of group E consist of two
elements. One terminus contains n copies of sequence 'a' next to a larger sequence designated
as 'b'. The other terminus has one directly repeated 'a' sequence next to a sequence designated
'c'. The terminal repeat 'ab' and 'ca' sequences are inserted in an inverted orientation (denoted
by primes) separating the unique sequences into a long (Ui) and short (Us) domains. Terminal




Most herpesvirus genes contain a promoter or regulatory sequence spanning 50
to 200 bp upstream of a TATA box, a transcription initiation site 20 to 25 bp
downstream of the TATA box, a 5' non-translated leader sequence of 30 to 300 bp, a
single major open reading frame (ORF) with a translation initiation codon that meets the
host requirements for efficient initiation, 10 to 30 bp of 3' non-translated sequence and a
canonical polyadenylation signal with standard flanking sequences (Roizman and Pellett
2001). Exceptions do exist, e.g. HSV-1 y134.5 gene has no TATA box and the promoter
regulatory sequences of HSV late genes may be located 3' to the TATA box. Gene
overlaps are common and ORFs can be expressed that are situated entirely antisense to
the each other (e.g. HSV-1 y134.5). A common feature of herpesvirus genomes is
clusters of 3' co-terminal transcripts, each designed to express a different ORF. Most
genes are transcribed by RNA polymerase II but EBERS of EBV, a set of small non-
polyadenylated RNAs are synthesised by RNA polymerase III (Howe and Shu 1993).
Most herpesvirus genes are not spliced. Nonetheless, every herpesvirus encodes at least
some spliced genes to which splicing enable differential regulation of a gene at distinct
parts of the virus life cycle. Herpesviruses also encode non-coding RNAs (e.g. latency-
associated transcripts of HSV and the EBERs ofEBV).
1.1.7 Herpesvirus Replication
As a prototype member of the Herpesviridae, observations made with HSV-l
can be applied to other members in the family in general, though details for individual
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viruses can vary substantially. Like all herpesviruses. HSV displays both lytic and latent
modes of interaction with its natural human host. Primary infection of epithelial cells
produces the lytic response where virus replication occurs followed by cell death.
Progeny virus particles then infect adjacent sensory neurons, establishing a lifelong
latent infection, where by the virus genome persists in the cell as an episome, with no
production of new virions and a restricted portion of the genome is transcribed.
Herpesvirus replication based on the HSV infection cycle can be divided into 8
stages, as illustrated in Figure 1.2. HSV entry into susceptible cells involves binding of
the viral glycoproteins gC and or gB to heparan sulphate chains on the cell surface,
followed by fusion of the viral envelope with a cell membrane (Spear et al. 2000). The
fusion step requires four glycoproteins (gD, gB, gH and gL) and a cellular receptor that
binds gD. Deletion of the genes for any one of these four glycoproteins is lethal and
results in production of virions that can bind to cells, provided gC is present but cannot
penetrate (Mettenleiter 2000). Binding of gD to one of these receptors triggers envelope-
fusion and release of the viral nucleocapsid and tegument into the cell cytoplasm. At
least four different membrane-bound molecules can serve as gD receptors (Spear and
Longnecker 2003): HVEM (herpesvirus entry mediator), a member of the tumor
necrosis factor receptor superfamily, nectin-1 and nectin-2, which are immunoglobulin
(Ig) superfamily members and specifc sites in heparan sulphate generated by certain 3-
O-sulfotransferases. After fusion of the envelope to the plasma membrane, some
tegument proteins remain in the cytoplasm whereas others are either transported to the
nucleus or remain associated with the capsid. The capsid with associated tegument
structures is then transported through the microtubular network to the nuclear pore.
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Upon entry into the nucleus, the viral DNA immediately circularises. Viral DNA
is transcribed throughout productive infection by host RNA polymerase II, but with the
participation of viral factors at all stages of infection. Viral gene expression is co-
ordinately regulated and sequentially ordered in a cascade fashion and three broad
classes of genes have been identified. These are the immediate early (IE or a), early (E
or P) and late (L or y). The IE genes, which do not need prior viral protein synthesis for
their expression, are the first to be expressed in the nucleus following viral entry.
Transcription of IE genes is activated by VP 16, a major component of the HSV
tegument (Campbell et al. 1984). VP16 acts through the target sequence TAATGARAT,
which is present in at least one copy in all HSV IE promoters. TAATGARAT is a
binding site for the cellular factor Oct 1, a member of a protein family initially
characterised by the ability to bind the 'octamer' sequence ATGCAAAT (Sturm et al.
1988). Upon release from the tegument, VP 16 binds to a cellular protein called host cell
factor (HCF), which carries VP 16 into the nucleus. The VP16-HCF complex binds to
Oct 1/TAATGARAT, forming the activator complex to promote the expression of the IE
genes.
Six HSV IE genes (ICPO, ICP4, ICP22, ICP27, ICP47 and Us1.5) are expressed
first, and five of these (ICPO, ICP4, ICP22, ICP27 and Us1.5) encode regulatory proteins
that stimulate expression of the E and L genes (Roizman and Sears 1995). The E genes
are activated next, giving rise to proteins required for replication of the viral genome.
Viral DNA replication then ensues, augmenting IE-dependent expression of the L genes
that encode the structural components of the virion (Roizman and Sears 1995). The bulk
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of viral DNA is synthesised by a rolling circle mechanism, yielding concatemers which,
are cleaved into monomers and packaged into capsids. Replication of HSV-1 DNA
requires seven virus gene products, comprising an origin binding protein, a single-
stranded DNA binding protein, a DNA polymerase composed of two subunits and a
helicase primase complex composed of three gene products. Homologues of all but the
origin binding protein have been identified in all three herpesvirus subfamilies.
Assembly occurs in stages; after packaging of DNA into preassembled capsids,
the virus matures and acquires infectivity by budding through the inner lamella of the
nuclear membrane. However, the transit of virions from the space between the inner and
outer nuclear membranes to the subcellular space is less well defined (Roizman and
Pellett 2001). It has been suggested that the virus may become de-enveloped by fusion
with the nuclear membrane and may then be re-enveloped in the Golgi compartment.
The alternative theory is that the virion buds through the outer nuclear membrane, with
the envelope intact and then enters the Golgi already enveloped. Whilst in the Golgi, the
oligosacharrides of the virion glycoproteins are processed by Golgi enzymes. The
enveloped virions are transported through the Golgi to the cell surface in vesicles, where
they are released from the cell.
1.1.8 Herpesvirus Latency
Latent infections can be characterised by three general properties: i) expression
of productive cycle viral genes is absent or inefficient; ii) immune detection of the cell
harbouring the latent genome is reduced or eliminated and iii) the viral genome itself
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persists intact so that at some later time a productive acute infection can be initiated to
ensure spread of its progeny to a new host (Flint et al. 2004). The latent genome can be
maintained as a non-replicating chromosome in non-dividing cells such as neurones e.g.
herpes simplex virus (HSV) and varicella zoster virus (VZV) or become an autonomous,
self-replicating chromosome in a diving cell e.g. Epstein-Barr virus (EBV) or be
integrated into a host chromosome e.g. adeno-associated virus.
Such a 'long term parking' of a viral genome in the latent infection is remarkable
for its stability. A balance among the regulators of viral and cellular gene expression
must be maintained. Generally, only a restricted set of viral gene products is made
(Millhouse and Wigdahl 2000). Viral proteins required for productive replication may
not be produced at all, a pattern exemplified by HSV. In contrast, some herpesviruses's
viral genome was not entirely quiescent during latency, as is the case for EBV. At least
nine viral proteins important for modulating the host immune responses are expressed in
latently infected cells (Crawford 2004).
Latent genomes retain the capacity to replicate and cause disease upon
reactivation. If latency is to have any value as a survival strategy, there must exist a
mechanism for reactivation so that infectious virions can spread to other hosts. The
precise molecular mechanisms that lead to reactivation from the latent state are not fully
understood and may differ from one virus to another. Reactivation may occur following
a variety of local or systemic stimuli such as physical or emotional stress, fever,
exposure to ultraviolet light, tissue damage and immune suppression. Although all
herpesviruses remain latent in a specific set of cells, the exact cell in which they remain
latent varies from one virus to another (Roizman and Pellett 2001). For example,
12
whereas latent HSV has been detected only in neurons, latent EBV has been found
primarily in B lymphocytes.
13
Figure 1.2 General overview of herpesvirus replication, based on HSV. 1: The virus initiates
infection by the fusion of the viral envelope with the plasma membrane following attachment to
the cell surface. 2: Fusion of the membranes releases two proteins from the virion: capsid and
tegument proteins: VHS shuts off protein synthesis while VP16, which activates transcription of
viral genome is transported to the nucleus. 3: The capsid is transported to the nucleus and
immediately circularises. VP16 interacts with the host transcriptional components to stimulate
transcription of the immediate-early genes. 4: A cascade of viral immediate-early (IE or a), early
(E or p) and late (L or y) transcripts and proteins are synthesised. 5: Viral DNA replication follows
a rolling circle mechanism, which yields head-to-tail concatemers of unit-length viral DNA. 6:
Nucleocapsids are assembled and package newly synthesised DNA. Controversy exists
regarding the mode of nucleocapsid egress from the nucleus, the site of envelopment and the
pathway leading to release of particles from the infected cell. Two general pathways of viral
egress, 7: The envelope fuses with the outer nuclear membrane, de-enveloping the capsid and
releasing it into the cytoplasm. The capsid buds into the Golgi apparatus, forming an enveloped
virion, which is transported to the surface by vesicular transport. Alternatively, 8: The virion
particle buds through the outer nuclear membrane and is transported by vesicular movement
through the Golgi apparatus to the exterior of the cells (adapted from Cohen and Straus, 2001).
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1.2 Varicella zoster virus
Varicella zoster virus (VZV) is a herpesvirus, classified in the subfamily
alphaherpesvirinae. This subfamily also contains the human herpes simplex virus types 1
and 2 (HSV-1, HSV-2), which are members of the genus simplexvirus and the animal
herpesviruses, pseudorabiesvirus (PRV), equine herpesvirus types 1 and 4 (EHV-I,
EHV-4) and simian varicella virus (SVV), which have been grouped with VZV into the
genus varicellovirus (Davison 2002). VZV is often compared to closely related and
better-studied herpesviruses for insights into its molecular biology, particularly HSV-1.
VZV is a ubiquitous human herpesvirus and is the causative agent of two diseases,
varicella (chicken pox) following primary infection and herpes zoster (shingles)
following reactivation from a latent infection in sensory ganglia of affected dermatomes
(Weller 1996). Primary VZV infection is associated with a cell-associated viremia and a
diffuse cutaneous rash. A variety of stimuli can induce this latent virus to reactivate,
travel back down the axons and produce a new round of productive infection at the site
of initial infection.
Herpes zoster is a pressing medical problem possibly because it may be followed
by severe neuropathic pain, post herpetic neuralgia (PHN), which is resistant to therapy
(Gann and Whitley 2002). The seriousness of VZV as a public health hazard has been
ameliorated by the development of an effective vaccine (Arvin and Gershon 1996).
Nevertheless, VZV persists as a problem because of the existence of a large pool of
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potentially infectious VZV in adults that could serve as a long-lasting reservoir from
which the sporadic reactivation of VZV provides a persistent source ofwild-type VZV.
1.2.1 Morphology
The VZV particle, like all other herpesviruses, is comprised of four major
elements: the core, the nucleocapsid, the tegument and the envelope (Figure 1.3).
Existing data regarding VZV structure and morphology are consistent with the models
developed for FISV. Recent advances in electron-cryomicroscopy and three-dimensional
image reconstruction techniques have led to many studies that have greatly extended our
knowledge of herpesvirus architecture (Butcher et al. 1998), (Trus et al. 1999). These
studies reveal a high degree of conservation in overall herpesvirus capsid structure. All
herpesvirus capsids studied to date are organised in a T=16 icosahedral lattices
composed of 150 hexamers and 12 pentamers. Heterotrimeric structures known as
triplexes are located between these hexamer/pentamer structures at local 3-fold
symmetry axes. Whereas HSV nucleocapsids have electron-dense cores, VZV
nucleocapsids obtained from virus grown in cell culture often lack dense cores, perhaps
reflecting the low infectivity of VZV released from cultured cells. The tegument, which
has long been considered an amorphous mass of proteins, has been shown to have an
ordered structure and forms an asymmetric cap in mature HSV-1 virions (Grunewald et
al. 2003). The product of VZVORF10 was found in its tegument together with IE
proteins encoded by VZVORFs 4, 62 and 63 (Kinchington et al. 1992). The enveloped
particle has a pleomorphic to spherical shape with a diameter of 180-200 nm. Spikes
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interspersing the envelope are made up of glycoproteins, which are approximately 8 nm.
The VZV particle is fragile, its lipid envelope renders VZV susceptible to disinfection
by organic solvents and the particle is subject to degradation by physical and chemical







Figure 1.3 A schematic diagram of VZV. The VZV virion consists of a nucleocapsid
surrounding a core that contains the linear double-stranded DNA genome. A protein tegument
separates the capsid from the lipid envelope, which incorporates the major viral glycoproteins
presumed to mediate cell entry.
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1.2.2 Genome Organisation
The complete DNA sequence of the VZV Dumas strain was first reported in
1986 (Davison and Scott 1986). The VZV genome is a linear double-stranded DNA of
about 124 884 bp with an average G + C content of 46%. The VZV genome organisation
shows distinct similarities and sequence homology with HSV DNA but there is a
substantial variation in the extent of this homology, most notably in the almost complete
loss of the repeats around the long unique sequence in VZV. The VZV genome is
arranged into two unique sequences UL (ca. 100 kbp) and Us (ca. 5200 bp), surrounded
by small inverted repeats 1RL/TRL (88bp) and large inverted repeats 1RS/TRS (ca. 7300
bp), respectively as shown in Figure l .4.
The genomic organisation of the virion DNA contains two major and two minor
arrangements with different orientations of the Ul and Us segments. The Us segment
exists equally in its two orientations. In contrast, one orientation of the Ul segment
predominates in approximately 95% of molecules and the other in only 5%. The VZV
genome contains approximately 70 unique open reading frames (ORFs) and three genes
that are duplicated in the repeats (ORFs 62/71, 63/70, 64/69) (Ruyechan and Flay 2000).
The VZV genome also has five regions in which a series of nucleotides is repeated,
which are designated R1 (ORF 11), R2 (ORF 14), R3 (ORF 22), R4 (Us repeat regions,
2 copies) and R5 (within an intragenic region ofUl).
VZV is considered to be genetically stable around the world not until the
unexpected isolation of two VZV strains with a D150N missense mutation within the gE
glycoprotein in North America in 1998 (Santos et al. 1998) and 2002 (Tipples et al.
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2002). The mutant viruses reveal a reduction in affinity to the 3B3 monoclonal antibody,
which is commonly used in diagnostic immunostaining. It appears to spread rapidly in
tissue culture and in the SCID-hu mouse model. The complete DNA sequences of the
two mutant viruses revealed that the increased cell spread phenotype was dependent
substantially on the single D150N polymorphism in glycoprotein gE (Grose et al. 2004).
Recently, the DNA sequence of the varicella vaccine virus (vOka) and its
parental virus (pOka) were completed (Gomi et al. 2002). Comparison of the sequences
revealed 42 base substitutions, which led to 20 amino acid conversions and length
differences in tandem repeat regions (Rl, R3 and R4) and in an origin of DNA
replication. Amino acid substitutions existed in 12 ORFs (6, 9A. 10, 21, 31, 39, 50, 52,
55, 59, 62, 64) of which 15 base substitutions, leading to eight amino acid substitutions,
were in the gene 62 region alone.
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1.2.3 VZV Replication
VZV replication is highly cell-associated and very few viruses are released at
any phase of replication in cell culture (Grose and Ng 1992). VZV readily infects human
fetal diploid cells and melanoma cells and also replicates in Vero cells and primary
African green monkey kidney cells. Replication is associated with expression of viral
proteins within 4 to 10 h and formation of multinucleated giant cells and other
cytopathic changes within 2 to 7 days. EM studies show that most VZV virions are
enclosed in cytoplasmic vacuoles; defective particles are numerous and virions appear to
disintegrate in the cytoplasm before reaching extracellular spaces. Degradation appears
to occur as a result of virus entry into acidic prelysosomal vacuoles in the cytoplasm
(Gershon et al. 1994). VZV is highly temperature sensitive, with inactivation occurring
at 56°C to 60°C and it is not infectious if the virion envelope is disrupted.
1.2.3.1 Attachment, Entry and Uncoating
Precise analysis of VZV replication kinetics is hampered due to the highly cell-
associated nature of VZV when grown in vitro and only few infectious virions are
released. However, the kinetics of replication of VZV is presumed to follow the cascade
of alpha, beta and gamma gene activation that characterises HSV replication as shown in
Figure 1.2. Previous studies have revealed that oligosaccharides derived from
glycoproteins of the VZV envelope contain mannose 6-phosphate (Man-6-P) (Gabel et
al. 1989). At least four viral glycoproteins (gB, gE, gH and gl) contain N-linked
complex oligosaccharides with Man-6-P groups and thus are ligands for the large cation-
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independent Man-6-P receptor (MPRCl). Man-6-P and other phosphorylated
monosaccharides protect cells from the cytopathic effect (CPE) of VZV with an order of
potency that parallels their affinity for binding to the MPRCi. Treatment of cells with
chloroquine, which reduces the expression of MPRtl at cell surfaces, also protects
against infection by VZV. Electron microscopic immunocytochemical observations have
revealed that enveloped virions are associated with MPRCl at the cell surface and that
newly enveloped virions are incorporated into MPRC' containing vesicles in the trans-
Golgi network (TGN) (Gershon et al. 1994). These observations are compatible with the
hypothesis that an interaction of viral glycoproteins with a MPR0 is important in viral
entry. MPRCl also plays a role in the diversion of VZV to late endosome (Chen et al.
2004), where virions are inactivated prior to exocytosis. Biopsies from VZV-infected
human skin supported the idea that because MPRCl expression is naturally lost in
maturing superficial epidermal cells when epidermal cells mature to form squames,
these cells do not divert VZV to endosomes and constitutively secrete infectious VZV
(Chen et al. 2004).
Since VZV does not possess a gD homolog, the virus may not utilise any of the
known herpesvirus entry mediators. Following the interaction of gD with its receptor,
HSV gB, gH and gL are required for fusion of the viral envelope with the cell
membrane. VZV possesses homologues of all three of these glycoproteins, however,
their roles in fusion of the viral envelope and subsequent penetration of the nucleocapsid
into the cell are unproven. It is plausible that the uptake of VZV, like that of HSV,
involves more than a single step and more than one type of receptor. The adsorption of
VZV is mediated by heparan sulfate proteoglycan (Zhu et al. 1995) and that a receptor
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for which Man-6-P is a ligand plays a subsequent role in viral entry. Once penetration
has occurred, the nucleocapsid is transported to the nuclear surface, through which it
penetrates and releases its genomic contents. It is not known whether cellular
cytoskeletal elements facilitate centripetal movement to the nucleus or in what form the
viral core arrives there (Cohen and Straus 2001).
1.2.3.2 Viral Gene Expression
While it has been assumed that each VZV gene is temporally regulated in the
same transcriptional group as HSV-l homolog, this may not be the case, particularly for
IE gene expression. VZV contains homolog to four of the five HSV-l IE genes (VZV
ORFs 4. 61. 62. 63). However, the VZV genome is more homologous to PRV and EHV-
1 than to that of HSV-l and these animal herpesviruses only express a single IE gene,
the respective homolog of VZVORF62 (Kinchington et al. 2000). Activation of VZV IE
gene expression also appears to differ from the mechanisms used by HSV-l. PRV and
EHV-1. In the latter viruses, all IE genes contain an upstream TAATGARAT sequence
motifs, through which a virion transactivator protein (homologous to VZV ORF10)
activates transcription. Only VZVORF62 promoter contains such an element, the VZV
IE genes ORF4 and ORF63 do not (Moriuchi et al. 1994b). Maybe, the latter genes are
activated directly by other transactivators in the virion, such as VZVORF62 protein.
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1.2.3.3 The Immediate Early Phase
The initiation of the VZV replicative cycle leads to transcription of a genes by
cellular RNA polymerase II. The transcripts are transported to the cytoplasm where they
are translated and give rise to IE proteins. The latter migrate back to the nucleus where
they regulate further gene expression. Due to their homology with HSV a genes ICP
27, 0, 4 and 22, respectively, VZV proteins encoded by ORFs 4, 61, 62 and 63 are
considered as IE proteins, although this has only been demonstrated for ORFs 4
(Defechereux et al. 1997), 62 (Forghani et al. 1990) and 63 (Debrus et al. 1995).
ORF62
ORF 62 is a diploid gene, which encodes a 140 kDa protein of 13 10 amino acids
which, is expressed as a nuclear IE phosphoprotein (Forghani et al. 1990) and is also a
major component of the virus tegument (Kinchington et al. 1992). 1E62 is a functional
homologue of HSV-1 ICP4 as demonstrated by its ability to complement ICP4 mutants
(Disney and Everett 1990). HSV-1 ICP4 is essential for replication, it is required for
transcriptional activation of (3 and y genes and for repression of a genes (Dixon and
Schaffer 1980). IE62 could stimulate the transcription of all VZV genes studied to date
in transient transfection assays (Perera et al. 1992), (Moriuchi et al. 1994b). IE62 can
also repress its own transcription (Disney and Everett 1990), although in neural cells
IE62 can enhance transcription from its own promoter (Perera et al. 1992). IE62
probably does not act on its own, but in synergy with other IE proteins or even with
cellular proteins. Immunofluorescence analyses have shown that IE62 can mediate the
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nuclear localisation of IE4, another IE protein that also possesses regulatory functions
(Spengler, et al. 2000). Coprecipitation experiments suggest that 1E62 may also interact
with, and be phosphorylated by, the ORF47 protein kinase in vitro (Kinchington et al.
2001). IE62 also cooperates with the cellular transcription factor USF to activate the
promoters of ORF28, ORF29 (Meier and Straus 1995), and ORF4 (Michael et al. 1998).
Only ORF62 has an upstream TAATGARAT sequence homologous to the HSV-1
TAATGARAT elements known to be essential for stimulation by VP16 (McKee et al.
1990). The upstream region of VZVORF62 contains three TAATGARAT elements
important for transactivation of the ORF62 promoter by the VZVORF10 protein in the
tegument (Moriuchi et al. 1995). The ORF10 protein forms a complex with two of the
TAATGARAT elements in the ORF62 promoter that lack an overlapping octamer-
binding motif. Two cellular proteins, Oct 1 and host cell factor (HCF) form a complex
with the ORF10 protein and at least one of the TAATGARAT elements on the ORF62
promoter.
ORF4
VZV ORF4 encodes a 51 kDa phosphoprotein present largely in the viral
tegument (Kinchington et al. 1995). Its localisation is mostly cytoplasmic and produced
very early on in infected cells, however, when coexpressed with ORF62. ORF4 protein
is primarily located in the nucleus (Defechereux et al. 1996). Although it has a high
homology with HSV-1 ICP27, in the carboxy-terminal region, IE4 appears to be
functionally distinct from its F1SV-1 homolog (Perera et al. 1994). VZV ORF4 deletion
mutant could not be complemented in cells expressing HSV-1 1CP 27 (Cohen et al.
26
2005). In transient expression assays, IE4 transactivates VZV promoters, either on its
own or in synergy with IE62 (Defechereux et al. 1993) but has no demonstrable
transrepressing activity (Perera et al. 1994). For example, ORF4 does not transactivate
expression of the ORF63 IE or ORF28 putative early gene promoter. In transient
expression assays, VZV ORF4 synergises with VZVORF62 to transactivate expression
of putative IE, E and L promoters. It has been shown to be effective both at
transcriptional and posttranscriptional levels. Transcriptional activation requires
dimerisation of the ORF4 protein. It acts as a transactivator when brought close to DNA
but transactivation probably requires the simultaneous presence of other functional
proteins interacting with the transcription complex, such as the TATA-binding protein,
the transcriptional factor 11B or the nuclear factor kB (Spengler et al. 2000).
ORF63
ORF63 is a diploid gene, encodes an IE protein of 45 kDa (Sadzot-Delvaux and
Rentier 2001) and is present in the virion tegument. This protein is encoded by VZV
ORFs 63 and 70 and is the putative homologue of HSV ICP22. IE63 is strongly
expressed during lytic infection in cell culture as well as in skin lesions (Debrus et al.
1995). IE63 is abundantly produced at the first stage of infection and is essential for
VZV replication (Sommer et al. 2001). Its activity as a potential transcription factor is
subject to controversy. It has been shown that ORF63 protein upregulates the VZV
thymidine kinase promoter and downregulates the IE62 promoter in transient
transfection assays (Jackers et al. 1992). Nevertheless, IE63 has recently been shown in
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transient transfection assay to downregulate the expression of the VZV UNA
polymerase gene (Bontems et al. 2002). More recently, the same laboratory has also
reported that IE63 is a transcriptional repressor of some VZV and cellular promoters and
its activity is directed towards the assembly of transcription pre-initiation complex (Di
Valentin et al. 2005). An interesting feature of the VZV 1E63 protein is its cellular
localization during the different phases of VZV infection. Indeed, at the first stage of
infection. IE63 is predominantly present in the nucleus (Debrus et al. 1995), along with
products of other latency associated genes, namely 1E4, ORF21, ORF29 and IE62 while
during latency, the protein exhibits an exclusive cytoplasmic localization (Lungu et al.
1998, Grinfeld and Kennedy 2004). These genes can be found both in the cytoplasm and
the nucleus when reactivation occurs. The presence of 1E63 protein and its cellular
localization modification might reflect an important role in the latency process. ORF63
protein has been detected in animal (Debrus et al. 1995), (Sadzot-Delvaux et al. 1995),
(Fleetwood-Walker et al. 1999) and human ganglia (Mahalingam et al. 1996),
suggesting a role in latency. Kennedy et al., (2001) has reported that expression of VZV
gene 63 appears to be the single most consistent feature ofVZV latency.
ORF61
ORF61 encodes a 62-65 kDa phosphoprotein that localises to the nucleus of
infected cells. Unlike the other VZV IE genes, ORF61 is not present in the viral
tegument (Kinchington et al. 1995). VZV ORF61 is homologous to HSV ICP0 and can
functionally complement an HSV-1 ICP0 deletion mutant. VZVORF61 protein
transactivates putative VZV IE, E and L promoters in transient expression assays
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(Moriuchi et al. 1993a). Depending on its cellular concentration and on host cell lines,
IE61 can either repress or transactivate the functions of 1E4 and 1E62 on VZV gene
promoters (Moriuchi et al. 1993a). The amino terminus of ORF61 contains a RING
finger domain that binds zinc and is required for the transactivating activity of the full
length protein (Moriuchi et al. 1994a). Deletion mutants of VZVORF61 can replicate,
but they are impaired for syncytia formation and growth in cell culture (Cohen and
Nguyen 1998). Cells infected with these mutants show reduce expression of gE but
normal levels of ORF62 protein. HSV-1 1CP0, the homolog of ORF61 shows different
patterns of activities in transient expression assays. Whereas ICPO activates the HSV-1
TK promoter in transient expression assays, ICPO does not activate the VZVORF36
promoter (Inchauspe and Ostrove 1989). Unlike ORF61, ICPO does not show repressing
activity in transient expression assays.
1.2.3.4 The Early Phase
Once the IE proteins have been synthesised and transported to the nucleus, they
allow the expression of p genes that are only expressed at very low levels in their
absence. VZV has a homologue for each of the seven core proteins involved in origin-
dependent DNA replication of HSV (Wu et al. 1988). These are encoded by VZV
ORF28 (DNA polymerase), ORF29 (single-stranded DNA binding protein). ORF16
(polymerase accessory protein), ORF51 (origin-binding protein) and ORFs 6, 52 and 55
(helicase/primase complex). The VZV origins of replication are located within the short
repeat regions of the genome, between ORF62 and ORF63 (and ORFs70 and 71).
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1.2.3.5 The Late Phase
After VZV genome replication, L proteins are assembled into nucleocapsids and
the viral genome is wrapped inside. VZV ORFIO encodes a 410 amino acid protein
incorporated into the virion tegument. This protein is the homolog of a-TIF, the HSV-l
virion-associated transactivator (VP 16) directly involved in the induction of IE gene
expression. VZV ORFIO transactivates the VZV ORF62 but not the putative IE ORF61
and ORF4 promoters (Moriuchi et al. 1993b). Surprisingly, ORFIO is dispensable for
VZV replication in cell culture (Cohen and Seidel 1994), while its HSV counterpart
VP 16 is essential for HSV replication and assembly of virus. However, cell lines
expressing ORFIO protein complement an HSV-l VP 16 mutant that lacks
transactivating activity.
The VZV major nucleocapsid component is a 155 kDa protein encoded by ORF
40, homologous to the HSV-l UL19. It is detected in the nucleus of infected cells where
the capsids are assembled. VZV nucleocapsids also contain a complex made of a 32 kDa
phosphoprotein and a 36 kDa nonphosphorylated protein possibly encoded by ORFs 33
and 33.5. The VZV genome encodes at least eight glycoproteins named gE, gB, gH, gl,
gC, gL, gK and gM encoded by ORFs68, 31, 37, 67, 14, 60, 5 and 50, respectively. Viral
glycoproteins are involved in interactions with target cells and play a crucial role in
eliciting the host's immune response.
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1.2.3.6 Assembly and Egress
At the end of the replicative cycle, expression of the three classes of viral genes
has occurred and assembly of large amount of nucleocapsid is observed in VZV-infected
nuclei. Two similar models of VZV replication have been suggested. One model
stipulates that nucleocapsids are enveloped as they exit and traverse the nuclear
membrane and then become incorporated into large cytoplasmic vesicles (Harson and
Grose 1995). The nucleocapsid passes through the inner nuclear membrane and acquires
its initial envelope. The enveloped particle travels through the perinuclear space where it
is engulfed within a vacuole. A vacuole containing one or more viral particles is pinched
off and resides within the cytoplasm. Viral glycoproteins are released from the trans-
Golgi network (TGN) in microvesicles and fuse with the cytoplasmic vesicles containing
viral particles. Virion laden vesicles fuse with one another to form a larger vacuole.
These vesicles migrate to the cell surface where fully enveloped virions with functional
glycoproteins are released by exocytosis.
Gershon, et al., (1994) proposed a slightly different scenario for VZV maturation
and release. In their views, nucleocapsids first acquire and then lose their envelopes as
they traverse the nuclear membrane. Nucleocapsids assemble in the nuclei of infected
cells, acquire an envelope from the inner nuclear membrane as they bud into the
perinuclear cisterna and fuse with the RER (rough endoplasmic reticulum) to release
nucleocapsids into the cytosol. Viral glycoproteins are synthesised in the RER
independently of the nucleocapsids and are targeted to the TGN (Zhu et al. 1995).
Within the TGN, vacuoles form 'envelopment' sacs with concave and convex faces.
Viral and cellular glycoproteins are separated in the envelopment sacs of the TGN so
that viral glycoproteins sort to the concave face, while cellular proteins, including the
mannose 6-phosphate receptor (MPRC1), sort to the convex face. The concave face
becomes coated with tegument, envelopment sacs encircle nucleocapsids and ultimately
fuse to enclose them with trapped tegument (Wang et al. 2001). The original concave
face becomes the viral envelope, while the convex face becomes a transport vesicle. The
vesicles that contain newly enveloped VZV transfer virions to late endosomes where
VZV is degraded and released to the external medium by exocytosis.
1.2.4 VZV Latency
The study of VZV latency is fraught with obstacles. Little information exists on
the molecular mechanisms leading to latency and to reactivation of VZV. Based on the
Fenner mousepox model, VZV is thought to access sensory nerve tissues and establish
latency via two mechanisms: i) direct hematogenous spread to sensory ganglia; ii)
retrograde axonal transport from infected epidermal and dermal tissues. The concept of
viremia is supported by the finding that PBMC are productively infected during varicella
and the number of cells latently infected in the ganglion (Ozaki et al.. 1994). In support
of this hypothesis also, simian varicella virus (SVV) DNA can be detected in ganglia of
experimentally infected monkeys on day 6 before the onset of rash and also in ganglia of
monkeys that never develop rash (Kennedy et al. 1998).
On the other hand, retrograde transport along neuronal pathways was supported
by evidence that the sites of zoster manifestations resembles the distribution of varicella
lesions (Hope-Simpson. 1965). Also, longitudinal clinical trials revealed that episodes of
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vaccine-associated zoster often occur at or near the prior site of inoculation, suggesting
latency had been established preferentially within the sensory ganglion serving that
single dermatome. If VZV spread to ganglia solely by a hematogenous route, then other
body sites should have been well represented among the post vaccination zoster cases
(Gershon et al., 1996). Further support of the latter mechanism is shown by the recent
guinea pig enteric ganglia model (Chen et al. 2003). Latent VZV infection of isolated
enteric neurons was established when culture mainly consist of neurons and exposed to
cell free virus.
The mechanism by which HSV establishes and maintains latency is different
from that of VZV. The differences are readily evident when considering the clinical
patterns of infection with each of these viruses. Three features of zoster suggest an
unusual mechanism of VZV latency and reactivation. First, the restricted geography of
zoster, which is scattered in grape-like clusters but limited to a single dermatome,
suggests that the peripheral lesions originate from multiple nerve endings rather than
from one or a few focal sites of peripheral infection. This implicates an extensive
neurone to neurone spread of VZV at the site of latency upon reactivation (Croen and
Straus 1991), (Meier et al. 1993). For comparison, reactivated HSV-1 lesions tend to be
small and focal, suggesting that few neurones become involved and reactivation of latent
HSV-1 in the latent neurone is all that is required for peripheral access.
A second unusual feature is zoster-associated pain that often complicates clinical
zoster. PHN is the most common complication manifestation of zoster and may last for
weeks, months or even years following resolution of clinical disease (Gilden et al.
1992), (Rowbotham and Fields 1996). The mechanism of PHN is unknown but it is
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likely a result of necrosis and inflammatory responses to demyelination and cell damage
during ganglionic replication. For comparison, such a long-term pain is not usually
experienced with reactivated HSV-1 and pain associated with lesions normally resolves
3-4 days after their appearance.
Finally, the frequency of zoster is unusual in that some 80% of VZV seropositive
individuals never show clinical evidence of reactivation. This suggests that either entry
into latency or reactivation from it are highly inefficient processes or, alternatively, that
reactivations of VZV are more frequent but are well controlled by the immune
surveillance mechanisms prior to the development of peripheral disease. With HSV-1
infection, reactivation can occur multiple times in the presence of active and fully
functional immunity and asymptomatic reactivation often occurs. Moreover, while HSV-
1 incidence decreases with age, zoster incidence increases dramatically, suggesting
triggers for reactivation are quite different for these two viruses.
No viral proteins have been detected in HSV latently infected cells and the only
transcripts detected are the latency-associated transcripts (LATs) (Wagner and Bloom
1997). There is no evidence that these RNAs representing stable introns are translated
into protein and their precise role in the life cycle of HSV remains controversial. LATs
are present as several non-polyadenylated collinear RNAs, including a major 2-kb LAT
and a 1,5-kb splice variant (Farrell et al. 1994). The 2-kb LAT is believed to be a stable
intron spliced from a low-abundance 8.3-kb primary transcript. It has been suggested
that the LAT plays a crucial role in viral reactivation. LAT mutant viruses show reduced
ability to reactivate in the mouse model (Sawtell and Thompson 1992) and have
decreased spontaneous and induced reactivation frequencies in the rabbit model (Perng
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et al. 1994). The LAT also has an important role in promoting the establishment and
maintenance of the latency (Maggioncalda et al. 1996), (Sawtell 1997) even though
earlier studies found no evidence to support this idea (Sederati et al. 1989). It has been
observed that LAT mutant viruses express viral productive cycle genes in greater
numbers in mouse neurons (Garber et al. 1997) and establish latent infection in fewer
neuronal cells than parental viruses (Sawtell 1997). It has been proposed that the LAT
may repress viral replication in neuronal cells by reducing IE gene mRNA levels and
facilitate the establishment of HSV-1 latency in neuronal cells (Mador et al. 1998). In
addition, the LAT may promote neuronal survival through an anti-apoptotic mechanism
(Ahmed et al. 2002), (Branco and Fraser 2005).
Far less is known about the nature and mechanisms regulating VZV latency but
what is known suggests a process that is very different from HSV latency. Current major
issues involving VZV latency have been the cell-type localisation of latent VZV, the
frequency with which VZV establishes latency and the nature and extent of VZV gene
expression during latency (Kennedy 2002), (Cohrs et al. 2004). Each will be discussed
individually in the following sections.
1.2.4.1 Cell Type Localisation of Latent VZV
Identification of the cell type harbouring latent VZV is important since the
pathogenesis of initial infection and reactivation may depend on the number and type of
cells initially infected (Steiner 1996), (Kennedy and Steiner 1994). Initially, in situ
hybridisation (ISH) revealed that VZV was latent exclusively in neurons (Flyman et al.
1983), (Gilden et al. 1987). These findings were later disputed by the apparent detection
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of VZV in non-neuronal satellite cells (Croen et al. 1988), (Meier et al. 1993) and by a
single report that found VZV in many neurons and non-neuronal cells (Lungu et al.
1995). However, ISH results of autopsy samples containing low amounts of latent virus
DNA are unpredictable and prone to misinterpretation (Mahalingam et al. 1999).
Improvements in ISH that incorporated polymerase chain reaction (PCR) and amplified
low copy number latent virus DNA revealed VZV DNA predominantly, if not
exclusively, in neurons (Dueland et al. 1995), (Kennedy et al. 1998), (Kennedy et al.
1999), (Kennedy 2000), (Kennedy et al. 2001). A similar finding was also reported by
Levin et al., (2003) and they found that latent VZV DNA is present primarily in large
neurones.
1.2.4.2 The Burden of Latent VZV DNA
Analysis of an animal model of HSV-1 latency suggests that latent genome copy
number may be an important parameter for subsequent induced reactivation in vivo
(Sawtell et al. 1998). Latent VZV DNA is present in low copy number as routine
Southern and northern blot hybridisation analyses did not succeed in detecting them in
extracts of human ganglia (Meier et al. 1993). Semi-quantitative PCR showed that 103-
103 copies of latent VZV DNA were present in 103 ganglionic cells (Clarke et al. 1995)
which is similar to the amount of latent HSV-1 found in human ganglia by Southern
analysis (Efstathiou et al. 1986). However, Mahalingam et al., (1993) only detected 6-31
copies of VZV genome per 103 cells. LaGuardia et al., (1999), reported 5.5 copies of
VZV DNA per 103 ganglionic cells, assuming 100 non-neuronal cells per neuron. Real¬
time quantitative PCR analysis detected 258 ± 38 copies of VZV DNA per 103
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ganglionic cells (Pevenstein et al. 2000). Recently, quantitative competitive PCR
detected an average of 4.7 copies ofVZV DNA per latently infected neuron (Levin et al.
2003). The large variation in the virus load in these studies might reflect the differences
in the natural history of the infection in the individuals from whom the samples were
obtained or discrepancies in the techniques used to estimate copy numbers.
1.2.4.3 Latent VZV Gene Expression
There have been several published studies of latent VZV gene expression using a
variety of different techniques on pooled and individual human ganglia, including
northern blot analysis, in situ hybridisation (1SH) and cDNA library construction
(Kennedy 2002). Most studies have reported the presence of RNA for VZV genes 21,
29, 62 and 63 (Cohrs et al. 1994), (Cohrs et al. 1995), (Cohrs et al. 1996), (Kennedy
2002) with conflicting results for the presence of RNA for gene 4, which has been
reported by some workers (Croen et al. 1988), (Kennedy 2000) but not others (Meier et
al. 1993). However, a more recent work has shown that ORF4 is indeed important for
establishment of latency, besides ORF63 (Cohen et al. 2005). Analysis of latently
infected human trigeminal ganglia by reverse transcriptase-dependent nested PCR, in
situ hybridisation, and immunohistochemistry, revealed that VZVORF66 to be a
previously unrecognised latently expressed virus gene (Cohrs et al. 2003a). IE 62 is a
major transcriptional activator, which can drive transcription from all kinetic classes of
virus genes and enhances the infectivity of transfected VZV DNA (Moriuchi et al.
1994b). To maintain latency, the effect of 1E62 on subsequent virus gene expression
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must be controlled. Cohrs et al.. 2004 suggested three models of the control of IE62
function as illustrated in Figure 1.5.
The first model of modulating IE62 activity is based on cellular location (Figure
1.5A). 1E62 localises to the nucleus early in virus infection and later accumulates in the
cytoplasm (Kinchington and Turse 1998). Interestingly, this protein has been shown to
localise predominantly in the cytoplasm during latency (Lungu et al. 1998). Later, it was
found that the protein kinase encoded by VZVORF66 (VZV66pk) phosphorylates IE62,
resulting in cytoplasmic accummulation of 1E62 (Kinchington et al. 2000), (Kinchington
et al. 2001). While the phosphorylation of 1E62 late in VZV lytic infection appears to be
a mechanism by which IE62 is incorporated into progeny virions, the cytoplasmic
location of IE62 during latency that results perhaps from VZV66pk phosphorylation
mitigates IE62 dependent gene transactivation (Cohrs et al. 2003a). Thus, this
mechanism allows IE62 remains within a cell without stimulating gene transcription.
A second mechanism of regulating IE62 activity is through the control at the
promoter level (Figure 1.5B). Consistent with this hypothesis is the finding that the
protein encoded by VZV gene 29 binds to a 40 bp region on the glycoprotein I promoter
(He et al. 2001). This protein was found to increase IE62 induced gl expression in
permissive cells and reduce IE62 transactivation in non-permissive cells (Ito et al. 2003).
VZV gene 29 and 21 proteins were tested to find out if they have the same function as
their HSV-1 homologues which can form a DNA binding complex in the nucleus of
virus infected cells (Shelton et al. 1994) and modulate 1E62 functions (McNamee et al.
2000). However, it was reported that VZV gene 29 and 21 proteins had no significant
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effect on IE62-induced activation of gene 20. 21. 28 or 29 promoters in tissue culture
system (Cohrs et al. 2002).
A third mechanism ofmodulating IE62 activity is through transcriptional control
(Figure 1.5C). The HSV-1 homologue of the VZV gene 63 protein (ICP22) has been
shown to alter phosphorylation of cellular RNA polymerase II, thereby reprogramming
the cellular transcription apparatus to more readily transcribe viral genes. By analogy,
VZV gene 63 protein might modify gene expression by interacting with transcription
factors but conclusive evidence is lacking. However, VZV gene 63 protein can complex
with IE62 and phosphorylated forms of VZV gene 63 protein reduce lE62-induced
promoter activation. Since the effect of ICP22 on RNA polymerase II is dependent on its
phosphorylation, the possibility exists that phosphorylated forms of VZV gene 63





Figure 1.5 Regulation of IE62 function. Model A: regulation by location. Cytoplasmic VZV IE62
is translocated into the nucleus where gene activation in trans is initiated. Phosphorylation of
IE62 by VZVORF66pk halts IE62 nuclear import, IE62 is restricted to the cytoplasm and gene
activation does not occur. Model B: regulation at the promoter. Nuclear IE62 is associated with
at least 3 virus proteins encoded by open reading frames 4, 9 and 63. The complex binds to VZV
gene promoters either through cellular transcription factors, in this case the previously identified
upstream stimulating factor (USF), or directly to the promoter itself. The IE62 complex further
associates with cellular RNA pol II and its associated transcription factors. However, RNA
transcription is blocked by downstream binding of VZV gene 29 protein. Model C: regulation by
transcription factor modification. As in Model B, nuclear IE62 and the associated VZV and
cellular proteins bind to gene promoters. However, transcription is blocked by modification of the
cellular RNA pol II complex. In this model either free or bound VZV gene 63 protein alters the
phosphorylation pattern of the C-terminal domain of cellular RNA pol II, resulting in
transcriptional control (adapted from Cohrs et al. 2004).
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1.2.5 Reactivation
VZV reactivation is associated with activation of transcription of all kinetic
classes of viral genes (Lungu et al. 1995). It is still not clear how alphaherpesviruses
move, assemble, and spread in the nervous system. Recent work by Tomishima and
Enquist (2002) suggested that viral egress can occur sporadically along the length of
infected axons and is not confined solely to axon terminals. They also reported that
extracellular particles are not involved in nonneuronal cell infections. Lungu et al.
(1998) have reported that five VZV encoded proteins (ORFs 4, 21, 29, 62, 63) exhibit
cytoplasmic localisation during latent infection and a nuclear and cytoplasmic
localisation during reactivation.
The guinea pig enteric ganglia model has demonstrated that presence of non¬
neuronal cells is a critical determinant of whether VZV would establish a latent or lytic
infection of cultured enteric neurons (Chen et al. 2003). The nature of the influence of
non-neuronal cells is not understood. It is hypothesised that they amplify VZV and that
the determination of whether infection will be latent or lytic depends on the number of
VZV to which the neurons are exposed. This might happen when VZV infected cells
fuse with neurons and introduce VZV gene products that are not present in the virion.
Only certain VZV proteins that are produced by infected cells are incorporated into viral
particles. However, all viral proteins in the cytosol of infected cells will enter a target
cell by diffusing through the fusion pore, whether or not these proteins are incorporated
into virions. Such proteins might play a role in lytic infection. If this were to be the case,
then latent infection would be established in neurons when they become infected by free
41
extracellular particles, but lytic infection would result when neurons become infected by
fusion with VZV infected cells.
1.2.6 Immune Evasion Mechanism of VZV
Both cell-mediated and humoral immunity are elicited during the course of
primary VZV infection. The early host responses to VZV are non-specific and involve
natural killer (NK) cells and interferons (IFN) that function to restrict virus replication
and spread (Arvin, 1996). VZV specific T cell recognition is critical for host recovery
from varicella and both major histocompatibility complex (MHC) class 1 restricted CD8*
T cells and MHC class II restricted CDC T cells are sensitised during primary VZV
infection (Sharp et al. 1992).
MHC I molecules are heterodimers consisting of a membrane bound heavy chain
(aC) and a light chain p? microglobulin (Pirn) which present peptides derived from
cytosolic proteins to CD8+ T lymphocytes. Antigenic peptides generated by cytosolic
proteases are transported into the endoplasmic reticulum (ER) by the ATP-dependent
transporter associated with antigen processing (TAP), where they associate with MHC I
heterodimers. The resulting trimolecular complex is transported from the ER through the
Golgi compartment to the cell surface where it presents the peptide to cytotoxic T
lymphocytes (Lehner and Trowsdale 1998). Each step in the MHC I biosynthesis and
assembly pathway has been shown to be a potential target for viral interference and the
subsequent modulation ofMHC I expression on cell surfaces.
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VZV was found to down-regulate cell-surface MHC 1 expression on infected
human fibroblasts and T lymphocytes (Abendroth et al. 2000) by impairing the transport
of MHC I molecules from the Golgi compartment to the cell surface. This effect may
enable the virus to evade CD8~ T-cell immune recognition during VZV pathogenesis,
including the critical phase of T-lymphocyte-associated viremia. Inhibition of late viral
gene expression by treatment of infected fibroblasts with phosphonoacetic acid (PAA)
did not influence the modulation ofMHC I expression, nor did transfection of cells with
plasmids expressing immediate early viral proteins. However, cells transfected with a
plasmid carrying the early gene VZVORF66 did result in a significant down-regulation
of MHC I expression, suggesting that this gene encodes a protein with an
immunomodulatory function.
CD4^ T cells that recognise VZV are almost exclusively of the Thl type, and
IFN-y is a major cytokine product of these memory T cells. The ability of VZV to inhibit
MHC class II expression in most infected cells, despite exposure to high concentrations
of IFN-y, provides a mechanism by which the virus can limit the antiviral activity of
CD4+ T cells. MHC class II are polymorphic heterodimers with a and p chains which
present exogenous peptides to CD4"1" T lymphocytes. The a and p chains form a
heterodimer in the ER. This complex associates with the invariant chain (Ii) and is
transported through the Golgi and trans-Golgi reticulum to endosomes in the cytoplasm.
The li chain is degraded in these endosomes, allowing antigenic peptides, which are
produced by proteolysis of endocytosed proteins, to bind to the a/b heterodimer. The
peptide-MHC II complex then presented on the cell surface (Pieters. 1997). In contrast
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to MHC class I, MHC class II proteins are expressed constitutively only on B cells,
monocytes, dendritic cells and thymic epithelium. IFN-y has an important function in
CD4T T cell recognition of infected cells because it is a potent inducer of MHC class 11
expression on many cell types.
The ability of VZV to inhibit MHC class II expression in most infected human
fibroblasts, despite exposure to high concentrations of IFN-y, provides a mechanism by
which the virus can limit the consequences of immune surveillance by CD4+ cells
(Abendroth et al. 2000). VZV inhibits MHC class II expression by interfering with the
Jak/Stat signal transduction pathway by reducing steady-state Jak2 and Statla but not
Jakl protein expression in IFN-y treated cells as shown in Figure 1.6. Statla is a
component of the Jak/Stat signal transduction pathway, which includes Jakl and Jak2.
CIITA and IRF1 expression is induced after IFN-y treatment by Statla. The failure to
detect CIITA and IRF-1 RNA in VZV infected IFN-y treated cells suggested that these
cells may have a disruption of the Jak/Stat pathway.
A third immune evasion mechanism for VZV was reported whereby the virus is
able to productively infect mature dendritic cells (DCs) (Gavin et al. 2003). Dendritic
cells (DCs) are potent antigen-presenting cells critical for the initiation of a successful
antiviral immune response through the stimulation of immunologically naive T
lymphocytes (Banchereau and Steinman 1998). DCs located in the periphery exist as
immature cells, expressing low levels of MHC class I and MHC class II molecules and
costimulatory molecules such as CD80 and CD86. Immature DCs readily take up
antigen and are induced to migrate to the secondary lymphoid organs, where they
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undergo maturation and present processed antigens to antigen-specific T lymphocytes.
VZV interference with mature DC function resulted in a selective downregulation of cell
surface expression ofMHC class I, CD80, CD83, and CD86 but did not alter MHC class
II expression (Gavin et al. 2003). More importantly, VZV infection of mature DCs




Figure 1.6 Interference by VZV with IFN-y induced up-regulation of MHC class II
expression via Jak/Stat signal transduction pathway. CIITA and IRF-1 expression is induced
after IFN-y treatment by Statla, which includes Jak1 and Jak2. The various proteins that are
affected in VZV-infected cells are crossed out (adapted from Abendroth et al. 2000).
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1.3 Clinical Manifestations of Varicella
A primary infection with VZV causes varicella, or chickenpox, a highly
contagious disease of childhood (Arvin 1996). Virus is spread by the airborne route from
the skin lesions and oropharynx of infected individuals to susceptible contacts. The first
symptoms of varicella are often a prodrome consisting of fever, malaise, headache and
abdominal pain typically begin about 24-48 h before rash (Arvin 1999). Each lesion
evolves within a few hours from an erythematous macule to the formation of a vesicle
surrounded by erythema, the classic 'dew drop on a rose petal'. The vesicle fluid
becomes cloudy and may develop an umbilicated appearance as the lesion begins to
crust. As the initial lesions progress through these stages, crops of new lesions continue
to form, usually in a 'centrifugal' pattern, i.e., from the face and trunk to the extremities.
Hypopigmentation of the underlying skin may be seen as the crusts resolve, but
extensive scarring is unusual unless secondary bacterial infection occurs. Skin lesions
appear on the trunk, face, scalp and extremities, with the greatest concentration on the
trunk. A hallmark of varicella is the presence of lesions in all stages of development at
the same time (LaRussa 2000). Healthy children develop an average of approximately
300 lesions. The average duration of lesion formation is three to five days in the normal
child, however, it is usually longer in adolescents and adults and certainly in the
immunocompromised. Fever often accompanies the rash. Body temperature usually
parallels the severity of rash and may range from normal to greater than 105°F. As the
appearance of new lesions slows, fever begins to decline. Other common symptoms
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include pruritus that may be severe when skin lesions are extensive, headache, malaise
and anorexia (Arvin 1999).
1.3.1 Pathogenesis
Primary VZV infection is presumed to be initiated by inoculation of the mucous
membranes of the respiratory tract with infectious virus transferred in respiratory
droplets or by contact with infectious vesicular fluid from an infected individual (Arvin
et al. 1996). In the absence of experimental data, early events in VZV pathogenesis have
been compared to mousepox (Grose 1981). (Grose et al. 2000) as shown in Figure 1.7.
According to this model, VZV is presumed to infect mononuclear cells in regional
lymph nodes after inoculation of mucous membranes, causing a primary viremia that
carries the virus to reticuloendothelial organs such as the liver and spleen for a phase of
virus replication. A secondary lymphocyte mediated viremia delivers systemically to the
cutaneous epithelial cells, where replication causes deep necrotic lesions of the
epidermis and dermis. The incubation period is usually 14-16 days, with a range of 10-
21 days.
A recent experiment in severe combined immunodeficiency mice with human
skin grafts (SCIDhu mice) supported the concept that infected T cells have the potential
to mediate VZV transfer to skin immediately after entering the circulation during the
primary viremia (Ku et al. 2004). It was suggested that the prolonged interval between
exposure and the appearance of varicella skin lesions reflects the time required for VZV
48
to overcome previously unrecognised but potent innate immune barriers, especially
alpha interferon production, mounted directly by epidermal cells in vivo (Ku et al. 2004).
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Infection of conjunctivae and or mucosa of upper
respiratory tract




Virus replication in liver, spleen and (?) other organs
Secondary viremia
I
Infection of skin and appearance of vesicular rash
Figure 1.7 Diagrammatic representation of the pathogenesis of chicken pox infection
based on mousepox. There are two viremias during the 14 days incubation period. The first
viremia occurs after local replication at the site of infection. At the end of the second viremia, the
typical chicken pox rash appears (adapted from Grose, 1981).
50
1.3.2 Complications
While chicken pox in the normal child is usually a benign illness, this infection
in the adult or immunocompromised individual is of increased severity, as evidenced by
enhanced morbidity and mortality. For example, in children receiving cancer
chemotherapy, nearly one third have progressive involvement of multiple organs,
including lungs, liver and the central nervous system (LaRussa 2000). The overall
mortality of chicken pox in the immunocompromised host has been reported to be 8 to
10%. The most serious complication of varicella is pneumonitis, which is characterised
by progressive tachypnea and cough (Choo et al. 1995). Secondary bacterial infection of
the skin, which is usually caused by Streptococcus pyogenes or Staphylococcus aureus is
also a common infectious complication of varicella (Peterson et al. 1996). These can
range in severity from impetiginised lesions and bullous impetigo to cellulites and
erysipelas. The common neurologic complications of varicella are meningoencephalitis
and cerebellar ataxia (Arvin 1999).
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1.3.3 Treatment
A live attenuated varicella zoster virus vaccine was developed in Japan at the
beginning of the 1970s (Takahashi et al. 1975) and was introduced into the routine infant
immunisation schedule of the United States in 1995. The vaccine virus was generated by
serial passage of a clinical VZV isolate, the parent Oka (pOka) virus, in human and
guinea pig embryo fibroblasts. Varicella vaccine virus (vOka) is attenuated and
immunogenic in susceptible healthy children (Krause and Klinman 1995). Concerns
have been raised about a potential age shift with the effects of varicella vaccination, i.e.
an increase in the number of varicella cases in older age groups, which generally results
in a more severe disease outcome (Wagenpfeil et al. 2004). A further concern is the
potential initial increase in herpes zoster incidence resulting from a decrease in the
spread of wild-type VZV following vaccination. Recently, Oxman et al., (2005) have
reported that the live attenuated Oka/Merck VZV vaccine markedly reduced morbidity
from herpes zoster and postherpetic neuralgia.
Medical management of chicken pox in the normal host is directed toward
prevention of avoidable complications. Meticulous care and good hygiene can avoid
secondary bacterial infection of the skin. Antiviral therapy was first shown to be
efficacious for the management of varicella in the late 1970s and early 1980s using the
non-specific inhibitors of viral replication, vidarabine and interferon (Whitley 2000).
Acyclovir, a synthetic acyclic purine nucleoside analogue which is a selective inhibitor
of VZV replication was then proven useful and has become the drug of choice.
Additionally, foscarnet, a pyrophosphate analogue, is available for intravenous therapy
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of varicella infections in high-risk immunocompromised hosts who are presumed to
have an infection caused by an acyclovir or penciclovir resistant virus (Enright and
Prober 2003).
1.4 Clinical Manifestation of Herpes Zoster
Herpes zoster (HZ or shingles) is a common disease caused by reactivation of
latent VZV that has an estimated annual incidence of 2 to 3 cases per 1000 persons
(Portenoy et al. 1986), rising with age and a lifetime prevalence as high as 20% (Stankus
et al. 2000). The age-specific incidence of HZ was shown by a rapid increase during
infancy and adolescent from 0.79/1000/annum to reach about 2.2 and remain around that
rate from 20 to 50 years of age (Hope Simpson 2001). Thereafter, the incidence rate
increases as steeply as in the first 20 years of life, to reach 12.2/1000 in octogenarians, a
15 fold that in those under 10 years old and 5.5 times that of persons between 20 and 50
years old (Hope Simpson 2001). It was found that the severity of the disease increased
with age but the condition did not occur in epidemics and there was no characteristic
seasonal variation.
HZ is a localised disease characterised by unilateral radicular pain and vesicular
eruption that is generally limited to the dermatome innervated by a single spinal or
cranial nerve (Ragozzino et al. 1982). Thoracic and lumbar dermatomes are most
commonly involved. HZ may involve the eyelids when the first or second branch of the
fifth cranial nerve is affected but keratitis heralds a sight threatening condition, herpes
zoster ophthalmicus. Early in the disease course, erythematous, macropapular lesions
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appear that rapidly evolve into a vesicular rash. Vesicles may coalesce to form bullous
lesions. In the normal host, these lesions continue to form over a period of 3 to 5 days,
with the total duration of disease being 10 to 15 days (Whitley 2001). Unusual cutaneous
manifestations of herpes zoster, in addition to ophthalmic disease, include the
involvement of the maxillary or mandibular branch of the trigeminal nerve, which
results in intraoral involvement with lesions on the palate, tonsillar fossa, floor of the
mouth and tongue. Neuromuscular disorders associated with HZ include the Guillain-
Barre syndrome, transverse myelitis and myositis.
The prodomal symptoms of HZ are usually acute segmental neuralgia with pain
and paresthesia in the involved dermatome (Wood et al. 1996). This generally precedes
the eruption by several days, occasionally by a week or more and it varies from
superficial itching, tingling, or burning to severe deep boring or sharp, stabbing,
lancinating pain (Oxman et al. 2000).
1.4.1 Pathogenesis
Hope-Simpson proposed that immunity to VZV plays a pivotal role in the
pathogenesis of herpes zoster (Hope-Simpson 1965) and subsequent observations
support the hypothesis that cell-mediated immunity to VZV is a major determinant of
the risk and severity of herpes zoster (Kost and Straus 1996). Whereas levels of antibody
to VZV remain relatively constant with increasing age, the increased incidence and
severity of herpes zoster and PHN among older adults are closely linked to a progressive
age related decline in cell-mediated immunity to VZV. The concept that VZV takes
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advantage of waning immunity to ensure its persistence in the population by causing
herpes zoster is supported by correlations between age and a diminished capacity of
peripheral blood T cells from persons who are immune and therefore latently infected, to
proliferate and produce interferon-y when stimulated with VZV antigens in vitro (Arvin
2005). VZV specific T cell immunity is elicited by primary VZV infection and is
required for the resolution of varicella. Memory CD4+ and CD8+ T cells that recognise
VZV proteins remain readily detectable in younger adults, in whom herpes zoster is
relatively rare. Robust memory T cell immunity to VZV may reflect either the extent of
the initial expansion of VZV-specific T cells elicited during primary infection or
periodic boosting on exposure to varicella or on abortive, subclinical reactivation. Loss
of VZV-specific T cell responses also defines periods of susceptibility to herpes zoster
in immunocompromised patients. In contrast, anti-VZV IgG antibodies persist and
persons who are at risk for herpes zoster because of declining T cell responses continue
to be protected from varicella. Functionally, VZV-specific memory T cells probably
control the later stages of reactivation that produce the typical signs of herpes zoster,
rather than preventing latent VZV genomes in the ganglia from beginning to replicate.
Over time, waning VZV-specific T cell immunity may place a person in a 'danger zone'
for symptomatic VZV reactivation. Recurrences of herpes zoster are uncommon among
immunocompetent persons, presumably because an episode of herpes zoster boosts




Complications of HZ have different manifestations and reflect different
pathogenic mechanisms such as direct viral invasion, sensory or motor neuropathies and
vasculopathy (Gilden et al. 2000). These complications depend on the localisation and
include ocular, neurologic, visceral (pneumonitis, esophagitis, enterocolitis, myocarditis,
pancreatitis) and other complications such as myositis and cystitis. HZ starts and ends
with pain of varying degrees. During its course different stages of pain can be
distinguished: the acute pain before and during the skin lesions and the chronic pain
after the rash has healed (Arvin 1999). Today, both the acute and chronic pain of HZ are
termed zoster-associated pain (ZAP) by the International Herpes Management Forum.
The most common complication of HZ is postherpetic neuralgia, a chronic ZAP, which
will be discussed in more detail in a separate section. HZ in the trigeminal ganglion is
associated most often with clinical manifestations in the first division of trigeminal
nerve, i.e. the ophthalmic branch (Arvin 1999). Clinical manifestations of this infection
among others include conjunctivitis, dendritic keratitis and optic neuritis. Other
complications of HZ involving cranial nerves include facial palsy, herpes zoster oticus
and Ramsey-Hunt syndrome. Motor paralysis due to inflammation and necrosis in the
anterior horn cells is also reported in HZ patients.
1.4.3 Treatment
The localised skin rash is not a serious problem but the prodromal pain associated
with herpes zoster is a sign of the active infection of sensory ganglia. The syndrome of
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zoster sine herpete also suggests direct involvement of the ganglia and autopsy studies
have suggested the destruction of neurons and satellite cells during VZV reactivation
(Gilden et al. 2000). As a consequence of this pathogenic process, the benefit of antiviral
therapy with acyclovir and related agents is limited in patients with herpes zoster.
Neurologic damage begins before the characteristic dermatomal rash appears and PHN
can be prolonged and intractable despite early antiviral therapy and aggressive pain
management.
Over the last 20 years, a series of effective and well-tolerated antiviral compounds
have been licensed for treatment of HZ (Balfour 1999). Three oral antiviral drugs
(acyclovir, valaciclovir, and famciclovir) are currently approved in the United States and
United Kingdom for treatment of HZ in immunocompetent host. Acyclovir was the first
oral antiviral compound marketed for treatment of HZ (Whitley 2001). While widely
and successfully prescribed, the efficacy of acyclovir for HZ is somewhat limited by its
poor oral bioavailability. Valaciclovir the prodrug of acyclovir has been developed to
provide an orally administered drug with an improved efficacy. Famciclovir, a prodrug
of penciclovir was also developed as the oral formulation because penciclovir is poorly
absorbed (Wood 2002). In double-blind placebo controlled trials, acyclovir reduces the
overall duration of pain and the incidence of PHN, defined as pain at 3 or 6 months after
enrolment (Wood et al. 1996). Famciclovir reduces the duration of PHN, defined either
as pain beyond rash healing or as pain beyond 30 days or 3 months from enrolment
(Tyring et al. 1995). In a comparative study of acyclovir and valaciclovir, valaciclovir
reduced the overall duration of pain considered as a continuum. Besides antiviral
therapy, steroids e.g. corticosteroids were shown to be beneficial to reduce acute zoster
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pain (Wood 2002). Nerve blocks, analgesics and antidepressants also have some efficacy
towards relieving acute pain.
1.5 Post-herpetic neuralgia
Zoster in immunocompetent patients most often resolves without sequelae.
However, many elderly patients have prolonged, often debilitating pain, known as post¬
herpetic neuralgia (PHN). PHN has been defined as severe pain occurring l month after
rash onset or that persists for greater than 3 months (Dworkin 1996). PHN is classed as a
neuropathic pain that is associated with mechanical allodynia (Watson 1989).
Increasing age is the most important predictor of PHN, where older age has been
consistently associated with an increase risk of developing PHN in patients with herpes
zoster. Hope-Simpson (Hope-Simpson 1975) reported that the incidence of PHN was 3-
4% in the 30-49 age group but rose to 29% in those 70-79 and 34% in the over 80 year
old age group. In addition to age, 4 risk factors for PHN have been identified which are
greater acute pain severity, greater rash severity, sensory dysfunction in the affected
dermatome during acute herpes zoster and the presence of painful prodrome preceding
the rash (Dworkin 1996). Patients with prolonged PHN often have ongoing disturbances
in physical and psychosocial functioning. In severe cases, PHN can lead to drug
dependency, depression, and even suicide (Chidiac et al. 2001).
A complete history and physical examination continue to be the standard for
making the diagnosis of PHN. Pain is typically localised to the dermatome affected by
the rash and most often described as burning, throbbing, or sharp and shooting in nature
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(Kanazi et al. 2000). Allodynia, the presence of pain in response to a normally
innocuous stimulus, is common in PHN and often causes patients great distress.
1.5.1 Pathogenesis
The pathogenesis of PHN remains unknown. Clinical virological correlations
suggest that virus persistence in ganglia, which produces a chronic ganglionitis, is the
cause. VZV specific DNA (Mahalingam et al. 1995) and VZV specific late
glycoproteins (Vafai et al. 1988) have been found in blood MNCs of PHN patients 1-8
years after zoster. In zoster patients who did not develop PHN, VZV DNA was only
found in MNCs up to 38 days, or not at all, after disappearance of zoster pain (Gilden et
al. 1988). Further evidence that the longstanding radicular pain of PHN reflects a
chronic ganglionitis has come from the detection of VZV DNA in blood MNCs and
cerebrospinal fluid (CSF) of two patients with zoster sine herpete (pain without rash)
(Gilden et al. 1994). It was reported that the pain disappeared after both patients were
treated with intravenous acyclovir. However, PHN is resistant to opioid and non¬
steroidal anti-inflammatory drugs (NSAIDS), which are the mainstay of treatments for
acute and inflammatory pain states. This suggests that inflammatory responses alone are
not sufficient to induce PHN. Neuropathic pain such as PHN is characterised by
neuronal hyperexcitability in damaged areas of the nervous system (Rowbotham 2001).
This hyperexcitability is due to molecular changes (e.g. abnormal expression of sodium
channels, changes in y-aminobutyric acid (GABA) inhibition at the level of the
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peripheral nociceptor, in the DRG. The mechanism in which latent VZV infection
interacts with the neurone to induce such molecular changes is unclear.
1.5.2 Treatment
Like zoster, PHN has no universally accepted treatment. Furthermore, PHN often
does not respond well to medications that are used to treat nociceptive pain, including
acetaminophen (APAP), nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids
(Kost and Straus 1996). In the US, only Lidoderm (topical lidocaine) and Neurontin
(gabapentin) have been approved by the US Food and Drug Administration for the
treatment of PHN (Stankus et al. 2000). Current antiviral agents such as acyclovir,
valaciclovir or famciclovir have been shown to reduce pain resulting from VZV and the
overall duration of pain (Whitley 2001) providing treatment is given within 72 h after
onset of the rash. Oral steriods may add to the benefit of antiviral therapy for reducing
the acute pain of herpes zoster but have no effect on the development of PHN (Stankus
et al. 2000). Tricyclic antidepressants e.g. amitriptyline, nortriptyline and desipramine
remain an important treatment for patients with PHN because they have an analgesic
effect in chronic pain that is independent of their antidepressant effect (Johnson 2002).
Anticonvulsants like gabapentin has been shown to reduce pain severity by 66% in PHN
patients in a randomised double-blind study (Berry et al. 2005). Opioids such as
morphine, oxycodone and methadone are in routine use for PHN in which they help in
pain relief and reduction in allodynia and disability (Watson et al. 1998). Although
sympathetic nerve blocks maybe effective in relieving pain during acute zoster, these
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blocks do not appear to provide prolonged relief in patients with long standing PHN
(Watson et al. 1998). Topical capsaicin treatment is licensed for the treatment of PHN
and was more efficacious than placebo in two of three small studies (Volmink et al.
1996). However, many patients experience local stinging and burning. Two small
placebo controlled studies have indicated a beneficial effect of lidocaine patches in PHN
(Rowbotham et al. 1996), (Galer et al. 1999).
1.6 Animal Models of VZV
The predominant obstacle to immunopathological studies of VZV is the lack of an
animal model that could mimic the clinical events observed during human infection.
Both in vitro and in vivo, VZV is remarkably species-specific to its primary host,
humans. In addition to its cell-associated characteristic in tissue culture, it has been
difficult to achieve sufficiently high titers of virus for use as inocula in the experimental
animal and to manipulate in vitro to enhance the susceptibility of other species.
Non-human primates can be infected but usually remain asymptomatic, with the
exception of gorillas and chimpanzees (Myers and Conelly 1992), (Cohen et al. 1996).
When African green monkeys, Eiythrocebus patas, and pygmy marmosets were infected
with VZV, no infectious virus was recovered but VZV IgG antibodies were induced.
Other models that have been used include the guinea pig (Myers et al. 1985), (Myers et
al. 1991), common marmoset (Provost et al. 1987), rat (Sadzot-Delvaux et al. 1990),
(Sadzot-Delvaux et al. 1995), mouse (Wroblewska et al. 1993) and rabbit (Dunkel et al.
1995).
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The guinea pig model reproduces some critical events in VZV pathogenesis,
including viremia and ganglion infection, and can be used to evaluate the host response
to viral antigens (Myers and Conelly 1992), (Lowry et al. 1992), (Sabella et al. 1993).
Animals remain asymptomatic, although some hairless weanling animals developed a
very short-term exanthematous rash (Myers et al. 1991).
The common marmoset appears to be similar in many aspects to the guinea pig, in
that infection leads to short-lived viremia, shedding of virus and seroconversion but with
few clinical signs of disease (Provost et al. 1987). The ocular model in the rabbit eye
was considered at one time as a potential model for herpes zoster ophthalmicus, but
some highly variable parameters renders its acceptance (Dunkel et al. 1995). Ocular
inoculation in mice resulted in detection of viral DNA but no viral protein found
(Wroblewska et al. 1993).
Adult rats inoculated subcutaneously into the footpad with VZV caused a long-
term persistence of virus in DRG where both RNA and protein could be detected
(Sadzot-Delvaux et al. 1995). Fleetwood-Walker et al., (1999) have previously reported
adaptation of this model and described the development of allodynia and hyperalgesia in
infected rats up to day 35 post-infection. This model was further characterised and
showed that infected rats develop chronic mechanical allodynia, which remains for
longer than 60 days post infection and resolves by 100 days post infection (Dalziel et al.
2004). Although ganglionic infection can be established in this model after peripheral
inoculation of VZV but the drawbacks of the rat model as a model of VZV latency in
humans are that VZV does not reactivate, non-ganglionic tissues have not been shown to
be free of VZV and VZV in rats is not restricted to ganglionic neurons (Cohrs et al.
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2004). Since PHN is caused by a reactivation of VZV and no reactivation has been
shown in the rats, there is concern of this model as a model of PHN in humans.
However, ganglia of PHN patients cannot be studies during life, therefore, the rat model
is so far the best studied model that could mimic the clinical situation of PHN in human.
VZV tropism for certain human cell types can be examined in the SCID-hu mouse
model (Ito et al. 2005), (Baiker et al. 2004). These animals have allografts of human
thymus/liver, containing CD4+, CD8+ and dual positive T cells or human skin implants
that can be inoculated with VZV. The closely related simian varicella virus (SVV) of
primates might also be a model to which human VZV latency can be compared due to
their similarities at the level of antigenic similarity, genome organisation and DNA
sequence (White et al. 1997), (Gray et al. 2004).
1.7 Project Aims
Investigating the molecular mechanisms of VZV pathogenesis has been difficult
because of VZV's restricted infectivity for non-human species in vivo and the highly
cell-associated nature of VZV replication in vitro. VZV latency also remains poorly
understood partly due to the previous lack of a good animal model system. These
obstacles have been addressed by the development of a rat model of VZV latency
(Sadzot-Delvaux et al. 1990). This model was further adapted and able to demonstrate
striking changes in behavioural reflex responses similar to changes seen in PHN patients
(Fleetwood-Walker et al. 1999). Thus, the model provides an excellent system to study
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the interactions of VZV with both the immune and nervous systems during a latent
infection.
Using the rat model, we would like to test the hypothesis that presence of some or
all of the genes found expressed in VZV latently infected neurones, results in an
increased sensitivity to noxious stimulus. It may affect the physiological function of that
neurone by either directly via a change in the nociceptive pathways and transcriptional
activity of the neurone or in response to a chronic immune response directed to these
proteins. The virus-host interactions that lead to development of the sensory changes
similar to PHN could be measured by well-established tests of mechanical allodynia.
The objectives of this study are:
i) to correlate between the observed altered sensory behaviour with the pattern of
gene expression in infected DRG
ii) to study the viral spread in the rat model
iii) to investigate which components of the virus are responsible for eliciting
allodynia
The development and further characterisation of this model could serve as a useful and
unique opportunity to study the host-virus interactions involved in the pathogenesis of
PHN. Ultimately, by exploiting the rat model, a better insight into understanding the
virus and cellular factor, which govern VZV latency and how the latent virus interacts
with the sensory neurone harbouring it could be gained. This is essential if advances
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2.1. Materials
2.1.1. Chemicals
All chemicals purchased were of molecular grade and obtained from Sigma
(Sigma-Aldrich Ltd., UK) unless otherwise stated.
2.1.2. Common Media, Buffers and Solutions
The media, buffers and standard solutions used in this study are listed in Table
2.1. Broth was stored at room temperature and all agar plates were kept at 4°C. Broth
and plates were used within 1 month or 2 weeks if antibiotics were added.
Table 2.1 Common Media, Buffers and Solutions
Media, Buffers, Solutions Recipes, per litre
Luria-Bertani (LB) Bacto-tryptone (10 g), Bacto-yeast extract (5 g), NaCl (5 g)
LB agar LB broth, bacto-agar (15 g)
lx PBS NaCl (0.1 M), KC1 (2.7 mM), Na2HP04 (4 mM), KH2P04 (1.8 mM)
lOx TAE Tris-acetate (40 mM), EDTA (1 mM; pH 8.0)
TBS Tris-HCl (50 mM; pH 7.5), NaCl (150 mM)
20x SSC NaCl (3 M), Sodium citrate (0.3 M), adjust to pH 7.0 with NaOH
TE Tris-Cl (10 mM; pH 8.0), EDTA (1 mM)
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2.2. General Molecular Techniques
2.2.1. DNA Extraction from Animal Tissues
DNeasy Tissue kit (QIAGEN) was used to extract DNA from tissues. Small
tissue pieces (~ 25 mg) were placed in a microcentrifuge tube with Buffer ATL (180 pi).
Proteinase K (20 mg/ml; 20 pi) was added and the reaction incubated at 55°C for 3 h or
overnight until the tissue was completely lysed. The sample was vortexed for 15 s and
Buffer AL (200 pi) was added, mixed thoroughly and incubated at 70°C for 10 min.
Ethanol (96-100%; 200 pi) was added to the sample and mixed. The mixture was
transferred to the DNeasy spin column and centrifuged for 1 min at 6000 x g and the
flow-through discarded. The DNeasy spin column was placed in a new collection tube (2
ml). Buffer AW1 (500 pi) was added and centrifuged as described above. The process
was repeated with Buffer AW2 (500 pi) but with centrifugation for 3 min at 13,000 x g
to dry the DNeasy membrane. For elution, the DNeasy spin column was placed in a
clean microcentrifuge tube (1.5 ml) and Buffer AE (100 pi) was pipetted directly onto
the membrane. The column was incubated for 1 min at room temperature before being
centrifuged for another minute at 6000 x g. The elution was repeated with the first
eluate. The DNA was kept at -20°C until use.
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2.2.2. DNA Extraction from Animal Cells
An appropriate number of cells (5 x 106) were trypsinised and centrifuged for 5
min at 300 x g. The pellet was resuspended in PBS (200 pi). Proteinase K (20 mg/ml; 20
pi) and Buffer AL (200 pi) was added to the sample, mixed thoroughly and incubated at
70°C for 10 min. The remainder of the protocol was similar to DNA extraction from
animal tissues (section 2.2.1).
2.2.3. DNA and Total RNA Extraction from Animal Cells or Tissue
Simultaneous isolation of DNA and total RNA from animal cells or tissues could
be performed in QIAGEN RNA/DNA kit according to the manufacturer's instruction. A
T175 flask of virus infected cells were trypsinised and collected as a cell pellet prior to
lysis. In order to trypsinised cells, medium was removed and cells were washed with
PBS. PBS was removed and cells were trypsinised with 0.1-0.25% trypsin in PBS. After
cells were detached from the flask, medium was added and cells were transferred to a
polypropylene centrifuge tube and centrifuged at 300 x g for 5 min. Supernatant was
removed, cell pellet was loosen by flicking the tube and lysis Buffer QRL1 with pre-
mixed (3-mercapthoethanol (1:100) were added. Buffer QRV1 (0.5 ml) was added,
mixed and centrifuged at 15,000 x g for 20 min at 4°C. The supernatant was carefully
transferred into an RNase-free 2 ml collection tube. Ice-cold isopropanol (0.8 ml) was
added and the tube was incubated on ice for 5 min followed by centrifugation at 15,000
x g for 30 min at 4°C. In the meantime, the QIAGEN-tip was equilibrated with Buffer
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QRE (1 ml) by allowing the buffer to enter the column by gravity flow. The supernatant
was discarded after the centrifugation and Buffer QRL1 (0.15 ml) was added. The
nucleic acid pellet was dissolved by heating the tube for 3 min at 60°C followed by
vortexing for 5 s and flicking sharply the tube. This step was repeated at least twice.
Buffer QRV2 was added (1.35 ml), mixed thoroughly by vortexing and centrifuged at
5000 x g for 5 min at 4°C. Sample was then applied to the equilibrated QIAGEN-tip and
allowed to enter the resin by gravity flow. Flow-through was collected for subsequent
DNA isolation and placed at room temperature. Buffer QRW (2 ml) was pipetted onto
the QIAGEN-tip and allowed to enter the resin by gravity flow. Buffer QRU (1 ml) pre¬
heated to 45°C was added onto the QIAGEN-tip and the RNA was eluted by gravity
flow into a 2 ml collection tube. Ice-cold isopropanol (1 ml) was added to the eluate,
mixed and placed on ice.
For isolation of genomic DNA, the flow-through from above was pipetted onto
the same QIAGEN-tip and was allowed to enter the resin by gravity flow and this
process was repeated with the same flow-through. Buffer QC (3 ml) were added to the
QIAGEN-tip and was allowed to enter the resin by gravity flow. The genomic DNA was
eluted with preheated Buffer QF (1 ml). Isopropanol (0.7 vol) at room temperature was
added to the eluate, mixed and incubated for 10 min at room temperature. The
isopropanol precipitated RNA and DNA were centrifuged at 15,000 x g for 30 min at
4°C and the supernatant was carefully removed. Ice-cold 70% ethanol was added,
vortexed briefly and centrifuged at 15,000 x g for 20 min at 4°C. The supernatant was
removed and this step was repeated once. The RNA and DNA pellets were air-dried
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approximately 10 min at room temperature with the tubes resting upside down on a
paper towel. The DNA and RIMA were dissolved in TE buffer (100 pi) and RNase-free
water (20 pi), respectively, by heating the tube for 3 min at 60°C, followed by vortexing
for 5 s and flicking sharply the tube and repeated at least twice. The DNA was then
stored at -20°C and the RNA was kept at -80°C until use.
The isolation method used for animal tissues was the same except in the starting
material where approximately 20 mg of tissues were used.
2.2.4. DNA Extraction from Whole Non-nucleated Blood
Proteinase K (20 mg/ml; 20 pi) followed by anti-coagulated blood (100 pi) was
added to a microcentrifuge tube (1.5 ml) and the volume was adjusted to 220 pi with
PBS. Buffer AL (200 pi) was added and mixed thoroughly. The reaction was incubated
at 70°C for 10 min. The rest of the protocol was similar to DNA extraction from tissues
(section 2.2.1).
2.2.5. Quantitation of Nucleic Acids
DNA and RNA concentrations were determined by the measuring of their
absorbance at 260 nm in a spectrophotometer (Cecil). An A260 of 1 corresponds to 50 pg
DNA and 40 pg RNA per ml water.
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2.2.6. Agarose Gel Electrophoresis
PCR products were resolved by electrophoresis in 2% (w/v) agarose gel
containing ethidium bromide (0.5 pg/ml). 15 pi of the PCR products were added with
Blue/Orange 6x loading dye [Promega, 15% (w/v) Ficoll 400, 0.03% (w/v)
Bromophenol blue, 0.03% (w/v) Xylene Cynol, 0.4% (w/v) Orange G, Tris-Cl (10 mM,
pH 7.5), EDTA (50 mM); 3 pi]. The electrophoresis was carried out at constant voltage
(13 cm x 15 cm gels at 110 V) for 60 min in a horizontal gel apparatus (Bio-Rad) with
lx TAE buffer. Fragments were sized using a 100 bp DNA ladder (Invitrogen). DNA
was visualised on a UV transilluminator and the gel photographed with a UVP camera.
2.2.7. Restriction Endonuclease Digestion
Restriction enzymes were purchased from New England Biolabs. Reactions were
carried out in a volume of 10-20 pi with 1 U enzyme per pg DNA and incubated at the
optimum temperature with the appropriate buffers following the manufacturer's
instruction.
2.2.8. Ligation using the pGEM-T Easy Vector System
Ligation reactions containing 2x Rapid Ligation buffer [Tris-Cl (60 mM, pH
7.8), MgCL (20 mM), DTT (20 mM), ATP (2 mM), 10% (w/v) polyethylene glycol
(MW8000); 5 pi], pGEM-T Easy vector (50 ng; 1 pi, Promega), T4 DNA ligase (3 W; 1
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pi, Promega) and PCR products were set up in a total volume of 10 pi, mixed and
incubated at 4°C overnight.
2.2.9. Sequencing
All plasmid inserts into pGEM-T Easy vector were identified and confirmed by
sequencing which was carried out by Mr. Ian Bennet using an automated LI-COR DNA
sequencer model 4000L (MWG-Biotech). Primers used were Ml3 reverse sequencing
primer (5'-GGA TTA CAA TTT CAC ACA GG-3') and M13 universal primer (5'-GTA
AAA CGA CGG CCA GT-3').
2.2.10. Southern Blot Analysis
Southern blot analysis was carried out in this study to confirm the identity of the
nested-PCR products. A 20-mer oligonucleotide (5'-CGT GCT GGG AGG AAT TGT
TA-3') specific to VZV gene 63 was synthesised to be used as a probe in Southern blot.
The oligonucleotide was ezymatically labelled at the 3' end by incorporation of a single
digoxigenin-labelled dideoxyuridine-triphosphate (DIG-dUTP) terminal transferase. 100
pmol of the oligonucleotide was added to 20 pi reaction mixtures containing 5x reaction
buffer [Potassium cacodylate (1 M), Tris-HCl (0.125 M), bovine serum albumin (1.25
mg/ml), pH 6.6; 4 pi], CoCl2 solution (25 mM; 4 pi), DIG-dUTP (1 mM; 1 pi), dATP
(10 mM; 1 pi) and terminal transferase (400 U; 1 pi). The reaction was mixed, incubated
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at 37°C for 15 min and placed on ice for 5 min. The reaction was terminated by adding
EDTA (0.25 M; 1 pi). The probe was stored at -20°C until use.
PCR products were electrophoresed in a 2% (w/v) agarose gel with DIG labelled
DNA molecular weight marker VIII (Roche) and a photograph of the gel was taken. A
small triangular piece was cut from the bottom left-hand corner of the gel to simplify
orientation during the succeeding operations. The gel was then incubated in denaturation
buffer (0.5 M NaOH, 1.5 M NaCl) twice for 20 min with gentle agitation and rinsed
briefly with dH20. The gel was transferred to neutralisation buffer (1 M Tris-Cl, 1.5 M
NaCl) for 20 min and repeated twice.
A support larger than the gel was placed in a tray containing lOx SSC and
covered with a Plexiglas plate. Two lengths of Whatman 3 MM paper wider than the gel
and long enough to reach the bottom of the dish on either side were placed on the glass
plate. When the blotting paper on top of the support was thoroughly wet, air bubbles
were removed by rolling with a pipette. Two sheets of blotting papers and a positively
charge nylon membrane (Roche) were cut 1 mm larger than the gel in each dimension.
The membrane was first wet in dH20 and then in 10x SSC for 5 min. The gel was placed
up-side down on the platform and any air bubbles removed. The gel was surrounded
with parafilm to ensure the buffer moved only through the gel and not around it. The
pre-cut membrane was then placed on top of the gel so that the cut corners were aligned.
A pipette was rolled across the surface of the membrane to remove any air bubbles. Two
sheets of Whatman 3MM papers were briefly wet in 10x SSC and placed on top of the
nylon membrane. A stack of paper towels (10-15 cm) were cut just smaller than the
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blotting papers were put on top of the papers. A second Plexiglas plate was placed on
top of the paper towels and weighed down with a 1 kg weight. The transfer of DNA was
allowed to proceed overnight.
The next morning, paper towels and blotting papers above the gel were removed.
The gel and the attached membrane were turned over, gel side up on a dry sheet of
blotting paper. The positions of the gel slots were marked with a soft lead pencil. The
gel was peeled from the membrane and discarded. The membrane was put into a UV
stratalinker to crosslink the DNA to the membrane.
The membrane was prehybridised in prewarmed hybridisation buffer (DIG Easy
Hyb, Roche) at 50°C for 30 min with gentle agitation. The hybridisation buffer was
discarded and new prewarmed hybridisation buffer containing DIG labelled probe
(0.002 pmol) was added. The hybridisation process was continued overnight at 50°C
with gentle agitation. The membrane was washed twice for 5 min each in 2x SSC 0.1%
(w/v) SDS at room temperature under constant agitation. The membrane was washed
twice more stringently for 15 min in 0.1 x SSC, 0.1% (w/v) SDS at 50°C.
The DIG Luminescent Detection kit (Roche) was used to detect the DIG-labelled
oligonucleotides using anti-digoxigenin, alkaline phosphatase conjugates and visualised
with chemiluminescence substrate CSPD (Disodium 3-{4-methoxyspirofl, 2-dioxetane-
3,2'- [5'-chloro] tricyclo [3.3.1.13,7] decan] 4-yl} phenyl phosphate). All incubations
were performed at room temperature with agitation. Following post hybridisation
washes, the membrane was rinsed briefly in washing buffer [0.1 M Maleic acid, 0.15 M
NaCl, 0.3% (v/v) Tween 20, pH 7.5]. The membrane was incubated for 30 min in lOx
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blocking solution [10% (w/v) propriety blocking reagent in Maleic acid buffer {Maleic
acid (0.1 M), NaCl (0.15 M), pH 7.5}] and then for another 30 min in antibody solution
(anti-DIG-AP conjugate diluted 1:10,000 in lx blocking solution). The membrane was
washed twice in washing buffer, 15 min each and equilibrated in detection buffer (0.1 M
Tris-Cl, 0.1 M NaCl, pH 9.5) for 5 min. The membrane was placed on a development
folder, DNA side facing up and 2 ml of diluted CSPD solution were applied. The
membrane was covered immediately with the second sheet of folder to spread the
substrate evenly and without air bubbles and incubated for 5 min. Excess liquid was
squeezed out and the edges of the development folder was sealed. The damp membrane
was incubated for 15 min at 37°C to enhance the reaction. The membrane was exposed
to Lumi-film (18 x 24 cm, Roche) for 3 h or longer if required.
2.3. Bacterial Work
2.3.1. Growth and Maintenance of Escherichia coli
Bacterial cultures for plasmid preparation were grown from a single colony
picked from a freshly streaked ampicillin (100 pg/ml) plate. A single colony was
inoculated into LB medium (5 ml) containing ampicillin (100 pg/ml), and grown with
vigorous shaking at 225 rpm at 37°C for 12-16 h.
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2.3.2. Transformation of E.coli cells with Plasmid DNA
The ligation reactions were centrifuged briefly and placed on ice. One vial of
One Shot Topi OF' competent cells was thawed for each ligation. Transformation was
carried out by adding the ligation mixture (5 pi) directly to the competent cells and mix
gently by tapping. The cells were incubated on ice for 30 min and then 30 s at 42°C and
quickly placed them on ice for 5 min. Pre-warmed SOC medium (250 pi) was added to
each vial and incubated at 37°C for 1 h with shaking at 225 rpm. Different volumes of
transformation mixtures (50 pi, 100 pi and 150 pi) were spread on separate LB agar
plates containing ampicillin (100 pg/ml), X-gal (80 pg/ml) and IPTG (0.5 mM). The
plates were inverted and incubated at 37°C overnight. Single white colonies were
selected for further analysis by plasmid isolation, PCR, restriction enzyme digestion or
sequencing.
2.3.3. Small-scale Preparation of Plasmid DNA
Small-scale extraction of plasmid DNA was carried out using QIAprep Miniprep kit
(QIAGEN) following the manufacturer's instruction. Overnight cultures (1.5 ml) were
centrifuged at 12,000 x g for 10 min and the supernatant removed. The bacterial cells
pellet were resuspended in ice-cold Buffer PI [Tris-Cl (50 mM, pH 8.0), EDTA (10
mM), RNase A (100 pg/ml); 250 pi]. Buffer P2 [NaOH (200 mM), 1% (w/v) SDS; 250
pi] was added and the tube was inverted gently 4-6 times to mix. Buffer N3 [KAc (3 M,
pH 5.5); 350 pi] was added and the tube was inverted gently 4-6 times. The suspension
was centrifuged for 10 min at 12,000 x g in a microcentrifuge. The supernatant was then
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applied to the QIAprep Spin Column and centrifuged for 1 min. The flow-through was
discarded. The QIAprep Spin Column was washed by addition of Buffer PE (750 pi)
and centrifuged for 1 min. The flow-through was discarded and the column was
centrifuged for an additional 1 min to remove residual wash buffer. The QIAprep Spin
Column was put in a clean 1.5 ml centrifuge tube. Buffer EB [Tris-Cl (10 mM, pH 8.5);
50 pi] was added to the centre of each column and centrifuged for 1 min to elute DNA.
Recombinant plasmids were screened by PCR, restriction enzyme digestion and
sequencing.
2.4. RNA Work
2.4.1. RNA Stabilisation in Tissues
Fresh tissue samples less than 0.5 cm thick were immersed in 10 volumes of
RNAlater RNA Stabilisation Reagent (Ambion).
2.4.2. Total RNA Extraction from Animal Tissues
Total RNA extraction from tissue was performed using the RNeasy Mini kit
(QIAGEN). Stabilised tissues were removed from RNAlater. Approximately 30 mg of
tissue was placed into 1.5 ml microcentrifuge tubes and disrupted in Buffer RLT with |3-
Mercaptoethanol (500 pi) using a disposable pestle (Sigma). The lysate was then
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min. The supernatant was transferred to a new microcentrifuge tube and 70% (v/v)
ethanol (500 pi) was added and mixed. The samples were then applied to RNeasy mini
columns and centrifuged for 15 s at 12,000 x g. The flow-through was discarded and
Buffer RW1 (350 pi) added. The columns were centrifuged for 15 s at 12,000 x g and
the flow-through discarded. DNase I (2.727 Kunitz; 10 pi) were added to Buffer RDD
(70 pi) and gently inverted to mix. The DNase I solution was applied directly onto the
RNeasy silica-gel membrane, and incubated for 15 min at room temperature. Buffer
RW1 (350 pi) was added to the column and centrifuged for 15 s at 12,000 x g and the
flow-through discarded. Buffer RPE (500 pi) was added and the columns centrifuged at
12,000 x g for 15 s. Another aliquot of Buffer RPE (500 pi) was added to the columns
and centrifuged at 12,000 x g for 2 min to dry the RNeasy silica-gel membrane. The
columns were transferred to new 1.5 ml microcentrifuge tubes for elution. RNase-free
water (30 pi) was placed directly on the membrane and centrifuged for 1 min at 12,000 x
g. A second elution was performed with the first eluate to obtain a higher total RNA
concentration. The RNA was then reverse-transcribed immediately (section 2.4.4) or
kept at-80°C.
2.4.3. Total RNA Extraction from Mamalian Cells
Cells grown in a monolayer in cell-culture vessels were trypsinised and collected
as a pellet prior to lysis. Medium from the flask was aspirated and cells washed with
PBS. PBS was decanted and 0.25% (v/v) trypsin was added. After cells were detached
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from the flask, medium containing serum was added to inactivate the trypsin. Cells were
transferred to polypropylene centrifuge tubes and pelleted by centrifugation at 1000 x g
for 5 min. The supernatant was completely aspirated and disruption of the cells was
followed by addition of Buffer RLT. The remaining of the extraction steps were the
same as the protocol used for total RNA extraction from animal tissues (section 2.4.2).
2.4.4. Reverse-Transcriptase Polymerase Chain Reaction
Template RNA was thawed on ice. Up to 2 pg of RNA was used with the
Omniscript Reverse Transcription kit (QIAGEN). A master mix containing lOx Buffer
RT (2 pi), dNTP mix (2 pi; 0.5 mM each dNTP), Oligo-dT primer (2 pi; 1 pM), RNase
inhibitor (1 pi; 10 U), Omniscript Reverse Transcriptase (1 pi; 4 U) and RNAse-free
water in a total volume of 20 pi for one reaction was prepared. The reaction was mixed
thoroughly and centrifuged briefly to collect residual liquid from the wall of the tube.
The appropriate volume of master mix was distributed into individual tubes and kept on
ice. Template RNA was added into tubes containing the master mix and mixed. The
reaction was incubated at 37°C for 1 h. An aliquot (2-4 pi of the RT product) of the
finished reverse-transcription reaction was added to the PCR mix for RT-PCR.
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2.5. Mammalian Cells and Viruses
2.5.1. Cells and Viruses
CV-1 (Monkey African Green Kidney Fibroblast) cells were grown and
maintained in Dulbecco's modified Eagles medium (DMEM; Gibco) supplemented with
L-glutamine (2 mM) and 10% (v/v) foetal calf serum (FCS) in a 5% CO2 incubator at
37°C. VZV strain Ellen (VR-568 mycoplasma free strain from ATCC, VA, USA), VZV
parental Oka (pOka) strain and VZV vaccine Oka (vOka) strain were all propagated on
CV-1 cells. VZV strain Dumas was propagated on Mewo cells. POka, vOka and Mewo
cells were kind gifts from Dr. Marvin Sommer and Professor Ann Arvin of Stanford
University.
2.5.2. Long Term Storage of Cells and Viruses
For long term storage, cells and viruses were frozen down in freezing mix [90%
(v/v) FCS, 10% (v/v) DMSO] and kept in liquid nitrogen.
2.5.3. Recovering Cells and Viruses from Liquid Nitrogen
Vials of cells or viruses from the liquid nitrogen were thawed quickly in a 37°C
water bath. A few drops of pre-warmed media were added carefully to the vials to
equilibrate the osmotic pressure slowly. The cell were then aspirated into universal tubes
containing 20 ml prewarmed media and centrifuged at 1000 x g for 5 min at room
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temperature. The cell pellet was resuspended in 5 ml of media and put into a T25 flask.
The flask was incubated overnight at 37°C in a 5% CO2 incubator and growth was
checked the next day. If cells were growing well, they were split into fresh medium and
moved into the next sized flask.
2.5.4. Virus Propagation and Harvesting of Virus
Early log phase CV-1 cells were always used for VZV infection. A vial of virus was
recovered from liquid nitrogen as mentioned in section 2.5.3 but the cell pellet was
resuspended in 10 ml of pre-warmed media. The virus suspension was added to the flask
containing cells where the media has been aspirated and incubated at 37°C. After an
hour, 2% (v/v) DMEM was added (40 ml) to the flask. The virus was harvested when
cells showed 80% cytopathic effect. The cells were then scraped from the flask using a
cell scraper and centrifuged at 1000 x g for 10 min. The pellet was mixed well until no
sign of cell clumps were visible, and the suspension of virus was used to infect new
batches of log phase cells.
2.6. Animals and Behavioural Testing
2.6.1. The Rat Model of VZV Latency
In this project, all tissues used for study were obtained from rats infected with
VZV and tested for allodynia. Briefly, the model is as follow: VZV was propagated in
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CV-1 cells and harvested when cells exhibited approximately 80% cytopathic effect.
Male Han Wistar rats were anaesthetised and injected subcutaneously in the left
(ipsilateral) glabrous footpad with approximately 4 x 106 infected cells per animal in 50
pi medium. Behavioural test was carried out at specific days post infection to test for the
development of allodynia with a calibrated set of von Frey filaments. Figure 2.1 shows a
simplified diagram of the rat model. During testing, rats were removed from their cages
and placed in lidded wire mesh cages that allowed full access to the paws. The rats were
left to acclimatise for 10-15 min until they were quite settled and had all paws flat on the
wire mesh cage (Figure 2.2A). Care was taken during the testing procedure to ensure
that the animals were not putting their weight on the hind paws. Animals showed no
obvious signs of discomfort and phenotypic changes only evident on formal testing.
Details of assessment of allodynia with a set of von Frey filaments (Figure 2.2B) are
described in section 2.6.4.
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Figure 2.1 A diagram of the rat model. Male Han Wistar rats were injected subcutaneously
with 4 x 106 infected (or mock infected) CV-1 cells in 50 ^l medium into the left hind paw.








Figure 2.2 A diagram of the acclimatisation of rats in wire mesh cages and von Frey
filaments. A) Acclimatisation of animals in wire mesh cages before testing. B) Von Frey
filaments with different target forces (g) (note the difference thickness of the hair, 0.6 g is the
lowest force and 60 g is the highest force) when applying to the footpad of rats during
behavioural testing.
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2.6.2. Source of Animals
Male Wistar rats (150-200 g; Harlan) were housed under standard light
conditions and food and water allowed ad libitum. All animal experiments were carried
out under the provision of Home Office project license (60/2760) and personal license
(60/8842).
2.6.3. Inoculations
Animals were anaesthetised with Halothane prior to footpad injections. The
glabrous skin of the left footpad was injected subcutaneously with approximately 4-8 x
106 VZV infected cells following previous experience (Dalziel et al, 2004) that on
average these amount of cells were present in a near confluent T175 flask. Control rats
were injected with uninfected cells and housed separately from the virus infected
animals.
2.6.4. Assessment of Allodynia
Behavioural tests were carried out prior to infection and at the specified times
post infection. Animals were randomised into groups according to their weight and mean
paw withdrawal threshold (PWT) based on the readings from pre-testing sessions. The
rats were placed in wire mash cages which allowed full access to the paws and were
allowed to acclimatise prior to testing for about 10 to 15 min. PWT were measured using
an ascending series of von Frey filaments. These hairs were applied manually to the
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middle region of the left hind paw plantar surface. The hairs were applied with sufficient
force to cause buckling of the filaments. Vertical elevation of the paw was considered as
a positive withdrawal response. Whenever two positive responses out of five
applications of the same hair were recorded, the next smaller von Frey hair was applied.
Whenever a negative response occurred, the next higher force was applied. Triplicates of
the ascending series were performed and the average was recorded.
2.6.5. Tissue Collection and Preservation
At the end of a study, animals were euthanised in a C02 chamber. Autopsy was
performed whereby lumbar L1-L6 DRGs ipsilateral and contralateral to the site of
injection were removed. Other tissues removed included foot pads, sciatic nerves,
spleen, spinal cord, brain and blood. The tissues were either snap frozen in cooled
isopentene bath kept in dry ice for DNA extraction (section 2.2.1) or immersed directly
into RNAlater for RNA extraction (section 2.4.2).
2.7. Polymerase Chain Reaction
DNA was extracted from VZV infected CV-1 cells (section 2.2.2) as a template or
positive control in polymerase chain reaction (PCR). Routinely, a nested or hemi-nested
PCR was carried out in a total volume of 50 pi in a Hybaid PCR Sprint thermal cycler.
A master mix was prepared which contained all the components needed for PCR
except the template DNA. The primary (1°) reaction mixtures composed of
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deoxynucleotide mix (10 mM each dNTP; 1 pi), lOx PCR reaction buffer with MgC^
[100 mM Tris-HCl, 15 mM MgC^, 500 mM KC1, pH 8.3; 5 ml], sense primer (100 ng; 1
pi), anti-sense primer (100 ng; 1 pi), HotStarTaq DNA polymerase (QIAGEN, 2.5 U;
0.25 pi) and dHiO. 100-500 ng of genomic DNA or equivalent volume of sterile
nuclease-free water (Sigma) as negative control was added finally to the individual tubes
containing the master mix.
A 15 min initial incubation at 95°C was required to activate the HotStarTaq DNA
polymerase followed by 35 PCR cycles (94°C, 30 s; 55°C, 30 s; 72°C, 60 s) and a final
elongation at 72°C, 10 min. Nested or hemi-nested PCR (2°) mixtures and conditions
were identical to the 1° reaction except an aliquot of 1-2 pi of the 1° amplification
product was used as the template and different sets of internal primers (P2 + P4 or P2 +
P3). All oligonucleotides were synthesised by MWG-Biotech and their details are listed
in Table 2.2.
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Table 2.2 Oligonucleotide Primers





GCG AGA TTC ACG AAG ATT GCG
TTA TCT AAT GGG TCG CAC C
TCA ATT ACA TCC GAT GGC G









GAT ATT ATC GTG AGG TGG
TTT CCT GGC GTT TGT ACG
CTT TTG CGT AAG GAT GAT CCG








ACA AGG CAG CAG TTT CAT TCG
CCG ACG CTG ATA ATA GGA CAA







CCG AGG ATT CGT AAG ACC AA
GCG CCA GAG ACA GAA ATC A








GGC ACC ACA CTT TCT ACA
CTG TGT TGT CCC TGT ATG
GAG GTC TTT ACG GAT GTC






Sense, same (5' to 3') direction as the ORF following VZV Dumas strain sequence (Davison
and Scott, 1986)
b
Antisense, opposite (5' to 3') direction from that of the ORF following VZV Dumas strain
sequence (Davison and Scott, 1986).
c Location of 5' nucleotide with respect to the rat (3-actin sequence (Nudel et al., 1983)
d Antisense location of 5' nucleotide with respect to the rat P-actin sequence (Nudel et
al., 1983)
* Oligonucleotide sequences adapted from Cohrs et al. 1996
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2.7.1. Nested-PCR Optimisation
Optimisation of the annealing temperature was performed for every set of primers to
obtain the best amplification of the target with the least unspecific products. PCR was
carried out as mentioned in section 2.7 but instead of DNA being added to each
individual tubes, it could be added to the master mix preparation and distributed evenly
to each microcentrifuge tubes. The PCR was performed in a gradient thermal cycler with
temperature ranging from 42°C to 64°C with a step of 2°C (Robocycler, Stratagene).
2.8. Developing Real-time PCR Assay
2.8.1. Optimisation of Real time PCR Assay
Optimisation of the reagents used to perform PCR is critical for reliable and
reproducible results. The following criteria were optimised: magnesium chloride
concentration, primer concentration, template concentration and SYBR Green I
concentration.
2.8.2. Standard Curve Construction
Assays were performed with 10-fold serial dilutions from 1 to 108 copy numbers
of a plasmid containing a 294 bp insert of the IE63 gene. For plasmid construction, the
corresponding sequence of the IE 63 region was amplified using primers VZV63P1 and
VZV63P3 (Table 2.2) and ligated into pGEM-T Easy vector (Promega, section 2.2.8),
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according to the manufacturer's instructions. Plasmid was extracted from selected
positive clones, its concentration was determined (section 2.2.5) and the corresponding
copy number was calculated using the formula below:
6.02 x 1023 (copies/mol) x concentration (g/pl)
= Amount (copies/pl)
MW (g/ mol)
MW = Molecular weight (g/mol)
9 "J
1 mol = 6.02 x 10" molecules (copies)
Average MW of dsDNA = (number of base pairs) x (660 Daltons/base pairs)
Example:
For pGEM-T Easy-63 plasmid that has a concentration of 215 ng/pl = 2.15 x 10"7 g/pl
and a total size of 3309 bp:
MW = 3309 (bp) x 660 (Daltons/bp) - 2.18 x 106 Daltons
1 mol = 2.18 x 106 g
Also 1 mol = 6.02 x 10 molecules (=copies)
6.02 x 1023 (copies/mol) x 2.15 x 10"7 (g/pl)
= 5.9 x 1010 (copies/pl)
2.18 x 106 (g/mol)
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The standard curve was plotted with fluorescence threshold (Ct) versus template
concentration and concentrations of the samples were determined by interpolation.
2.8.3. Melting Curve Analysis
Melting curve analysis must be carried out at the end of the PCR amplification when
using SYBR Green I format to identify specific PCR products from artefacts.
Temperature dependent fluorescence measurements were made whilst slowly increasing
the temperature of the reaction products from 65°C to 95°C. A graph of the first negative
differential of the fluorescence signal with respect to temperature was plotted against
temperature.
2.9. Laser Capture Microdissection
2.9.1. Preparation of Slide
Cryostat sections of snap frozen tissues were prepared on non-coated slides by
Ms. Deborah Hall at the Department of Pathology, Easter Bush Veterinary Centre. The
sections were stained with haematoxylin-eosin for better visualisation of the tissue
architecture.
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2.9.2. Lifting of Single Cell
LCM was carried out using a PixCell LCM system (Arcturus Engineering, Santa
Clara, CA). A haematoxylin-eosin stained slide was examined under the microscope and
area of interest was selected using a joystick to move the slide easily until the cells of
interest were in the centre of the optical field. A thermoplastic polymer coating, ethylene
vinyl acetate (EVA), attached to a rigid support was placed in contact with the tissue
section with a transport arm. Then, with the simple push of a button, an infra red laser,
focused to the size of the desired target, was pulsed which melts the film directly above
the targeted cells. The focally melted polymer expanded and impregnated the voids in
the targeted tissue and then solidified as it rapidly cooled. At this point, the tissue-
containing polymer had become a mechanically strong, 5 pm thick, solid composite
bonded onto the surface of the pure polymer film. In this manner, multiple identical cells
was separately targeted and bonded to the polymer film. When the film and the cap were
lifted off the tissue section, the tissue sheared at the edges of the polymer/tissue
composite, leaving all the untargeted and unimpregnated tissue still attached to the glass
slide. Only the selected cells that were targeted by the laser and captured by the polymer
film transferred with it, while the rest of the tissue remained intact and ready for further
dissection. The LCM process was repeated over and over on the same section until
sufficient cells were collected. The cells on the cap were lysed in Buffer ATL (100 pi)
containing Proteinase K (10 mg/ml) at 55°C overnight. DNA was extracted from
approximately 30-40 cells using the DNeasy Tissue Kit (Qiagen) following the protocol
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described in section 2.2.2. Nested-PCR was performed using primers specific for VZV
63 (VZV63P1 + VZV63P3; VZV63P2 + VZV63P4, Table 2.2).
2.10. Microarray
2.10.1. RNA Preparation
Tissues from 9 DRGs spanning lumbar segment L4, L5 and L6 ipsilateral to the
site of injection were pooled from 3 VZV infected rats. Only animals showing the
highest allodynia response were selected in this study. Animals were also mock-infected
with CV-1 cells to serve as control in the study. Total RNA was extracted with RNeasy
Mini kit (QIAGEN, section 2.4.2). The RNA was eluted with 30 pi RNase-free water,
quantitated by UV spectrophotometer (Cecil) and quality checked with an Agilent 2100
Bioanalyser (Agilent Technologies) according to the manufacturer's instruction. Briefly,
1.0 pi of RNA was heat denatured at 70°C for 2 min and cooled on ice for at least 5 min
in order to minimise secondary structure. Meanwhile, the RNA Agilent chip was
prepared by loading gel and markers as per manufacturer's instructions. Each chip was
loaded with up to twelve 1 pi samples of total RNA. Concentrations were determined by
comparison to RNA ladder (150 ng) and integrity determined with visualisation of 18S
and 28S ribosomal peaks and lack of small, degraded RNA fragments.
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2.10.2. Affymetrix Hybridisation and Staining
GeneChip hybridisation and staining were carried out by Dr. Kevin Robertson at
the Scottish Centre for Genomic Technology and Informatics (GTI) following the
standard Affymetrix protocol. In brief, double-stranded cDNA was synthesised from the
total RNA using the T7-01igo (dT) Promoter Primer Kit. An in vitro transcription (IVT)
reaction was performed to produce biotin-labelled cRNA from the cDNA. The cRNA
was cleaned up and fragmented before hybridisation to the array. Following
hybridisation, the probe array underwent an automated washing and staining protocol on
the fluidics station. The probe array was then scanned with the Affymetrix GeneChip
Scanner controlled by the Affymetrix Microarray Suite software. The software defines
the probe cells and computes intensity for each cell.
2.10.3. Affymetrix Microarray Data Analysis
Pairwise comparative analysis were carried out using the Affymetrix Microarray
Suite 5.1. During the comparison analysis, each probe set on one array (i.e. uninfected)
was compared with its counterpart (i.e. infected) on the other array. A Wilcoxon's
signed rank test was used to generate a p-value (probability that the two probe sets are
different). From this p-value, threshold values have been set which define whether the
level of a transcript has increased or decreased or unchanged.
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2.10.4. Microarray Data Validation with Real-time PCR
Due to time limitation, validation was only performed on prostaglandin D2
synthase (Ptgds) that showed to be the most highly up regulated gene from the
microarray data. Primers Ptgds_for (5'-GGAGAAATTCATCACCTTTAGC-3') and
Ptgds rev (5'-CCACATCACCATGTGTTACCTG-3') were designed to amplify a 136
bp fragment of the Ptgds transcripts. After reverse-transcription, the Ptgds cDNA was
cloned into pGEM-T Easy vector (section 2.2.8) and sequence confirmed to serve as a
positive control in real-time PCR. Total RNA was extracted from infected and control
animals using RNeasy Mini kit (QIAGEN) as detailed in section 2.4.2. RT-PCR,
quantitation and melting curve analysis was performed on a Rotorgene 3000 machine
(Corbett Research). Standard curves for Ptgds and beta actin were established to
quantify the experimental samples. The cycling conditions were as followed: 10 min at
95°C, 20 s at 94°C, 20 s at 57°C and 20 s at 72°C repeated 40 times. Melting curve
analysis was performed wherein the annealing temperature was decreased by 0.5°C
during each step. Each sample was compared to the standard curve in order to determine
the original starting amount of a particular transcript and to a melting curve to ensure the






Little information exists on the molecular mechanisms involved in VZV latency and
reactivation. This has indirectly hampered the knowledge of the mechanisms of post
herpetic neuralgia (PHN) that often follows viral reactivation. Although the latent virus
can be detected in human dorsal root ganglion (DRG), the difficulties encountered in
obtaining ganglia from autopsy explain the slow progression of knowledge (Kennedy
2002). To circumvent this limitation, it is necessary to reproduce experimentally the
events observed during human latency, a difficult endeavour when working with a virus
known to be species-specific and to remain cell-associated in vitro. Many attempts have
been made to induce VZV latency either in vitro by infection of dissociated DRG cells
from human or non-human origin or in vivo, using mice, rats or guinea pigs (Sadzot-
Delvaux and Rentier 2000). Even though none of the animal models described so far is
satisfactory to evaluate all aspects of VZV pathophysiology in humans, many of them
are useful to investigate acute infection, the immune response or latency. Different
models help to answer different questions.
The rat model of VZV latency has been used to study many aspects VZV latency
such as modelling latency establishment (Sadzot-Delvaux et al. 1990), (Sadzot-Delvaux
et al. 1995) and viral gene expression during latency (Kennedy et al., 2001), (Grinfeld et
al. 2004). The adaptation of this rat model and the ability to show striking changes in
behavioural reflex responses represents a useful and unique experimental setting to
investigate the cellular and molecular mechanisms involved in the establishment of PHN
(Fleetwood-Walker et al. 1999), (Dalziel et al. 2004).
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To date, transcripts encoding VZV open reading frames (ORFs) 4, 21, 29, 62, 63, 66
have been detected in human ganglia (Cohrs et al. 2003a), (Kennedy et al. 2000), (Cohrs
et al. 2000). All but one of these viral transcripts i.e. ORF66 have also been detected in
the rat model of VZV latency (Kennedy et al. 2001), (Sadzot-Delvaux et al. 1995).
ORF21 and ORF66 have been shown to be dispensable for the establishment of latency
(Xia et al. 2003), (Sato et al. 2003) while ORF4 and ORF63 are important for latent
infection (Cohen et al. 2005), (Cohen et al. 2004). There have been fewer studies of
VZV gene translation, although expression of VZV gene 63-encoded protein is well
established in both human and rat (Kennedy et al. 2000), (Kennedy et al. 2001). One
report, published by Lungu et al. (1998) described the localisation of proteins encoded
by VZV genes 4, 21, 29, 62 and 63 in the cytoplasm of latently infected neurones in
DRG of human subjects who had died without clinical evidence of herpes zoster. This
observation has been confirmed by a recent report by Grinfeld and Kennedy (2004).
The aim of this work was tried to correlate the altered behavioural changes in the
rats, i.e. showing allodynia, with gene expression in the infected DRG. The approaches
taken to achieve this objective included:
• Analysis of gene expression in infected whole DRG by nested-PCR and real-time
PCR.
• Analysis of purified populations of neurones as an alternative approach to whole
DRG.
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• Utilisation ofmicroarray technology to investigate the global gene expression in
DRG of infected and uninfected rats. Details of this experiment will be discussed
in Chapter 4.
3.2. Results
3.2.1. Development of nested-PCR for VZV Genes 63 and 10
A nested-PCR involving two rounds of amplification reactions was established for
the identification of VZV DNA in the latently infected DRG. The first round of PCR
was performed with a pair of external primers specific to VZV genes 63 and 10
(VZV63P1 + VZV63P3, VZVIOPI + VZV10P3 (Cohrs et al. 1996); Table 2.2).
Subsequently, an aliquot (l ql) of the first round of PCR product was subjected to a
second round of PCR. The second round of PCR was performed with two new primers
(VZV63P2 + VZV63P4, VZV10P2 + VZV10P4 (Cohrs et al. 1996), Table 2.2) that
hybridised to sequences internal to the first round primer-target sequences. In this way,
only specific first round PCR products will be amplified in the second round. Gene 63
was chosen due to its frequent expression during latency in both human and rat
(Kennedy et al. 2001) and it was intended that this PCR would be adopted to analyse
mRNA expression. Likewise, gene 10, which is a late gene would serve as a control for
productive viral gene transcription, as it has not been shown to be expressed in latently
infected cells.
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CHAPTER 3 RESL LTS AND DISCI SSION
In order to confirm that the primer pairs worked, they were first tested with DNA
extracted from VZV infected cells (section 2.2.2). The nested-PCR was performed with
100 ng of the template DNA as described (section 2.7). Figure 3.1 shows a nested-PCR
amplification of genes 63 and 10 in VZV infected cells. Single distinct bands were








12 3 M 4 5 6
VZV10P1+P3 (459 bp)
VZV10P2+P4 (347 bp) VZV63P1+P3 (294 bp)
VZV63P2+P4 (220 bp)
Figure 3.1 Amplification of VZV genes 63 and 10 with nested PCR. Amplified PCR products
were analysed by electrophoresis in an 1.5% (w/v) agarose gel. Lanes 1, nested PCR product of
VZV10P2+VZV10P4; 2, primary amplification with VZV10P1+VZV10P3; 3, negative control
without template; M, 100 bp marker; 4, negative control without template; 5, primary PCR
product of VZV63P1+VZV63P3; 6, nested PCR product of VZV63P2+VZV63P4.
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3.2.2. Sensitivity of nested-PCR
In order to test the sensitivity of the nested PCR assay, a plasmid control was
constructed. The corresponding sequence of the VZV63 region was amplified using
primers VZV63P1 + VZV63P3 (Table 2.2) and ligated into the pGEM-T Easy vector
(Promega), according to the manufacturer's instructions (section 2.2.8). Positive
recombinants were confirmed by restriction enzyme analysis with EcoR 1 (section 2.2.7)
at 37°C with 1 pg of the plasmid in 10 pi reaction mixtures as shown in Figure 3.2A.
PCR was also performed with primers VZV63P1 + VZV63P3 (Figure 3.2B). One of the
positive clones was further confirmed by sequencing and named pGEM-T Easy-63.
The concentration of pGEM-T Easy-63 was determined with a spectrophotometer
(section 2.2.5). Serial 10-fold dilutions of pGEM-T Easy-63 containing 10"' to 10 copies
were prepared. 2 pi of each dilution was used and 100 ng of CV-1 DNA was added into
each 50 pi reaction mixture. Nested-PCR was carried out as described in section 2.7. 1
pi of the primary PCR product was used as a template for the secondary amplification.
Figure 3.3 shows the sensitivity of the nested-PCR assay with VZV63 primers. Primary
PCR could only detect down to 100 copies per 100 ng DNA. however the sensitivity of
detection was improved to below 10 copies per 100 ng DNA after a second round of
PCR. The results from this experiment showed that the detection limit of the VZV63






Figure 3.2 Restriction enzyme analysis and PCR to confirm VZV63 positive clones. (A)
Recombinant plasmids were digested with EcoR\ to confirm the presence of insert (full arrow).
(B) PCR was performed with VZV63P1 + VZV63P3 on the positive clones and gene 63 products
of the right size were detected (dotted arrow).
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Figure 3.3 Sensitivity of the nested PCR assay. A) Primary PCR with serial 10-fold dilutions of
the plasmid containing 109 to 10 copies of gene 63. B) 1 pi of the primary PCR reaction was used
in the secondary PCR. Sensitivity of PCR was 100 copies and below 10 copies per 100 ng DNA
for primary and secondary PCR, respectively.
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3.2.3. Detection of VZV DNA in Whole DRG by nested-PCR
In order to maximise efficient use of animal resources, tissues for the preliminary
PCR analysis were taken from animals tested previously and stored in the tissue bank of
the laboratory. DNA was extracted individually from LI to L6 lumbar DRG from both
ipsilateral and contralateral to the side of injection (section 2.2.1). 100 ng of DNA was
used in the PCR amplification following the conditions used for gene 63 in order to
investigate the presence of VZV DNA in the DRG. No products were seen on the
agarose gel for the DRG samples after the first round of 35 cycles of PCR despite a band
for the positive control (DNA from VZV infected cells). It was speculated that the copy
number of the latent viral genome in the DRG was very low since in VZV infected cells
viral DNA could be detected after one round of PCR. Therefore, a nested PCR would
have to be performed. Indeed. PCR products with the correct size were seen after the
nested-PCR. Figure 3.4 shows an example of a nested-PCR of infected DRGs positive
for VZV DNA.
Due to a limitation in detection, the concentration of the starting DNA template was
increased to 500 ng. With this cut-off concentration, a '+' in the nested-PCR indicated
the presence of VZV DNA and a meant that it is not detected. During the PCR
analyses, contamination of the negative controls (FLO or AHV-1 DNA) occurred
frequently and thus made the results unreliable and had to be repeated. Steps taken to
overcome this contamination problem included preparing the PCR reaction mixtures in a
separate PCR room where no access of any form of DNA was allowed. All the PCR
components including primers were aliquoted into small volumes. QIAGEN HotStarTaq
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DNA polymerase was used to minimise hands-on time and the likelihood of introducing
contaminants into the reaction mixtures when hot start method was performed. Another
advantage of using QIAGEN HotStarTaq DNA polymerase was that the modified
recombinant Tuq polymerase could be added together into the PCR master mix but it
will not be activated at temperature below 95°C, therefore preventing the formation of
mis-primed products and primer-dimers at low temperatures. Separate sets of pipettes
with hydrophobic filtered tips were also used.
Table 3.1 shows the nested-PCR analysis of DRG from infected animals analysed
with the VZV63 primers. Shown are results for ten animals euthanised at different time
points post infection with a mean of 30 days and with different paw withdrawal
thresholds. VZV DNA could be detected in most of the animals especially those with
high to marginal response to allodynia. No virus was found in animals, which had
resolved to the baseline, e.g. 1267 and 1794. Viral DNA could be detected not only on
the ipsilateral but also on the contralateral side to the injection. As there was no control
uninfected tissues available at the time of this experiment being carried out, non-specific
control DNA (A11V-1) and water were used as negative controls in the PCR. Both
negative controls did not show any VZV63 specific amplification in the DRG samples
tested. However, no correlation has been found as to which DRG along the lumbar
segment harbours the viral DNA. The finding of VZV DNA in a particular DRG
segment is probably affected by the individual viral load and the efficiency of viral
spread to the DRG.
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Ipsilateral Contralateral
Figure 3.4 An example of the VZV63 nested-PCR on lumbar DRG tissue from an infected
animal. A nested PCR was performed and products at the right size for VZV63 were detected in
some of the DRGs. Negative controls with H20 and AHV-1 DNA showed no specific VZV63
amplification. DNA from VZV infected cells was positive. L1-L6 = lumbar DRG.
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3.2.4. Southern Blot Confirmation of the Presence of VZV DNA
In order to confirm the results from the nested PCR, an oligonucleotide specific
to gene 63 was synthesised and labelled with DIG-dUTP at the 3' end to be used as a
probe in Southern blot analysis. Figure 3.5 shows that positive results in nested PCR are
confirmed by Southern blot with a band at the correct size for the gene 63 amplified
products. Negative results were confirmed to be true negatives, indicating that Southern
blot was no more sensitive than nested PCR and the results from nested-PCR were
reliable within the detection limit. Beta actin was positive for all the negative samples
tested indicating that the DNA was intact.
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M H?0 LI L2 L3 L4 L5 L6 LI L2 L3 L4 L5 L6 +
Actin
Southern blot
M H,0 - + 1234567 H;0 - M + LI L2 L3 L4 L5 L6 LI L2 L3 L4 L5
Figure 3.5 Southern blot confirmation of nested PCR results. Samples positive for gene 63
in nested PCR (A) was confirmed with corresponding positive bands in Southern blot (B). (C)
Samples negative for gene 63 in nested PCR. (D) Beta actin was detected in all negative
samples. (E) Southern blot confirmed the negative samples in nested PCR were true negatives.
+ = positive control with VZV DNA from infected cells; - = negative controls with AHV-1 DNA; M
= marker.
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3.2.5. Detection of VZV DNA in Microdissected Cells
An alternative approach was attempted to investigate the presence of VZV DNA in
the DRG by looking at a single population of neurones. Laser capture microdissection
(LCM) is a method used to select and isolate cell clusters from tissue sections (Emmert-
Buck et al. 1996), (Suarez-Quian et al. 1999). Once captured, the cell clusters can be
analysed with respect to their DNA. RNA or protein content.
Details of the LCM protocol were described in section 2.9. After dissection, the cap
containing the targeted cells was removed using a transport arm and automatically
placed on to a microcentrifuge tube that contains the extraction buffer. DNA was
extracted from approximately 30 to 40 neurones and analysed by nested PCR with
primers specific for VZV63. However, since no quantitative method was used to
determine the viral load in these microdissected cells, the results shown here was
qualitative and not able to compare with other reports on VZV burden in the ganglion.
Figures 3.6A and B show photos of tissue pre- and post-microdissection, respectively.
Figure 3.6C shows that viral DNA could be detected and beta actin was positive in all
samples tested. The PCR samples were processed in duplicate but due to the sensitivity
of detection, one of the two replicates (L4C and L5I) did not show the same results.
These results proved that LCM could be used to isolate single population of cells in the
DRG in which viral DNA could be retrieved for further study.
Before After
Beta-Actin VZV63
L4I L4.C L5I L5C t
M L4I L4C L5I L5C + r-^—^ rS
Figure 3.6 Single cell lifted by laser capture microdissection (LCM) and PCR analysis. A)
Two single neurons are highlighted (arrows) before LCM; B) the same section after LCM where
the two cells were being lifted; C) PCK analysis ot the UNA extracted from microdissected cells
with VZV63. Approximately 30 microdissected neurones were lifted and lysed in the microfuge




In order to overcome the sensitivity problem in nested-PCR, a quantitative and
more robust assay was developed. Real-time PCR (qRT-PCR) has become one of the
most powerful analytical tools for quantification of defined nucleic acid sequences.
Since only minute amounts of template are required, applications include the evaluation
of gene copy number and mRNA expression and the diagnosis of pathogens and
mutations. The principle of qRT-PCR is that the recurring measurement of a fluorescent
signal is proportional to the amount of amplification product. Several detection systems
are now available and are either based on hybridisation probes such as Taqman probes
(Holland. 1991), Molecular Beacons (Tyagi and Kramer 1996) and Scorpions
(Whitcombe, 1999) or on intercalation by fluorescent dyes, such as the dsDNA binding
dye SYBR Green 1 (Wittwer, 1997). While hybridisation probes offer the advantage of
target sequence specificity, a specific probe is required. Given that the synthesis of
fluorescence-labeled probes is still a major cost factor, the availability of a general
detection method is of great benefit to those studies that aim at the quantification of a
high number of genes.
Optimisation prior to carrying out the qRT-PCR assay with experimental
samples will generate data that reflect on the quality of the assay design and produce
valuable information to indicate where problems may lie. By using the minimum primer
and probe concentration to give the best assay conditions, it is often possible to reduce
the concentration of oligonucleotides included in the assays and so increase the
specificity of the assay as well as saving costs. The template chosen for the optimisation
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process can be derived from any convenient source where there is an excess supply. The
most common sources include: cDNA, synthetic single stranded DNA amplicon,
purified PCR fragment and cloned fragment within a plasmid. For purpose of
optimisation here, the pGEM-T Easy-63 plasmid was used as a template with VZV63P1
+ VZV63P3 primers (Table 2.2). The following parameters were optimised: magnesium
chloride (MgCE), SYBR Green 1. template and primer concentration. Melting curve
analysis was carried out to check for product specificity.
3.2.6.1 MgCI2 Titration
The PCR reaction was carried out in the presence of different MgCE
concentration ranging from 1-5 mM. The optimal MgCE concentration is the one which
has the lowest threshold cycle (Ct), the highest fluorescent intensity and the steepest
curve slope. Ct value is the number of the first cycle at which the measured fluorescent
signal exceeds the threshold limit. Therefore, in the example shown in Figure 3.7A, the
optimum MgCE concentration is 3 mM. The melting curve shows that primer-dimer
only formed in the no template control (in the presence of 5 mM MgCE). At 1-5 mM
MgCE. a specific product was shown by a sharp melting curve (Figure 3.7B)
3.2.6.2 SYBR Green I Concentration
Different dilutions (1: 1000 to 1: 40000) of SYBR Green I (Biogene) was
prepared from the stock solution following the manufacturer's instructions. The SYBR
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Green I dilutions were used to optimise the PCR reaction mixtures in order to get the
best fluorescent intensity and amplification. As shown in Figure 3.8A. only a dilution of
1:1000 gives amplification and a specific product (shown by melting curve, Figure
3.8B).
3.2.6.3 Template Concentration
The template concentration tested was at 100 ng and 10 ng. The Ct for DNA
working template dilutions should be 10-30. Higher dilutions are used if initial Ct < 10
or higher concentrations if initial Ct > 30. A high template concentration can lead to an
early reaction plateau and results that are difficult to interpret. Figure 3.9 shows that
template concentration indeed makes a difference in the Ct value. A higher concentration
leads to earlier Ct and a lower concentration has a delayed Ct.
3.2.6.4 Primer Concentration
A matrix of different concentration of the forward and reverse primers
encompassing the range from 0.05 pM to 0.9 pM was tested. As shown in Figure 3.10
the optimal primer concentration was 0.3 pM for forward and reverse primers given their
lowest Ct and a specific product in the melting curve analysis.
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Figure 3.7 Effect of MgCI2 concentration. (A) Different concentrations of MgCI2 ranging from
1-5 mM were used to optimise the real-time PCR reaction. 3 mM of MgCI2 gives the highest
fluorescence and best amplification. (B) Melting curve showed a specific product and primer
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Figure 3.8 Effect of SYBR Green I. (A) The concentration of SYBR Green I did make a
difference in the fluorescence intensity of the assay. Only dilution at 1: 1000 gave a specific
product as shown in the melting curve analysis (B).
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Figure 3.9 Effect of template concentration. Different concentrations of template did affect
the C, of the assay. Higher concentration (100 ng) resulted in an earlier C, while lower
concentration (10 ng) resulted in a later C,
Figure 3.10 Effect of primer concentration. Concentration of 0.3 pM for both forward and
reverse primers gave the best amplification and specificity of all the other combinations tried in
the primer optimisation matrix set up.
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3.2.7. Construction of a Standard Curve
Having chosen the optimum concentration for the primers, SYBR Green I and
MgCE, it is important to determine the efficiency of the qRT-PCR reaction. A standard
curve is a useful tool for examining the quality of the overall qRT-PCR assay and it
should encompass as large a dynamic range as possible of a 10-fold dilution series over
5 to 7 logs. A miniprep of pGEM-T Easy-63 plasmid was prepared (section 2.3.3). The
plasmid was linearised with Nco\ and its concentration determined (section 2.2.5) in
order to calculate the corresponding copy number using the formula given (section
2.8.2). A standard curve was constructed by preparing ten-fold serial dilutions of
plasmid containing from 1 to 10s copies of VZV63. Uninfected rat dorsal root ganglion
tissue DNA (500 ng) was added to the plasmid standard to compensate for the potential
inhibition of amplication reactions by the added DNA. Each standard was run in
triplicate using the optimised conditions as outlined below. The optimised PCR reaction
mixtures contained H2O (1 1.7 pi), 10 x PCR buffer without Mg (2 pi), Mg (3 mM; 2.4
pi), dNTP mix (10 mM each dNTP; 0.4 pi), forward primer (0.3 pM; 0.4 pi), reverse
primer (0.3 pM; 0.4 pi), FastStart Taq (2 U, 0.2 pi), SyBr Green 1 (1:1000; 0.5 pi) and
template DNA (2 pi) in a 20 pi reaction. Figure 3.1 1 shows an amplification plot with a
o
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large dynamic range of the measurement from 10 to 1 copy of the plasmid and the
specificity of the assay were shown by a sharp melting peak in the melting curve
analysis. The post real time PCR products could be analysed on an agarose gel for the
correct size when there were doubts about the identity of the specific product, but often
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it was unnecessary if the melting curve analysis showed a single melt curve consistently
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Figure 3.11 An example of a standard curve experiment in the Rotorgene 3000 machine.
(A) The dynamic range of the assay was shown in the amplification plot. (B) The melting curve
showed a specific product. (C) The standard curve showed that there was a linear correlation
between the plasmid concentration and the threshold cycle (C,). (D) The post real time PCR
products of serial dilutions of plasmid copy numbers were analysed on an agarose gel showing
products of the right size.
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3.2.8. Quantitation of VZV DNA Viral Load with Real-time PCR
The viral load in the infected DRG could now be quantitated with the established
standard curve constructed for VZV63. DRG samples were run in triplicate and
quantitation was only considered valid if their values were within the linear range of the
standard. Figure 3.12 shows the viral load in 12 DRGs from single animal. The viral
load in the DRG ranged from 42 ± 24 (standard error of the mean) to 795 ± 459 copies
per pg DNA.
The calculations for equivalent number of cells containing VZV genome were as
follow:
The size of a haploid rat genome which contains the number of nucleotide pairs in one
set of 23 chromosomes is ~ 2.75 x 109 bp
Therefore, a diploid genome contains ~ 5.5 x 10Q bp
Ignoring the differences in AT vs GC composition, the average base pair weighs
~ 660 Dalton (660 g /mol)
So, the weight of one mole of diploid genome:
5.5 x 109 bp x 660 bp = 3.63 x 1012 g
And 1 mole = 6.02 x 1023 copies = 3.63 x 1012 g
Therefore, a diploid genome will contain 3.63 x 1012g/6.02 x 1023= 6.0x 10"12g
= 6 pg DNA per cell
Assuming there is 6 pg DNA per cell.
1 pg DNA ~ 1.7 x 103 cell equivalents
Therefore, it was estimated that there were between 42 ± 24 to 795 ± 459 VZV genomes
















200 5 ^ n
L11 L2I L3I L4I L5I L6I L1C L2C L3C L4C L5C L6C
Lumbar dorsal root ganglion
Figure 3.12 An example of viral load in the infected DRGs of an animal. Viral load in the
different lumbar DRG was quantitated by real-time PCR. This animal was euthanized 10 days
post infection and had developed a high degree of allodynia. Each bar represents the mean viral
load ± SEM. L1I-L6I = ipsilateral lumbar DRG; L1C-L6C = contralateral lumbar DRG.
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3.2.9. Detection of Viral Transcripts in Infected Cells
The detection of VZV DNA in the DRG suggests that the virus is present in the
DRG of infected animals. The next step taken to gain a better understanding of the viral
transcription was to study gene expression in the DRG. In order to study the gene
expression in the DRG. reverse-transcriptase PCR (RT-PCR) assay was first optimised
in an in vitro system due to the abundant expression of all classes of viral transcripts.
RNA was extracted from VZV infected cells (section 2.4.3) and reversed transcribed
(section 2.4.4). 2 pi of the reversed transcription reaction was used in PCR. A nested
RT-PCR was performed with 35 cycles for each round of amplification. Transcripts for
gene 63 and 10 were readily detected in the first round of RT-PCR. Beta actin was
positive in all the samples tested. Negative controls with TDO and without reverse











Figure 3.13 RT-PCR assay of VZV infected cells in vitro. 1 pg of the RNA was reverse-
transcribed and 2 pi of the reverse transcription reaction were used to perform RT-PCR. Lane 1,
100 bp marker; 2, negative control (H20) without template; 3, -RT reaction (omitting reverse
transcriptase enzyme); 4, RT-PCR with beta actin primers; 5, positive control for beta actin; 6, -
RT reaction; 7, RT-PCR with VZV63 primers; 8, positive control for VZV63; 9, RT-PCR with
VZV10 primers; 10, positive control for VZV10.
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3.2.10. Detection of Viral Transcripts in Infected DRG
After establishing the RT-PCR assay in the in vitro system, the next step was to
try to use the assay to detect latent viral transcripts in the infected DRG. Figure 3.14
shows that no transcript of VZV63 could be detected in any infected DRG even after a
nested RT-PCR. Southern blot was carried out on these samples and they were proved to
be true negatives. The RT step was working since the beta actin gene was amplified and
there was no specific amplification for -RT reactions. RT-PCR of individual ganglia or
pooling several DRGs did not result in detection of transcripts.
3.2.11. Detection of DNA and RNA Transcripts Simultaneously
in the infected DRG
One way to ensure that the difficulty in detecting the viral transcript was not
caused by the virus not getting to the DRG was to be able to analyse the same samples
for their DNA and RNA content. A different method of isolating DNA and total RNA
from the same sample was used here. The details of this protocol are described in section
2.2.3. This method allows the simultaneous isolation of genomic DNA and total RNA
from animal cells or tissue samples with the QIAGEN RNA/DNA kit. The principle of
the QIAGEN RNA/DNA kit is based on selective purification of RNA and genomic
DNA by anion exchange on QIAGEN resin in a QIAGEN-tip. Figure 3.15 shows that
both DNA and total RNA could be successfully isolated from VZV infected cells. PCR
and RT-PCR were able to amplify specific regions of the VZV62 and VZV63
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sequences. RNA obtained from this isolation method had to be DNase treated with care
to remove all traces of genomic DNA.
When this method was repeated by pooling a group of six DRGs, both DNA and
total RNA were obtained (Figure 3.16). However, when RT-PCR was performed on
these samples, the viral transcripts could not be detected and only bands for beta actin
were seen. VZV62 and VZV63 DNA were amplified in these samples. Therefore, these
results proved that the non-detection of RNA transcripts in the samples was not a matter
of the virus not getting to the DRG but instead it was likely due to a very low expression
below the detection limit of the RT-PCR assay.
3.2.12. RT-PCR Optimisation
Many approaches have been tried to detect the transcripts in the infected DRG by
optimising the RT-PCR assay. A different cDNA priming method using gene specific
primers was tried as it has been reported that this method synthesised the most specific
cDNA and provided the most sensitive method of quantification (Lekanne Deprez et al.
2002). Different RT systems were tried, annealing temperature and MgCf concentration
for the PCR were optimised. None of this worked even the pooling of more DRGs. The
cDNA samples were also analysed by real-time PCR using the optimised VZV63 PCR
conditions. However, there was no specific amplification seen in the melting curve
analysis. Since the viral load has been found to be presence in low copy numbers in the
DRG, it might suggest that the mRNA expression would also be low, resulting in the
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Figure 3.14 Detection of viral transcripts using primers specific for VZV63 VZV63
transcripts were not detected in the infected DRGs but beta actin was positive for all these
samples. Lane 1, 100 bp marker; 2, -RT (omitting reverse transcriptase enzyme); 3, RT-PCR (4
DRGs); 5, RT-PCR (1399); 7, RT-PCR (1398); 9. RT-PCR (4DRGs); 11, 13, RT-PCR (cDNA
from infected cells); 15, positive control (VZV63); 16, positive control (beta actin); 4, 6, 8, 10, 12,
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Figure 3.15 Simultaneous isolation of DNA and total RNA from VZV infected cells. A) PCR
and RT-PCR analyses of DNA and RNA with primers specific for VZV62 and beta actin. B) PCR
and RT-PCR analyses of DNA and RNA with VZV63. Both the VZV62 and VZV63 DNA and
transcripts were detected in the cells. Genomic DNA was removed after DNase treatment. Beta
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Figure 3.16 PCR and RT-PCR analysis of the DNA and total RNA isolated simultaneously
from the infected DRG. DNA and RNA were isolated from infected DRG simultaneously. Only
VZV62 and VZV63 genes were detected but not their transcripts. Beta actin was positive in both
DRG samples analysed. L4I, L5I = infected lumbar DRG L4 and L5 ipsilateral; 1,2 = cDNA from
infected cells; +C = positive control
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3.2.13. Viral Spread in the Rat Model of VZV Latency
In order to investigate how the virus spread in the rat model after VZV injection into
the footpad, an experiment was carried out to analyse the viral load in DRGs and other
tissues at early time points (24 h. 48 h and 72 h) post infection. Two animals were
studied at each time point and tissues analysed were DRG. footpad, sciatic nerve, spinal
cord, brain, spleen and blood.
Table 3.2 shows the presence of VZV63 DNA by nested-PCR at 24 h, 48 h and 72 h.
Viral DNA could be detected as early as 24 h after the infection in both ipsilateral and
contralateral DRG to the side of injection. As expected, viral DNA could be detected at
the ipsilateral footpad, which is the initial route of infection but not on the contralateral
footpad. Both ipsilateral and contralateral sciatic nerves contained viral DNA at all the
time points investigated. In order to check if there was a haematogenous dissemination
of the virus in the rats, blood specimens from these animals were analysed. No viral
DNA was detected in the blood of any of the animals at 24 h to 72 h. There was also no
VZV DNA found in the spinal cord (whole cord analysis) and brain at any of the time
points studied. This result suggests that latency is limited to the peripheral nervous
system as is the case in humans.
Figure 3.17 shows a schematic diagram of viral spread in the rat model. VZV
injected into the left footpad is predicted to travel via axonal transport to the DRG along
the sciatic nerve which is the main nerve innervating the leg. This hypothesis is
supported by the finding of viral DNA in the sciatic nerve. The virus then reaches the
DRG, the site for VZV latency. We have show that the virus does spread to the
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contralateral DRG and in the contralateral sciatic nerve, the mechanism by which this
occurs is not clear. However, the results suggest that the hematogenous route is not
likely.
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Table 3.2 Detection of viral nucleic acids in the DRG at the early time point of infection
(24 h, 48 h, 72 h) in the rat model. Two animals were studied at each time point. '+' denotes
presence of viral gene 63; denotes viral gene 63 not detected. L1I-L6I = lumbar DRG





LI 1 + - +
L2I + - +
L31 + - +
L41 - - +
L51 - + +
L61 - - +
L1C + + +
L2C + - -
L3C - + -
L4C - - -
L5C + + +
L6C - - -
Footpad I + + +
Footpad C - - -
Sciatic I + + +
Sciatic C + + +
Blood - - -
Spinal cord - - -
Brain - - -
Spleen - - -
132
Brain














Figure 3.17 A schematic diagram of the viral spread in the rat model. VZV was injected
subcutaneously into the left footpad of the rat. Viral DNA was found in the footpad (I), sciatic
nerve (I and C) and in the lumbar DRG, L1-L6. Tissues found positive for VZV63 were in red.
VZV63 was not detected in brain, spinal cord, L4C, L6C, spleen and the right footpad. The
central nervous system is coloured in purple.
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3.3. Discussion
In this study, the distribution and viral load of VZV DNA in the latently infected
dorsal root ganglion (DRG) obtained from animals developing allodynia were studied
with nested-PCR and real-time PCR. An alternative approach of isolating single
populations of neurons was also investigated. A viral spread experiment was carried out
to provide a better insight of the viral dissemination in the rat model.
3.3.1. Detection of VZV DNA in Infected Whole DRG
The nested PCR for VZV63 developed in this study has the ability to detect
down to 10 copies of plasmid DNA. When fewer than 10 copies of plasmid DNA was
analysed, the nested-PCR detected the samples infrequently and therefore replicates had
to be included. A similar sensitivity of detection was also reported in a recent study
comparing a TaqMan real-time PCR assays with nested PCR assays to detect HSV-1,
HSV-2 and VZV in clinical samples (Weidmann et al. 2003).
In order to investigate the gene expression in the infected DRG and to correlate it
with the altered behavioural changes in the rats, the first thing was to confirm the
presence of viral gene in the DRG. VZV63 DNA was detected in the ipsilateral DRG of
infected rats with the nested PCR system. Others have reported on the detection of VZV
gene expression in the DRG in a similar rat model (Kennedy et al. 2001), (Grinfeld et
al. 2004) with in situ hybridisation and in situ PCR techniques, respectively. However,
in this study, virus was not only found in the ipsilateral DRG but also in the contralateral
DRG concurrent to a 'contralateral effect' seen in some of the rats following infection of
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only one footpad. This bilateral allodynia was reported by Dalziel et al., (2004). They
proposed that the altered bilateral effects were related to the dose of VZV injected into
the hindpaw and hypothesised that virus spread to the contralateral side was the cause of
the allodynia. Animal studies of neuropathic pain states following unilateral nerve
constriction have also reported bilateral effects (Attal et al. 1990), (Colvin et al. 1996).
The contralateral effect could also be explained by an alternative hypothesis that pain is
not only generated by the injured nerve fibres themselves but also by intact nerve fibres
in the vicinity of injured nerve fibers (Schaible and Richter 2004). It has been shown
that after an experimental lesion is introduced in the L5 DRG, spontaneous action
potential discharges are observed in C-fibres in the uninjured L4 DRG. These fibres
might have been affected by the Wallerian degeneration (Wu et al. 2001). Nevertheless,
the finding of VZV DNA in the contralateral DRG suggested that the presence of virus
indeed has contributed to the 'bilateral effect', however this possibility has to be further
investigated.
3.3.2. Viral Load in the Latently Infected DRG
Even though nested PGR was sensitive to the point whereby viral DNA could be
detected within its detection limit in the DRG, however it was still a qualitative assay. In
order to quantitate the viral load in the DRG, a real-time PGR assay was developed. It
has been shown that in some animal experiments, the latent viral genome levels in the
sensory ganglia influence the reactivation frequency of HSV-1 and HSV-2, suggesting
that the quantity of latent viral genome copies per ganglion (or latent viral load) may be
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a significant determinant of herpesvirus reactivation from the nervous system (Sawtell et
al. 1998), (Sawtell 1998).
Within the sensitivity of the real-time PCR assay, it was estimated that there
were 42 ± 24 to 795 ± 459 copies of VZV genome per lCf cell equivalents. This means
that there are only 0.02% to 0.5% of cells in the rat DRG containing VZV genome. This
low abundance of viral DNA in the DRG could imply a low level of mRNA transcripts
and this could have explained the difficulties in the detection of the viral transcripts in
the DRG. Latently infected rabbits were found to contain on average 16.8 copies of
HSV-1 DNA per 100 cells equivalents (Hill et al. 1996) while latently infected mice
contained on average 50 copies of virus per 100 cell equivalents (Katz et al. 1990). At
the single cell level, the HSV-1 DNA burden was shown to range from 10 to 1000
copies per individual latently infected mouse neuron (Sawtell et al. 1998). The amount
of VZV DNA present in human ganglia was determined to be 557 to 55543 per 105
ganglion cell equivalents (Cohrs et al. 2000). At the single cell level, VZV DNA was
found at a rate of two to five copies per 100 neuronal cells (LaGuardia et al. 1999). A
recent report using LCM and real-time PCR to estimate the copy numbers of HSV-1 gG
and VZV gene 62 from human trigeminal ganglion has reported 6.9 VZV genomes per
positive cell (Wang et al. 2005). The estimated number of latent genomes per ganglion
reported in the literature varies widely, in part depending on the method used to
calculate that number and also different tissues used.
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3.3.3. Detection of VZV DNA in Microdissected Cells
Laser capture microdissection (LCM) technique has proved to be a useful tool to
isolate single cells from a mixed population in the DRG. The ability to detect VZV DNA
in the microdissected cells will allow the study of gene expression in subpopulation of
neurones in which VZV polypeptides are being expressed. It is important to study the
neuronal subtypes as it has been shown that there is differential gene expression within
DRG neurons (Luo et al. 1999). In the DRG, there is small-, medium- and large-sized
neurons. Within the small neurons itself for example, there is heterogeneity in gene
expression, which, presumably reflects, at least in part, the different sensory modalities
transmitted. However, the LCM technique developed in this work could be refined
further by integrating immunocytochemistry with LCM in order to approach the
complicated heterogeneity. For example, cells could be stained for specific VZV
markers so that cluster of cells of interest could be selected and captured. These cells
could then be used for similar studies discussed here or in Chapter 4.
3.3.4. Detection of VZV Transcripts in the Infected DRG
Precise estimates of the number of VZV transcripts in human ganglia do not
exist. That routine RT-PCR assays on unselected total RNA from human ganglia have
not been reported to be positive suggests that the number of viral transcripts in latently
infected tissues is low (Silverstein and Straus 2000). This contrasts with the data
regarding HSV-encoded LATs, which are estimated at 100 or more copies for every
latent viral genome (Ramakrishnan et al. 1994). Thus, the quantity of VZV RNA in
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latently infected human ganglia must be substantially below this level, since HSV LATs
are readily detected by Northern blot hybridisation and RT-PCR assays (Stevens et al.
1987), (Croen et al. 1988).
Since the viral DNA load in the DRG is very low, this suggests that not many
copies ofVZV genome are present in the DRG. Therefore, this may also reflect a limited
mRNA expression, which hampers the detection of these RNA transcripts in the RT-
PCR. Due to the limitation in sensitivity of the RT-PCR assay, a method of simultaneous
isolation of the DNA and RNA from the same sample was adopted. This method has
allowed the study of the DNA and gene expression in the same sample. However, results
shown that RNA transcripts were not detected even in samples where the viral genome
was found to be present. This again has suggested that a low level of RNA transcription
due to the low abundance of VZV DNA in the DRG. The viral transcripts could not also
be quantitated by real-time PCR has indicated that the level of expression of the latent
virus was very low in the infected DRG and it was beyond the sensitivity of detection of
the assay.
Due to the fact that SYBR Green I binds to any double-stranded DNA, the assay
used might not be as specific as the probe based system. A sequence-specific probe was
reported to provide better sensitivity for low copy number detection without the need to
worry about unspecific products or primer dimers (Wittwer et al. 1997). A different
nested real time PCR approach claimed to be able to overcome the limitation in
sensitivity in order to quantitate Hepatitis B virus (HBV) DNA in serum (Brechtbuehl et
al. 2001). The nested assay was sensitive to the level of a single HBV genome in the
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PCR reaction. This approach might be applicable in future in order to quantitate the viral
gene expression in the DRG.
3.3.5. Viral Spread in the Rat Model
This experiment was carried out with the aim of investigating the virus
dissemination in the rat model after VZV infection. The finding of VZV DNA in the
DRGs as early as 24 h post infection had suggested that the virus reaches the DRG
possibly via the sensory nerve terminals present in the richly innervated glabrous skin of
the footpad. The virus was predicted to ascend the neuronal pathway to the DRG, the
site ofVZV latency. However, the mechanism of spread of virus from the ipsilateral side
to the contralateral side was not clear.
The finding of VZV DNA in DRG contralateral to the side of inoculation suggests
that there might be another route apart from axonal transport where the virus travels in
the rat model. The simplest explanation for this finding is that these animals develop
viremia but in this study viremia was not detected in the VZV-infected rats from 24 h to
72 h. A similar finding was reported by Annunziato et al., (1998) where they could not
detect viremia by PCR in the VZV infected rats two weeks after inoculation into the
footpad with cell-free virus, however these rats developed antibody to VZV. Since virus
inoculation is expected to elicit an immune response to viral antigens, they concluded
that virus replication did not occur. They also suggested the likelihood that the blood
samples were not obtained at the appropriate time point to detect VZV viremia in the rat
model since in the guinea pig model, viremia occurs 2-5 days after inoculation (Lowry et
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al. 1993). It may also be that viremia occurred but at a level below the level of detection
of the PCR assay. Another alternative explanation for the finding of VZV infection
contralateral to the inoculation sites is that virus spreads via the cerebrospinal fluid
(CSF). VZV has been found in human CSF in the absence of clinical indications of
encephalitis or meningitis (Annunziato et al. 1998).
No viral DNA was detected in the spleen, brain and spinal cord (taken from the
cervical enlargement region) at all time points studied in this experiment. A similar
finding was reported by Grinfeld et al., (2004), where they found no peripheral tissues
(spleen, liver, lung and kidney) were positive for VZV genes 62 and 63 in VZV infected
rats. This and our finding suggest that VZV infection in the rats mainly restricted to the
peripheral nervous system.
3.4. Conclusion
In agreement with previous findings, rats inoculated subcutaneously with VZV into
the footpad harbour the VZV DNA in their DRG. However, due to only a small fraction
of cells in the DRG harbours latent VZV and due to the low-level expression of the viral
transcripts, they were beyond the level of detection of the RT-PCR and real-time PCR
assays developed. It is not possible to draw any correlation between the altered
behavioural changes with the gene expression in the DRG from the results as there is no
clear pattern observed. VZV DNA was also detected in DRG contralateral to the site of
inoculation but viremia was not able to be demonstrated. The viral spread experiment
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CHAPTER 3 RESU LTS AND DISCUSSION
has confirmed that VZV injected into the footpad of rats primarily used a retrograde






The ability to study thousands of genes simultaneously at one time was impractical
until microarray technology was introduced in the mid 1990s (Brown and Botstein
1999), (Dhiman et al. 2002). Many studies have used microarray analysis to examine the
host response to infection with herpesviruses, including HHV-6 infection of transformed
T cells (Mayne et al. 2001), Epstein-Barr virus (EBV) infection of transformed B cells
(Carter et al. 2002), human cytomegalovirus (HCMV) infection of primary human
fibroblasts (Browne et al. 2001), Kaposi's sarcoma-associated herpesvirus (KSHV)
infection of dermal microvascular endothelial cells (Moses et al. 2002), HSV-1 infection
of mouse trigeminal ganglia (Kramer et al. 2003) and VZV infection in human T cells,
fibroblasts and SClDhu skin xenografts (Jones and Arvin 2003). Viral gene transcription
has also been investigated by microarray analysis in BSC-1 cells infected with VZV
(Cohrs et al. 2003) and viral and cellular gene transcription in fibroblasts infected with
small plaque mutants of VZV (Jones and Arvin 2005). These studies have demonstrated
many commonalities in host cell responses to herpesviruses. For example, interferon
response genes were modulated by all herpesviruses that have been evaluated by
microarray analysis. Herpesvirus infections tend to affect the regulation of other immune
system genes as well, including interleukins and other cytokines. Genes involved in
basic cellular processes such as cell cycle control, transcription and translation also tend
to be altered by herpesvirus infection.
The study presented here was designed to investigate changes in host cell gene
transcription in dorsal root ganglion following VZV-induced allodynia. The hypothesis
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we wished to address was the presence of VZV proteins in latently infected or
reactivating neurons results in an increased sensitivity to noxious stimulus via a change
in the transcriptional activity of the neurone.
Two forms ofmicroarray currently in wide use are the cDNA array format (Pease et
al. 1994) and the oligonucleotide array format (Schena et al. 1995). cDNA arrays are
commonly developed using protocols introduced in the Brown laboratory at Stanford
University (http://cmgm.standford.edu/pbrown/mguide/index.html). cDNA arrays are
made by robotic deposition of DNA spots 50-150 jam in diameter onto a coated glass
surface. These moderate sized DNA arrays typically have around 10,000 spots on an
area of 3.6 cm". This technology allows the comparison of fluorescently labelled cDNA
populations from control and experimental samples in dual colours requiring less than
600 ng of mRNA per sample for a 10,000 spot DNA chip. High-density oligonucleotide
arrays are readily available from a number of commercial supplier included for example
from Affymetrix, Santa Clara, CA (www.affymetrix.com) and Agilent Technologies
(www.chem.agilent.com) (Lipshutz et ai. 1999).
4.1.1. Affymetrix GeneChip Array
The Affymetrix GeneChip technology platform consists of high-density
microarrays and tools to help process and analyse those arrays. The advantages of
Affymetrix GeneChips included high specificity and sensitivity. It is possible to get
rapid results, it has the capability to monitor the expression of a large number of genes in
the genome and it is the most widely used commercial microarray platform. However,
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the disadvantages are that it is significantly more expensive than custom microarrays,
demands stringent quality control and Affymetrix only makes GeneChip arrays for
common experimental animals.
Affymetrix combines oligonucleotide synthesis and photolithography to produce
DNA arrays that contain 65,000-400,000 DNA oligonucleotides on a 1.6 cm2 glass
surface (Ramsay 1998), (Lockhart et al. 1996). In DNA photolithography, ultraviolet
light shines through holes in masks in order to direct parallel and stepwise synthesis of
oligonucleotides. At each step in the synthesis, oligonucleotides are deprotected by light
at the appropriate positions by the mask. The chip is then flooded with activated
nucleotides, which couple to the deprotected positions. Uncoupled residues are then
washed away, another mask is applied and the deprotection steps are carried out with the
next nucleotide. Repetition of the cycle approximately 70 times, with 70 different masks,
allows synthesis of the complete array of thousands of 25-mer oligonucleotides in
parallel.
Once fabricated the gene chip probe arrays are ready for hybridisation. The
nucleic acid to be analysed is isolated, amplified and labelled with a fluorescent reporter
group and incubated with the array. The array is read on a scanner and the patterns of
hybridisation are detected including measure of fluorescence intensity. This approach to
gene expression monitoring is advantages because it allows the user to avoid genes that
are repetitive or homologous to other known genes. Typically 20 pairs of
oligonucleotides are arrayed to represent each gene, which improves the quantification,
specificity and reliability of gene expression data (Lockhart et al. 1996).
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4.1.2. Rat Expression Set 230A
In this study, Affymetrix Rat Expression Set 230A GeneChip arrays were used to
analyse gene expression in mock (non-infected) and VZV infected DRG tissue. This
array contains oligonucleotide probes specific for around 15,866 known rat genes
present in the mouse unigene database. The array also contains probes representing
around 10,400 Expressed Sequenced Tags (ESTs) sequences. ESTs are single pass

















Data analysis and interpretation
I
Validation of results
Figure 4.1 The workflow of the microarray experiment is outlined. Shown here are the




Experiments were undertaken in which DRG were obtained from VZV infected
rats, which showed altered behavioural changes after infection. The experimental
procedure was as described in section 2.6. Control animals were injected with non-
infected CV-1 cells and following testing showed no significant changes in behavioural
response compare to paw withdrawal threshold (PWT) from pre-inoculation testing.
Figure 4.2A shows the VZV-induced altered behavioural changes in the infected and
control rats. A drop in PWT was observed at day 3 for both infected and uninfected
groups. This is commonly observed and may be attributed to an injection trauma at the
site of injection (Fleetwood-Walker et al. 1999). It is notable that the PWT of the
infected animals remained low compared to the control group, which returned almost to
the baseline values at day 7. The experiment was terminated at day 10 when the infected
animals were still sensitive but the control animals were back to the baseline (p<0.05).
Only individual animals that showed allodynia (PWT less than 15 g) were used for
tissue collection on post infection day 10 (Figure 4.2B).
4.2.2. Preparation of Target Sample
The extraction of high quality RNA for labelling and subsequent microarray
hybridisation was essential in this study to ensure the success of reverse transcription
and further verification analysis. Lumbar L4-L6 DRG, ipsilateral and contralateral to the
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site of injection, were dissected from the animals and immersed immediately in
RNAlater (Ambion) to prevent degradation of the RNA in the tissues prior to RNA
extraction. In the microarray experiment only DRG from the ipsilateral side were used. 9
DRGs from the three animals showing the highest allodynia response (average PWT at
0.8 g, 1 g and 1.4 g) were pooled, disrupted and lysed in lysis buffer followed by
homogenisation in a QIAshredder spin column to obtain a clear lysate (section 2.4.2).
Total RNA extraction was carried out with the RNeasy Mini kit (QIAGEN) and the
RNA was eluted with 30 pi of RNase-free water. The elution was repeated with the first
eluate in order to increase the yield of the RNA. For this study, due to the limitation of





























Figure 4.2 In vivo experiment. (A) Graph shows VZV-induced allodynia in animals to be used
in the microarray experiment. Animals were injected in the left hindpaw on day 0 with either 4 x
106 VZV infected CV-1 cells (VZV, n=6) or uninfected CV-1 cells (control, n=6). The mean
withdrawal thresholds in grams for ipsilateral paws were determined and plotted against time
post infection in days for each group and SEM shown. Statistically significant differences
between injected and non-injected hind paws (*P < 0.05, Mann-Whitney U test, n=6). Mock-
infected control animals did not show significant behavioural changes before and after VZV
infection. (B) Individual animals were shown. Tissues from the 3 animals showing the highest
allodynia response (in red box) were pooled for RNA extraction.
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4.2.3. Integrity and Quality of RNA
Messenger RNA (mRNA) typically comprises only 1-3% of total RNA samples
and it is not easily visualised even with the most sensitive of methods. In contrast,
ribosomal RNA, makes up > 80% of total RNA samples, with the majority of that
comprised by the 28S and 18S rRNA species in mamalian systems. Traditionally,
mRNA quality has been assessed by denaturing agarose gel electrophoresis of total RNA
followed by staining with ethidium bromide. This method relies on the assumption that
rRNA quality and quantity reflect that of the underlying mRNA population. If the 28S
and 18S rRNA bands are discrete with no significant smearing and the 28S rRNA band
is approximately twice as intense as the I8S rRNA band, then the mRNA in the sample
is of good quality. The primary drawback to this method is that microgram amounts of
RNA must be sacrificed.
In recent years, successful attempts have been made to improve on this approach
and in this study an Agilent 2100 Bioanalyser and RNA6000 Nano LabChip Kit were
used to measure nanogram quantities of total RNA. The bioanalyser fractionates RNA
molecules according to size and the amounts of I8S and 28S rRNA are automatically
calculated. Theoretically, intact RNA will have a 28S:18S rRNA ratio of 1.7-2.0.
However, in practice, this ratio is rarely obtained with samples extracted from animal
tissue and variation from source to source is observed (Robertson, K., personal
communication).
Figure 4.3 shows an example of the electropherograms of the purified RNA
samples extracted from the mock and infected tissues. The RNA was intact as shown by
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relatively low number of small peaks in the profile and a ratio of 28S:18S of
approximately 1.0 for both samples. In this study, once the RNA samples quality had
been confirmed, samples were labelled and hybridised to the Affymetrix gene chip
following the standard protocols which were carried out by Dr. Kevin Robertson at the
Scottish Centre for Genomic Technology and Informatics.
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Figure 4.3 RNA quality and integrity check with the Agilent 2100 Bioanalyser Panel A and
B show gel-like images and electropherograms of RNA samples from control and VZV infected
animals, respectively. RNA from these samples was of good quality as seen by very few small
peaks and a good 28S:18S ratio.
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4.2.4. Microarray Data Analysis
After hybridisation of the biotin labelled cDNA, arrays were washed and stained
with streptavidin-phycoerythrin as outlined in the Affymetrix expression analysis
technical manual. The arrays were then scanned using the Affymetrix GeneChip scanner
2500 and image analysis and quantitation were undertaken using Affymetrix MAS 5.1
software according to standard Affymetrix protocols. In brief, each transcript on the
array is represented by a set of 13 to 20 probe pairs (depending on the array). A probe
pair consists of a 25-mer "perfect match' (PM) oligonucleotide derived from a 3' region
of the original coding strand of the gene. This is accompanied in an adjacent microarray
feature by a 25-mer "mismatch' (MM) sequence, which has a nucleotide change at
position 13 of the sequence. A "signal" value representing transcript abundance is
derived for each probe set via a process involving: background subtraction, noise
correction and a comparison of the hybridisation signal for the PM and MM probes. The
latter comparison enables the analysis algorithm to account for cross hybridisation and
stray signal, which may affect quantitation of the transcript. During this process, a
detection algorithm calculates a detection p-value and generates a "present", "marginal'
or "absent" (P. M or A) value for each transcript.
Before comparing two arrays, data were normalised to correct for technical
variations between arrays. In this study, all arrays were normalised by scaling the overall
intensity of the arrays to an arbitrary value of 100. This method assumes that the overall
intensity of the arrays is identical and the majority of genes do not change in expression.
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After normalisation, scaling factors for all the arrays were within an acceptable range
(i.e. within 3 fold of each other) (Robertson. K.. personal communication).
4.2.5. Microarray Quality Control
In the Rat Expression Set 230 a set of 'housekeeping' genes (e.g. GAPDH. beta
actin. hexokinase 1) are included on the array. These genes are represented by probe sets
derived from the 3'. middle and 5' regions of the gene. By calculating a 375' signal
ratio, the user is able to assess whether full-length cDNA transcripts have been produced
during the reverse transcription step of the labelling process. Optimal cDNA synthesis
will produce a ratio value of around 1. To assess the sensitivity of the hybridisation,
signal and detection values for Affymetrix spiked transcripts (i.e. bioB. bioC, bioD and
ere) were noted. For all arrays, the spike transcript at lowest concentration (bioB,
concentration 1.5 pM) was detected indicating that the hybridisation, washing, staining
and scanning were optimal.
The performance of the arrays was further assessed prior to data analysis, which
was being carried out with the help of Dr. Kevin Robertson. A scatter plot comparing the
two arrays using the default expression measure provided by Affymetrix Microarray
Suite 5.1 (MAS) was produced using S-PLUS software (Insightful Corporation), which
allows exploratory data analysis and statistical modelling. Result is shown in Figure
4.4A. I he scatter plot confirmed that the data had a symmetrical 'flared' distribution and
showed a dynamic uninterrupted range of expression values from low to high signal
values. The flared distribution occurs as a result of variation increasing as signal levels
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decrease and is entirely typical of data normalised in the manner described above. Most
of the variation between the two groups exists at the lower end of the gene expression
levels. This suggests that the variability is in part due to array sensitivity and
consequently, differences in low intensity genes may be unreliable.
To further investigate the signal distribution across the arrays, a 'box-and-
whiskers' representation of the data was produced in S-PLUS (Figure 4.5). This figure
confirmed that after normalisation the data was symmetrical and the decision was made
to proceed with the data analysis.
4.2.6. Comparison of Uninfected and Infected Samples and
Identification of Differentially Expressed Genes
In this study, control and infected samples were hybridised to two independent
Affymetrix GeneChip Rat Expression Set 230A arrays. In order to detect and quantify
changes in gene expression, a pair-wise comparison was undertaken in MAS 5.1. In this
analysis, one array was designated as the baseline (uninfected) and the other as the
experimental sample of interest (infected).
The Affymetrix MAS comparison algorithm was used to compare the difference
values (PM-MM) for each probe pair on the baseline array with its corresponding probe
pair on the experimental array. This process generates a change p-value which indicates
the probability that there was a difference in transcript expression between the two
samples. The process also produces a change value (up, down or unchanged). A second
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algorithm is used by the software to produce a 'Signal Log Ratio' (SLR) value, which
indicates the magnitude of change. In this system, the log scale used is base 2, which
ensures that the output of the analysis is intuitive. A SLR of 1.0 indicates a 2-fold
increase in transcript expression and a SLR of -1.0 indicates a 2-fold decrease in
expression. A SLR of zero would indicate no change. In this analysis, data were sorted
and filtered using a combination of the output values described above. To increase the
likelihood that genes identified in this analysis were valid, an arbitrary signal threshold
value of 50 was selected.
During the course of this study, an expression measure motivated by a log scale
linear additive model was reported to provide more consistent estimates of fold change
and improvement in detecting differentially expressed genes compared to the MAS
algorithm (Irizarry et al. 2003). This summary statistic is referred to as the log scale
robust multi-array analysis (RMA). In order to validate the methods described above,
this method of analysis was also adopted in the study. As can be seen in Figure 4.4B. the
data seemed to be less variable at low levels of expression. Figure 4.6 shows a diagram
of the comparison of genes obtained from MAS and RMA. Since RMA provides more
consistent estimates of fold change and significantly reduce variation at low level of
expression, only 7 genes were found to be significantly regulated by the two methods
and they were shown in Figure 4.7.
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A
Figure 4.4 Representative scatter plot of overall expression level data from the GeneChip
Rat Expression Set 21 OA experiment with two different normalisation methods. The
control (uninfected) is plotted on the x-axis while the experiment (infected) is plotted on the y-
axis. (A) Note the tight clustering of most data about y=x but a 'flare' distribution is obvious as
the signal intensity decreases when data were analysed with MAS. A cut-off of 50 for the signal
intensity was applied to the dataset in order to increase the stringency of the selection of probe













Figure 4.5 Box and whiskers plots show the distribution of the data before and after
normalisation. Data was symmetrical after normalisation. The median value is represented by
the central line inside the box. Above this line are data in the third quartile and below this line are
data in the first quartile. The upper and lower quartiles are the 75th and 25th percentiles,
respectively.
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Figure 4.6 A comparison of genes found regulated by MAS and RMA analyses. There are
a total of 15866 transcripts represented on the RAE230A GeneChip. Out of this figure, 894 and
881 genes were found to be up and down regulated more than 2 fold by MAS, respectively. Only
8 genes were expressed more than two fold either up or down regulated by RMA. There were 5
genes found to be up regulated and 2 genes down regulated more than 2 fold by both methods.
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4.2.7. Identification of Significantly Regulated Genes
Individual control and infected samples were analysed on an array. Each gene
was given a present (P), absent (A) or marginal (M) call and a value of signal intensity
after an array analysis using the MAS 5.1 software. This study is based on a mixed
population of cells with less than 100% of cells infected, therefore a small fold change in
the expression might represent a large change in the real biological system.
Of the 15866 probe sets represented on the RAE 230A GeneChip. 5295 probe
sets were not detected (33%) on either array (A to A) and were removed from the
analysis. 9556 genes were detected in both samples (P to P), of which 332 had altered
expression with 57 of them showing an increase in expression. Of the 57 increased in
expression, there were 32 with a signal of > 50. which is the cut-off value selected for
filtering and only 5 had a fold change of greater than 2. From the pool of P to P genes,
there were 260 genes decreased in expression and only 2 were significantly down
regulated.
There were 320 genes found to go from absent to present (A to P) after infection
of which only 3 met the cut-off of 50 and were up regulated 2 fold or more. 692 genes
went from present to absent (P to A) after infection and 2 of them met the cut-off of 50
and were down regulated more than 2 fold.
Figure 4.7 shows significantly regulated genes, which have a fold change of
greater than 2 (SLR>1). These genes included prostaglandin D2 synthase (Ptgds), SI00
calcium-binding protein A9 (S100a9), cholinergic receptor (Chrna6), vitronectin (Vtn),
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ID Control Infected *SLR Fold Change Gene Title
1367851..at 362.9 1143.7 1.5 3.151556903 prostaglandin D2 synthase (Ptgds)
1387125..at 19.8 67.7 1.2 3.419191919 S100 calcium-binding protein A9 (S100a9)
1367598 .at 23.3 53.7 1.2 2.30472103 transthyretin (Ttr)
1369845..at 51.3 105.8 1 2.062378168 cholinergic receptor, alpha polypeptide 6 (Chrna6)
ocoCOcoCOCO at 25.8 56.7 1 2.197674419 vitronectin (Vtn)
1371776..at 272.6 54.4 -2.4 -5.011029412 phosphatidylinositol 3-kinase (Pik3r1)
1368247 at 127.9 65.4 -1 -1.955657492 heat shock 70kD protein 1A (Hspala)
* Signal log ratio (SLR) was determined by comparison of the signal intensities for the baseline
(control) and the experimental (infected) array. This is computed using a one-step Tukey's














Figure 4.7 Significantly altered genes which have a fold change of > 2. Significantly
regulated genes (A) which met the filtering criteria of having signal intensity greater than 50 and
SLR >1 are shown in the graph (B).
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4.2.8. Sorting of Data based on Biological Functions
In order to identify biologically novel and interesting differentially expressed
transcripts, genes were assigned into various functional groups. The functional
categories included cell-cell communication and signalling, inflammation and immune,
growth, transcription factors, ion channel, neuropeptide, synapse and genes involved in
tissue maintenance. Table 4.1 shows genes having signal of > 50 categorised into
different functional groups.
Genes that may indirectly regulate the excitability of sensory neurones include
ion transporters, neuropeptides, receptors, signalling molecules and proteins with
synaptic functions. Multiple ion channel genes that may directly contribute to alter
excitabilities of ipsilateral sensory neurons were observed to be regulated in the
ipsilateral DRG. Down regulated ion channels include potassium channel (Kv9.3) and
voltage-gated sodium channel (Sen 11a). There were a number of genes known to be
expressed in neurons. Many of the genes whose expression was altered play a definite
role in neuronal physiology. These included genes encoding neurotransmitter receptors
such as G protein-coupled receptor 56 and cholinergic receptor and proteins involved in
signalling, including neuregulin which is essential for neuronal development by
regulating the composition of neurotransmitter receptor in maturing synapses. Down
regulation of synaptic proteins was also observed e.g. vesicle-associated membrane
protein 2. Several genes involved in cell growth and development were down regulated
such as insulin-like growth factor 2. Viral regulation of these genes may be important for
viral replication and growth. Genes important in transcription are mostly down regulated
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i.e. activating transcription factor 5 and transcription factor 8. Other genes that are
regulated can be broadly categorised as genes that are important for tissue maintenance,
remodelling and plasticity. For example, solute carrier family 7, member 1, which is
involved in amino acid transport activity is down regulated. However, genes involved in
neuroinflammation and immune activation were found to be up regulated e.g.,
prostaglandin D2 synthase and CD74 antigen.
Due to the mixed heterogeneity of the sample, it was also important to look at
those genes with low signal intensity. Genes from 'Present1 to 'Absent' or vice versa
with signal less than 50 in different functional groups are shown in Appendix 4.1 and
4.2. As there were too many from the 'Present1 to 'Present1 list with signal less than 50
and many of them were ESTs, therefore they were not analysed further. There were too
many genes in each list to be discussed within the scope of this study. Even though most
of them have low signal, it is more important to look at the magnitude of changes in
expression before and after infection rather than to focus on the simple fold change. The
low signal in these genes potentially limit the confidence with which one can interpret
the data as true but when factors of heterogeneity of the samples were taken into account
and the fact that not all cells were infected, then the small changes in expression might
be important. These genes might be interesting to look at in the future.
165





























































































































































































































































































































































































4.2.9. Grouping Genes into Related Pathways- Pathway Analysis
It is recognised that genes and gene-products rarely, if ever, function in isolation
within a biological system. Most commonly, they function as components within a
cascade of networks. As a result, it is important to analyse microarray data in the context
of signalling pathways and gene networks which it is hoped will lead to a higher level of
understanding of the system. Ingenuity pathway analysis is an application that utilises
the Ingenuity Pathways Knowledge Base (1PKB) to computationally analyse
experimentally derived genomic or proteomic datasets to identify gene or protein
networks of interest. IPKB is the world's largest curated database of biological networks
created from millions of individually modelled relationships between proteins, genes,
complexes, cells, tissues, drugs, and diseases. It can be used to concurrently analyse
multiple datasets across different experimentation platforms and identify key functions
and pathways that distinguish biological states.
To learn more about the biological function of genes changing in expression in
response to infection, transcripts with a signal of greater than 50 in one or both of the
samples were imported into Ingenuity Pathway Analysis software (Ingenuity Systems,
Mountain View, CA). This filtering step was employed to exclude genes on or below an
arbitrary level of detection in both groups and enable a focussed analysis of genes which
have reliably detected by the array. The Ingenuity Pathway Analysis program uses the
IPKB to relate gene products with each other, based on their interaction and function.
Thus the knowledge base consists of associations extracted from literature, lists of
canonical pathways and functions for individual genes. The Ingenuity Pathway Analysis
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suite identifies dynamically generated biological networks, global canonical pathways
and global functions. Highly regulated biological networks are dynamically identified
using association rules among focus genes in a particular experiment. Each of these
networks are ranked by a score based on negative log of/>value computed using a right-
tailed Fisher's exact test that tests for the proportion of regulated genes in a particular
network over competing networks. The score is the probability that a collection of genes
equal to or greater than the number in a network could be achieved by chance alone. A
score of 3 indicates that there is a 1/1000 chance that the focus genes are in a network
due to random chance. Therefore, scores of 3 or higher have 99.9% confidence level of
not being generated by random chance alone. This score was used as the cut-off for
identifying gene networks.
There were four groups of networks found after the analysis but only one showed
a high possibility that it was true with a score of 14 as illustrated in Figure 4.8. Network
1 has a group of 7 focus genes involving in cancer, cellular movement and reproductive
system disease. Focus genes (shown in bold) are the genes designated as being
differentially expressed in this study and which directly interact with other genes or gene
products in the IPKB. Genes included in this network were insulin-like growth factor 2
(lgf2), vitronectin (Vtn), calcium/calmodulin-dependent protein kinase II alpha subunit
(Camk2a), phosphatidylinositol 3-kinase (Pik3rl), cholinergic receptor (Chrna6), heat
shock 70kD protein (Hspala) and creatine kinase (Ckm). Interactions between the focus
genes and other genes in the network were not clearly related but the focus genes will be
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4.2.10. Validations of Selected Gene by Quantitative Real-Time
RT-PCR
After candidate genes were identified in a microarray experiment, independent
confirmation experiment using real time PCR or other techniques should be performed.
Due to time constraints, only prostaglandin D2 synthase (Ptgds) was validated here using
quantitative real time PCR because of its striking difference in expression after infection
and separate immunohistochemical studies within the group which had also showed that
related proteins in the prostaglandin pathway, Cox-2 and PGE2 were upregulated (Grant,
D. and Dalziel, RG, personal communication). Beta actin was chosen as a housekeeping
gene to correct for sample to sample variations in RT-PCR efficiency and errors in
sample quantitation.
4.2.10.1. Construction of a Ptgds Clone
A cDNA clone containing Ptgds was constructed to be used as positive control in
real-time PCR. Since Ptgds is localised in the central nervous system and male genital
organs of various mammals (Urade and Hayaishi 2000), rat brain was used to extract
RNA with a RNeasy Mini kit. RT-PCR was carried out as outlined in section 2.4.4. The
amplified products were analysed on an agarose gel as shown in Figure 4.9. A clear
distinct band of 136 bp was seen on the gel showing that the primers are specific and
beta actin confirmed the integrity of the template and RT reaction.
After confirming the size was correct, the PCR product was purified and cloned
into pGEM-T Easy vector as described in section 2.2.8. Four white colonies were
172
selected and grown overnight in 5 ml of culture containing ampicillin. Plasmids were
extracted from the cultures and digested with EcoR\ in order to check for positive
recombinants. Figure 4.10 shows all four clones selected containing the insert with the
right size after restriction digest with EcoRl. One of the positive clones was also
sequenced and was used for further experiments.
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Ptgds (136 bp)
Figure 4.9 RT-PCR of Ptgds. Lane 1, 100 bp marker; 2, negative control without reverse
transcriptase; 3, positive control for beta actin; 4, RT-PCR with beta actin primers; 5, 6, 7, RT-
PCR with Ptgds primers.
Figure 4.10 Restriction enzyme analysis to select for positive Ptgds clones. Plasmids
were digested with EcoRI to check if they contained the Ptgds insert. Lane 1, 100 bp marker;
lanes 2, 4, 6, 8, undigested plasmid; lanes 3, 5, 7, 9 digested plasmid.
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4.2.10.2. Construction of Standard Curve
A standard curve for Ptgds was generated by preparing 10-fold serial dilutions of
Ptgds plasmid from 104 to 1 copy (Figure 4.11A). The real-time PCR amplification of
the Ptgds standard was linear over the range from 104 to 1 copy (r2=0.9956).
Optimised PCR reaction mixtures used contained FFO (11.7 pi). 10x PCR buffer
without Mg (2 pi), Mg (3 mM; 2.4 pi), dNTP mix (10 mM each dNTP; 0.4 pi), forward
primer (0.3 pM; 0.4 pi), reverse primer (0.3 pM; 0.4 pi), FastStart Taq (2 U, 0.2 pi),
SYBR Green 1(1:1000; 0.5 pi) and template DNA (2 pi) in a 20 pi reaction. A 40 cycles
programme was used in a real-time PCR machine (Rotorgene 3000) with conditions as
follow: 10 min at 95°C, 20 s at 94°C, 20 s at 57°C and 20 s at 72°C. Melting curve
analysis was performed to ensure the production of a specific product. Figure 4.1 IB
shows a specific product for Ptgds and further verification on an agarose gel shows the
right size (Figure 4.11C).
A relative qRT-PCR quantitation was performed where Ptgds transcripts were
normalised to cellular beta actin transcripts in the same cDNA preparation in control and
infected DRG. Beta actin was shown in the microarray experiment to have a constant
expression in the control and infected DRG. It was suggested that three or more
housekeeping genes should be used for normalisation, as no one housekeeping gene is
the best (Vandesompele et al. 2002). However, due to time limitation, the transcripts
expression was only normalised against beta actin. Replicates of each sample were
included and repeated with different priming methods, i.e. oligo dT and gene specific
primers (GSP). The fold change difference from both methods was comparable.
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indicating a high reproducibility of the results. Although the absolute qRT-PCR values
were not identical to the microarray data due to the intrinsic differences between the two
techniques, the results from qRT-PCR showed the same relative regulation of
transcription and therefore corroborate the microarray data (Figure 4.12). The finding
that prostaglandin D? synthase was upregulated in the infected DRG in microarray was
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Figure 4.11 Real-time PCR assay set up for Prostaglandin D2 synthase (Ptgds). (A)
Standard curve for Ptgds. (B) Melting curve analysis shows a single distinct peak. (C) Post real¬
time PCR analysis of the Ptgds genes to confirm the correct size. Lane 1, 100 bp marker; 2-6,





control (Oligo dT) VZV (Oligo dT) control (GSP) VZV (GSP)
Prostaglandin D2 synthase
Figure 4.12 Validation of prostaglandin D2 synthase (Ptgds) with real time PCR. Fold
change differences of transcripts from two different priming methods (oligo dT and gene specific
primer, GSP). Ptgds is shown to be upreguiated in VZV infected DRG compare to control tissue
corroborating to the result from microarray.
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4.3. Discussion
This work represents a global analysis of the transcriptional responses of host cells
following VZV-induced allodynia in a rat model. Affymetrix Rat Expression Set 230A
oligonucleotide arrays were used to screen for changes in gene expression in DRG
following development of allodynia in the VZV infected and mock-infected rats. The
microarray data reflect changes in gene expression in the entire infected DRG, which is
a heterogeneous tissue, composed of many different types of cells, such as neurons, glia,
and connective tissue cells. It is important to note that since neurons are only -10% of
the ganglion cell population (Stevens 1989) and only a small fraction of cells in the
DRG harbour latent VZV, even large differences in gene expression in individual
infected cells might give rise to very small differences in expression on a whole
ganglion basis.
4.3.1. Changes in Host Gene Expression in Infected DRG
Of the changes observed, more genes were down regulated than up regulated in the
different functional groups. Many genes encoding ion channels and receptors, cell-cell
communication and signalling pathways and proteins related to neurotransmission
showed decreased, rather than increased expression after infection. This may be
indicative of overall suppression of gene expression in injured DRG neurons. However,
genes associated with inflammation and immune markers were shown to be up
regulated.
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The alterations in expression of neuron-specific genes observed in this study could
represent a direct effect of VZV on cellular gene expression in the DRG. Alternatively,
the virus may act indirectly on cellular gene expression e.g., by inducing neuronal injury
which would then alter host gene expression. The expression of several genes with
known roles in neurotransmission and signalling is altered in the infected DRG, some of
this genes including G protein-coupled receptor 56 and potassium voltage-gated channel,
affect neuronal excitability in an interconnected manner (Massengill et al. 1997), (Davis
et al. 2002), (Kramer et al. 2003). This may suggest that presence of VZV in the DRG
could lead to changes in neuronal physiology and could alter sensation consistent with
the altered behavioural changes in the rat model after VZV infection.
A number of ion channels whose expression was altered in the infected DRG were
also identified. These include the down regulation of potassium channel (Kv9.3) and
voltage-gated sodium channel (Scnl la) consistent with findings from other array studies
of neuropathic pain models (Wang et al. 2002), (Valder et al. 2003).
Electrophysiological recordings have previously demonstrated that C-fibers and A fibers
develop abnormal excitability following peripheral nerve injury, a phenomenon which
implicates changes in gene and protein expression of ion channels. Post-injury changes
in the distribution and activity of sodium channels within the DRG and the site of injury
has the ability to regulate a state of hyperexcitability (Cummins et al. 2000).
Comparison of the global lists of regulated genes between this study and other
reports are complicated by the different experimental conditions, biological system and
variable criteria used to identify regulated genes in the different studies. However, there
were similarities in gene regulation identified in this study to other separate array studies
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looking at the effects of peripheral nerve injury on DRG gene expression in different
neuropathic pain models (Wang et al. 2002), (Costigan et al. 2002), (Valder et al. 2003).
Wang et al., (2002) reported on regulation of immediate early genes, ion channels and
signalling molecules that contributed to the excitability of neurones and genes involved
in neuroinflammation in a spinal nerve ligation model of neuropathic pain. A similar
trend of gene regulation was also found in this study. Costigan and workers found
reorganisation of cell structural components, activation of genes expressed by immune
and inflammatory cells and downregulation of genes involved in neurotransmission in a
model of sciatic nerve transection. Similar regulation of injury-responsive genes
identified in injured DRG were reported by Valder et al., (2003) and they also
demonstrated that injury-induced changes occurred not only in neurons but also in non-
neuronal cells.
There are several reports on the global analysis of the transcriptional response of
host cells to VZV infection (Cohrs et al. 2003b), (Jones and Arvin 2003), (Jones and
Arvin 2005), (Kennedy et al. 2005). Studies by Cohrs, et al., (2003b) and Kennedy, et
al., (2005) were investigating the gene expression profile of VZV lytic infection in tissue
culture. Jeremy and Arvin (2003) reported a study on transcriptional changes in cellular
genes after VZV infection of human T cells and fibroblasts in vitro and human skin
xenografts in SCIDhu mice in vivo. They found no significant differences in gene
regulation between pOka (VZV parental Oka strain) and vOka (VZV vaccine strain) in
any of the cell types. However, significant changes in cellular gene regulation were
observed between the three differentiated human cell types, suggesting specific
differences in the biological consequences of VZV infection related to the target cell.
181
The classification of genes that were affected included those involved in immune and
stress responses, cell adhesion, cell structure, signal transduction, cell cycle, apoptosis
and other cell functions. Interferon response was found markedly induced in T cells.
More recently, Jones and Arvin (2005) had investigated on the viral and cellular gene
transcription in fibroblasts infected with VZV small plaque mutants using 42K human
cDNA microarrays. They found that infection of fibroblasts with wild type or small
plaque VZV mutants was associated with down regulation of NF-kB and interferon
responsive genes, down regulation of TGF-P responsive genes accompanied by reduced
amounts of fibrotic or wound healing response genes, activation of cellular proliferation
genes, alteration of neuronal growth markers and cellular genes encoding proteins
important in protein and vesicle trafficking. In the study reported in this thesis, not many
interferon responsive genes were found significantly regulated either because the change
is small or gene expression occurs in a small number of cells, which are below the level
of sensitivity of this assay. Thrombospondin 4, which is a major activator of LTGF-p
(latent form of TGF-p), was found to be down regulated in this study (Table 4.1).
Transforming growth factor-beta (TGF-P) signalling pathway controls multiple cell
processes including fibrotic or wound healing responses and it must be activated from its
latent form (Jones and Arvin 2005). Down regulation of thrombospondin 4 reflected that
the signalling through this pathway might be inhibited. Since TGF-P inhibits cell cycle
progression, blocking this inhibition should enhance viral replication. Limiting the
wound healing response could enhance the spread of the virus by inhibiting the repair of
damaged cells.
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4.3.2. Significantly Regulated Genes and their Functions
The microarray results presented in this present study do not include an
exhaustive list of differentially expressed genes affected by VZV-induced allodynia in
the rat model. This is mainly due to the different biological system used, i.e. most of the
studies reported had been carried out in a tissue culture system where 100% infection
could be assured while this study involved a complex tissue with mixed heterogeneity.
Seven genes were found to be significantly regulated in this study.
Phosphoinositide 3-Kinases (PI3K.s) are proteins coupled to a variety of cell
surface receptors and play a key role in signal transduction cascade regulating
fundamental cellular functions such as transcription, proliferation, and survival (Maurel
and Salzer 2000). PI3Ks also are important in disease processes such as inflammation
and cancer.
Transthyretin, a plasma protein that functions as a transporter of thyroxine and
retinol. mainly synthesised by the liver and choroid plexus of the brain. Altered
transthyretin level in the cerebrospinal fluid has been linked to neuronal dysfunction
such as Alzheimer's disease (Nunes et al. 2005).
SI00 calcium-binding protein A9 or calgranulin B is a small calcium-binding
protein that is highly expressed in neutrophil and monocyte cytosol and is found at high
levels in the extracellular milieu during inflammatory conditions. It has been reported as
a potent inducer of neutrophils and involved in neutrophil migration to inflammatory
sites (Ryckman et al. 2003).
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Heat shock proteins (HSP) are essential for the repair or removal of defective
proteins as a result of various mechanical or chemical stresses, including oxidative free
radicals and toxic metals, and plays major role during normal growth and differentiation
of mammalian cells (Linquist 1986). HSP is also associated with the immune response,
i.e. it helps the endogenous antigen process that guides the antigenic peptides to
immunorecognition (Suto and Srivastava 1995).
Vitronectin, also called serum spreading factor or complement S-protein, is a 75-
kD glycoprotein in plasma and tissue. A multifunctional protein, it promotes attachment
and spreading of animal cells in vitro, inhibits cytolysis by the complement C5b-9
complex, and modulates antithrombin Ill-thrombin action in blood coagulation (Fink et
al. 1992).
Nicotinic acetylcholine receptors are a family of ligand-gated, pentameric ion
channels. The main function of this receptor family is to transmit signals for the
neurotransmitter acetylcholine at neuromuscular junctions and in the central and
peripheral nervous systems (Marubio and Changeux 2000).
Due to time constraint, only prostaglandin D2 synthase was chosen to be
validated and this gene will be discussed in detail in section 4.3.4.
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4.3.3. Validation of Microarray Results
Genes identified by a single microarray experiment as having a more than 2-fold
expression difference cannot be generally accepted as true without a repetition of the
experiment or by validation and genes identified with differences less than 2-fold should
not be eliminated as false positives without repetition or powerful validation (Rajeevan
et al. 2001).
Validation of expression differences is accomplished with alternate methods such
as Northern blot hybridisation or RNase protection assay. However, these assays are
time-consuming, labour intensive and require large amounts ofRNA (>5 pg total RNA).
Conventional RT-PCR can be done with smaller amounts of RNA (20-40 ng) but
quantification is difficult and relies on endpoint analysis of the PCR product. These
limitations can be largely overcome by incorporating high throughput real-time PCR
into the study. qRT-PCR is well suited to validate and confirm microarray results
because it is rapid, fully quantitative and require less than 1000 fold RNA than the
microarray experiment. For verification a relative quantification strategy was applied,
which is based on the expression levels of a target gene versus a reference gene and is
adequate for investigation of physiological changes in gene expression levels.
Housekeeping genes are present in all nucleated cell types since they are necessary for
basic cell survival. Mostly mRNA synthesis of these genes is considered to be stable in
various tissues. Here, prostaglandin D2 synthase (Ptgds) was validated and found to be
upregulated, corroborating to the microarray analysis.
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4.3.4. Prostaglandin D2 Synthase
Prostaglandins (PGs) are the major arachidonic acid metabolite released from
phospholipid membranes by phospholipase A2. Different molecular species are produced
by different synthetases after conversion to prostaglandin H2 by two isoforms of the
cyclooxygenase (Cox) enzyme, namely Cox-1 and Cox-2 (Larsen and Henson 1983),
(Goodwin 1989). The actions of prostaglandin D2, prostaglandin E2, prostaglandin F2a,
prostaglandin I2 and thromboxane A2 are mediated by stimulation of prostanoid DP, EPi_
4, FP, IP and TP receptors, respectively (Coleman et al. 1994). PGD2 is formed from the
product of Cox activity, PGH2, by two distinct PGD synthases, the lipocalin-type
synthase (L-Ptgds) and the glutathione-dependent hematopoietic PGD synthase (H-
Ptgds). Figure 4.13 shows the prostaglandin metabolism pathway and the genes that
have been either found to be regulated in microarray or immunohistochemisty.
PGD2 is the most abundant PG in brain and regulates sleep, temperature and
nociception (Urade and Hayaishi 2000). It signals through two distinct G protein-
coupled receptors, DPI and DP2 that have opposing effects on cyclic AMP (cAMP)
production. Activation of DPI receptor, which is positively coupled to cAMP, resulted
in protection of neurones whereas activation of the DP2 receptor, which is negatively
coupled to cAMP induced toxicity (Sawyer et al. 2002). Recent work has shown that the
DPI receptor of PGD2 mediates neuronal protection in in vitro neuronal cultures (Liang
et al. 2005). The unexpected finding that PGD2 confers neuroprotection is similar in
effect with PGE2 EP2 and EP3 receptors. The dependence on cAMP-mediated signaling
for this neuroprotective effect suggests that other PG receptors that are similarly couple
186
to cAMP may also protect neurones. These data could support an emerging new
hypothesis that prostaglandin may have a neuroprotective role and may present a novel
potential new therapeutic strategies that target specific PG receptors pathway.
Previous work in the lab has shown that Cox-2 and PGE2 was upregulated in the
infected DRG by immunohistochemistry. These observations coupled with the
upregulation of Ptgds in the microarray experiment and real-time PCR, may suggest that
the PG synthesis pathway is activated in the VZV-induced allodynic rats. There is a
likelihood that Ptgds might play a similar neuroprotective role in the neurons, preventing
damage incurred by VZV in the rat model. Cox-2 inhibitor such as Celebrex has been
tested in the rat model and showed to alleviate allodynia (Dalziel, R.G., personal
communication). Further studies will be interesting to look at the involvement of
prostaglandins in modulation of pain and its function in conferring protection.
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Figure 4.13 A schematic diagram of the prostaglandin metabolism pathway. Arachidonic
acid, the most abundant precursor of prostaglandins in mammals, is transformed into PGH2 by
the action of Cox-1 and Cox-2. Further enzymatic conversion of PGH2 by prostacylin synthase,
various isomerases and thromboxane synthase leads to the prostanoids, i.e. the functionally
important prostaglandins and thromboxanes. Red arrow shows genes found upregulated in
microarray and blue arrow shows genes and products upregulated using immunohistochemistry.
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4.3.5. Limitations of Microarray
The great value of microarrays lies in the large number of transcripts that can be
assayed simultaneously. However, microarrays can have several limitations. Microarrays
require more RNA than quantitative real-time PCR (qRT-PCR). Errors in identification
of regulated transcripts (false positive or false negative) depend on the threshold to
identify a transcript as regulated as well as on the complexity of the tissue source.
One of the limitations at the time when the microarray data analysis is carried out is
that our knowledge of the rat genome is limited and the functions of the identified gene
are incomplete. Although the RAE 230A GeneChip contains 15866 probe sets, it has an
abundance of expressed sequence tags (EST). Not all of these probe sets can be
definitively mapped to a physiologic pathway and therefore their assessment in MAS is
limited. Given the rapidity with which genomics is expanding, it is only a matter of time
before more complete data are available. However, this limited knowledge impeded a
true representation of the physiologic pathways changed in the infected neurones.
Another problem with oligonucleotide arrays is sensitivity. Some group of
transcripts that are expressed in the DRG might fall below the microarray detection
threshold. Lack of sensitivity may result from technical issues such as poor probe
performance or low copy number transcripts. Tissue heterogeneity and neuronal
subpopulation restricted gene expression, may lower the concentration of a transcript in
the total RNA sample to below detection threshold (Mimics et al. 2001). Finally, the
cost of the effort involved in microarray assays introduces practical constraints in the
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number of RNA samples that can be analysed, thereby reducing the number of replicate
experiments and the statistical power of the results (Wurmbach et al. 2002).
4.4. Conclusion
The microarray results presented here do not include an exhaustive list of genes
affected by VZV infection, however genes associated with inflammation, immune and
cytokine tended to be up-regulated, whereas genes involved in membrane excitability
(ion channels) or neurotransmission (neurotransmitters and vesicle trafficking genes)
tended to be down-regulated. The facts that infection might not be 100% following VZV
inoculation into the rats and that DRG is a complex tissue represented in a mixed
population of cells has reduced the number of significant genes being detected. As there
are no array replicates in this experiment, all array values should only be considered as
indicative of a real biologically relevant alteration in transcript level unless further
validation has been done. Elucidating the specific role of genes regulated in sensory
neurons after VZV infection will provide insight into many major biological issues
including cell survival, growth, intercellular communication and the factors contribute to
sensory abnormalities as in PHN. Microarray technology provides a powerful tool for
beginning this analysis in a high throughput mode by revealing the extent of change in
neuronal gene expression. In effect, this pilot study has proved that the Affymetrix array







After 15 years of clinical trials, a live attenuated VZV vaccine (Oka-Merck;
VARIVAX) was licensed in the United States in 1995 (Krause and Klinman, 1995).
The live attenuated varicella vaccine, the Oka strain (vOka) was originally a wild-
type VZV isolate referred to as the parent Oka (pOka). POka was isolated from a
child with varicella and passaged 6 times in human foreskin fibroblasts and stored at
-70°C (Takahashi et al. 1974). The varicella vaccine was generated by passaging
pOka 11 times in human embryonic lung cells, 12 times in guinea pig embryo
fibroblasts, once in WI-38 cells and 9 times in MRC-5 cells (Takahashi et al. 1974).
This procedure resulted in attenuation when susceptible children were inoculated
with vOka (Johnson et al. 1997). While most healthy children and adults who are
given the varicella vaccine develop immunity without experiencing any signs of
disease, the virologic basis for this clinical attenuation of vOka however is not
known.
The virulence of vOka in human skin xenografts in SCID mouse skin has been
shown to be diminished as measured by a reduced yield of infectious virus,
decreased viral protein synthesis, failure to invade the dermis and a slower
destruction of epidermal cells compared to pOka (Moffat et al. 1998). This provided
the first evidence of virologic basis of the clinical attenuation of vOka. Sequencing
of the pOka and vOka genomes indicates variations in many of the ORFs, some of
which are predicted to alter viral proteins, precluding a simple genetic explanation
for the attenuation of vOka (Gomi et al. 2001), (Gomi et al. 2002).
In order to investigate the role in PHN of the latently expressed VZV genes in the
DRG, it will be necessary to construct viruses that lack these genes and analyse their
192
I
phenotype in the rat model. Due to the difficulties in obtaining VZV virion DNA for
transfection and in obtaining cell-free virus to plaque purify VZV mutants from wild-
type virus, one way of generate recombinant VZV genomes has been using cosmid
DNA (Cohen and Seidel 1994). The cosmid system based on the Oka strains has
proved useful for studying the role of the viral gene in in vitro experiments. The aims
of this experiment were:
• To investigate if there was any changes in the behavioural response in the rat
model caused by pOka, vOka and VZV Ellen strains. VZV Ellen is a standard
laboratory strain used to infect rats during the course of this work.
• To investigate the possibility of using the Oka strains to generate mutant
viruses using cosmid DNAs. If the Oka viruses cause allodynia in the rats
then mutant viruses could be constructed and tested to see if there is any
effect of the deleted gene(s) in the rat model.
An outline of this experiment is shown in Figure 5.1.
5.1.1. In vivo Experiment
VZV Ellen, pOka and vOka were propagated in CV-1 cells as described in
section 2.5.4. Cells and virus-infected cells were checked for their growth on a
regular basis. Viruses were harvested when cells showed 80% cytopathic effect
(CPE). Each T175 flask of virus-infected cells were harvested and resuspended in
150 pi ofmedium. Six animals were used for each group of virus strain.
Pre-testing and randomisation of animals was as described in section 2.6.4.
Each animal was injected subcutaneously into the left hind paw with 50 pi of the
suspension containing approximately 4 x 106 VZV infected cells or control non-
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infected CV-1 cells. Animals were then tested at days 3, 7 and 10 post infection for
the development of allodynia (section 2.6.4). Lumbar DRGs LI to L6 ipsilateral and
contralateral to the side of injection were obtained for PCR analysis.
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Propagation of viruses in CV-1 cells
▼
Harvest viruses when 80% cytopathic effect
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Figure 5.1 Flow chart showing the experiment carried out to investigate the effect of
different strains of VZV in the rat model. Three groups of six rats were injected with VZV
Ellen, pOka and vOka, respectively. Animals were tested for allodynia at specific days post




5.2.1 Altered Behavioural Response in the Rats
Figure 5.2 shows the comparison of the development of allodynia in rats
following infection with different VZV strains. The graphs show a summary of two
independent experiments, which were carried out as described in section 5.1.1. The
results of these experiments were represented as percentage of positive and negative
responses to allodynia. A positive response is defined as paw withdrawal threshold
(PWT) equal to or less than 15 g and a negative response is defined as PWT of
greater than 15 g. 15 g was chosen as a cut-off point based on previous observations
(Dalziel et al. 2004).
From these experiments, 67% of rats infected with VZV Ellen were found to
develop allodynia at days 3, 7 and 10 post infection. Flowever, in the pOka and vOka
groups, the figure drops to 50% and 17%, respectively. The difference in the
percentage of rats developing allodynia suggests that pOka and vOka do not induce
allodynia as readily as VZV Ellen. This may indicate that there is a decrease in
'pathogenicity' of pOka and vOka in the rat model. The failure of vOka and pOka to
reproducibly produce long term allodynia in the rats may be due to the genetic











Figure 5.2 Graph bars show the overall sensitivity of the animals when infected with
different strains of VZV. Three groups of six rats each were injected with either VZV Ellen,
pOka or vOka. The animals were tested at 3, 7 and 10 days post infection for development
of allodynia. Shown are animals with a positive response (PWT =< 15 g).
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5.2.2 PCR analysis
In order to investigate if the changes in the behavioural responses in the rats
infected with the different strains of VZV were related to the presence of VZV
genome, PCR analysis were carried out on the lumbar DRG of these animals. Only
tissues from one study were analysed here. The design and development of the
nested-PCR assay using VZV63 primers were as described as in section 3.2.1. Table
5.1 shows that VZV DNA could be detected in rats developing allodynia (with a
PWT =< 15 g) after infected with Ellen. No viral DNA was detected in pOka
infected rats, which did not develop allodynia. A single rat in the vOka group
developed allodynia and this animal was positive for the presence of VZV DNA in
the DRG. The results here show that when animals did not develop allodynia, there is
no viral genome being detected in the DRG. Presence ofVZV DNA in vOka infected
rats suggested that the virus was able to reach the DRG.
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Table 5.1 Detection by PCR of VZV DNA in the rat DRG infected with different VZV
strains. PCR analysis was carried out with primers specific for gene 63. PWT = paw
withdrawal threshold; + = positive; - = negative.
Animal Virus strain Ipsilateral PWT (g) VZV Gene 63
932 Ellen 15 +
1781 Ellen 60
1277 Ellen 11.7 +
1740 vOka 60





This study has provided some early information on the ability of the different
strains ofVZV to cause allodynia in the rat model. The results show that the standard
laboratory strain, VZV Ellen is more capable of inducing allodynia in rats than are
pOka and vOka. The Oka viruses were less 'pathogenic' in this model compared to
the VZV Ellen strain and the duration of allodynia in vOka infected rats was less
than in either pOka or Ellen infected rats during the 10 days of the study.
5.3.1 Effects of Different Strains of VZV in the Altered
Behavioural Changes in the Rat Model
Both VZV Oka viruses have been shown in this study to cause the development
of allodynia in the rat model, however, the percentage of vOka rats developing
allodynia were more than two fold less than the number of pOka rats. This might be
due to the genetic variation in the genomes of these viruses rather than their ability to
replicate in vitro since it has been shown that pOka and vOka have similar growth
effects in tissue culture (Moffat et al. 1998), (Zerboni et al. 2005). Comparison of the
complete DNA sequences of vOka and pOka reveals that as many as 15 base
substitutions, representing 8 amino acid differences were found in the gene 62 region
alone (Gomi et al. 2002). An infectious centre assay of a plaque-purified clone (S7-
01) of vOka containing 8 amino acid substitutions in ORF62 showed smaller plaque
formation and less efficient virus spreading activity than did pOka in human
embryonic lung cells (Gomi et al. 2002). Another clone (S-13) with only 5
substitutions in ORF62 spread slightly faster than S7-01 but not as effectively as
pOka. Transient luciferase assays in 293 cells showed that transactivational activities
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of the IE62 products of S7-01 and S7-13 were lower than that of pOka. Based on
these results, it appears that amino acid substitutions in ORF62 are implicated in
virus growth and spread from infected to uninfected cells. The IE62 product of vOka,
which contained all eight amino acid substitutions, had less activity than the parental
IE62 in activating all three kinetic classes of VZV promoters in CV-1 cells (Gomi et
al. 2001). This data might also suggest that the substitutions in 1E62, which is a
major transactivator, play an important role in the differences in the replication and
the attenuation ofVZV.
VZV Ellen had been passaged more than 100 times since its isolation in 1964
(Straus et al. 1981). Prolonged passage in tissue culture cells appear to induce
changes that have a significant impact on VZV virulence for human epidermal and
dermal cells in vivo, since only the low passage clinical isolates like pOka were
shown to be fully virulent in skin implants (Moffat et al. 1998). Both Ellen and vOka
have been found to replicate to lower titres in SCIDhu mice with epithelial implants
(Moffat et al. 1998). In contrast, the results shown in the present study suggested that
VZV Ellen caused allodynia more readily than pOka or vOka in the rats. This might
be caused by the lab adapted strain, VZV Ellen replicate more efficiently in tissue
culture and produce more infectious virus. However, in this experiment, the viral
titres were not determined for each virus before inoculation, therefore further work
has to be done to investigate this possibility.
Recently, the attenuation of vOka in skin xenografts in the SCIDhu mouse model
was investigated by using chimeric pOka and vOka recombinant viruses generated
from cosmid DNAs (Zerboni et al. 2005). These workers have shown that vOka
attenuation is multi-factorial and can be produced by genes from different regions of
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the vOka genome. Others studies using recombinants made from cosmids in the
SCIDhu model have demonstrated that VZV infectivity in skin can be diminished
even by a single amino acid substitution, such as disrupting ORF47 kinase function
in the mutant or altering C-terminal residues in gE (Besser et al. 2003), (Moffat et al.
2004). These findings indicate that VZV attenuation in skin can be achieved by very
restricted alterations in the genome sequence.
The PCR analyses of the DRG infected with the different VZV strains in this
study shows that viral DNA could be detected in the infected DRG in VZV Ellen
infected rats which developed allodynia. Presence of vOka genome in the DRG could
also be detected, indicating that this virus has reached the DRG. However it is
difficult to draw any conclusion here due to the limited availability of rats developing
allodynia in these groups. Therefore, in this study, it is speculated that besides the
genetic variations, the less efficient viral spreading to the DRG might have caused
the Oka strains to be less pathogenic in the development of allodynia compare to
Ellen strain in the rat model.
5.4 Conclusion
VZV Ellen induced allodynia more readily than the Oka vaccine strain or its
parental virus. The reasons for these observations were not clearly understood but the
difference in the pathogenicity of vOka and pOka might be due to the multiple
nucleotide differences between them that are predicted to change amino acid
residues. These changes have been identified that could affect all three putative
kinetic classes of VZV proteins, including immediate early regulatory proteins, early
proteins and the late glycoproteins. The lack of viral spread to the DRG might be
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CHAPTER 5 RESULTS AND DISCUSSION
another possible explanation for these viruses to be less capable of inducing
allodynia in the rats. These experiments shows that the approach of using the Oka
viruses to generate mutant viruses in a cosmid system which, could then be tested on





The mechanism that leads to post-herpetic neuralgia (PHN) is not clearly
understood. Until recently, research has been hampered by the lack of suitable animal
models due to the species-specific nature of the virus. The introduction of a rat model of
VZV persistent infection (Sadzot-Delvaux et al. 1990) with striking changes in
behavioural responses (Fleetwood-Walker et al. 1999) which mimic the human situation
has allowed the use of this model to study the mechanisms underlying PHN. The rat
model is characterised by a limited expression of immediate early and early genes while
late genes remain silent, mimicking the situation seen in human latency in terms of
restricted viral gene expression (Grinfeld et al. 2004).
This study was intended to determine if the changes in the behavioural responses
in the rats correlated with gene expression in the DRG. In agreement with previous
findings, rats inoculated subcutaneously with VZV in the footpad harbour VZV DNA in
their DRG (Sadzot-Delvaux et al. 1995), (Kennedy et al. 2001), (Grinfeld et al. 2004).
However, it is difficult to draw any correlation between findings of viral DNA in
specific DRG with the development of allodynia in the rats since there is no clear pattern
of the distribution of VZV DNA in the lumbar DRG. VZV DNA could be found in the
DRG of most rats developing allodynia. This suggests that the behavioural changes in
the infected rats may be due to the presence of VZV in the DRG but the extent of gene
expression could not be determined due to the low level of viral transcripts. Replicating
virus has not been demonstrated in this model and so the observed allodynia is unlikely
to be associated with ongoing virus replication as would be seen in the acute phase of
herpes zoster (Sadzot-Delvaux et al. 1990), (Sadzot-Delvaux et al. 1995), (Fleetwood-
Walker et al. 1999). This hypothesis is supported by the report that treatment of VZV-
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infected rats with valaciclovir, an antiviral drug, does not block the development of
allodynia (Dalziel et al. 2004), suggesting that continued lytic virus replication is not
required for induction of allodynia by VZV.
When the viral load of the DRG was quantified, there was difference in the viral
burden in each ganglion. This could suggest a variable susceptibility of diverse neuronal
populations to viral infection and difference in the efficiency of viral spread in the DRG.
However, further studies would need to be conducted to address this hypothesis. A study
carried out to quantitate HSV viral load in human cranial nerve ganglia has found no
significant correlation among ganglia from the same individual (Vrabec and Alford
2004). Their results supported the hypothesis that neuronal subpopulations have variable
susceptibility to HSV infection.
Following peripheral nerve injury, it has been reported that phenotypic changes
occur in peptide expression in DRG that may contribute to sensory sensitisation and
chronic pain (Hokfelt et al. 1994), (Cummins et al. 2000), (Woolf and Salter 2000).
Dramatic changes in gene expression of ion channels and signaling molecules that
directly affect the excitability of neurons in the DRG and the spinal cord have been
reported (Wang et al. 2002). Upregulation of neuropeptides such as NPY and galanin in
the DRG of VZV infected rats has also been reported (Garry et al. 2005). Although the
underlying pathophysiological mechanisms may be similar to other forms of neuropathic
pain, it is unclear how latent VZV infection interacts with the nervous system to induce
these changes. The question of whether VZV-induced allodynia affects neuronal gene
expression was addressed by using microarray transcript profiling of host gene
expression in ganglia from latently infected versus mock infected rat DRG.
206
Results from the microarray analyses have shown that many genes encoding ion
channels and receptors, cell-cell communication and signalling pathways and proteins
related to neurotransmission were down regulated after VZV infection, indicating an
overall suppression of gene expression in injured DRG neurons. Genes associated with
inflammation and immune markers were shown to be up regulated. It is expected that the
markers for inflammation are up regulated in the DRG, since DRG axons are the
primary infection site where cells of monocyte origin can be recruited. Among the
significantly regulated genes, prostaglandin D2 synthase was found to be highly up
regulated and this observation was validated by real time PCR. A new hypothesis has
suggested a neuroprotective role of prostaglandins in the central nervous system (Liang
et al. 2005).
The patterns of changes in gene expression reported in this study are in
consistent with the literature. Some genes that have been found to be regulated in the
DRG in neuropathic pain models are not among those reported here because either the
regulation is small or gene expression changes were not detected. Analysis of gene
expression in infected DRG using microarray technology can be complicated greatly by
cellular heterogeneity. Latent VZV genomes reside in the nuclei of neuron cell bodies in
the DRG. However, DRG comprise not only clusters of sensory neurons and their nerve
fibers but also nerve fibers derived from cells located outside the DRG that pass through
or terminate within the ganglion and small glial cells called satellite cells that completely
envelop the neuronal cell bodies (Lazarov 2002). Also contained in DRG are Schwann
cells, endothelial cells of the microvasculature, blood cells and motor neurons. The level
of change of any transcript in the RNA samples from a complex tissue is likely to be
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much lower than that observed in a homogenous tissue. Any particular gene of interest
may only be expressed in a small subset of cells, leading to a signal for that gene on the
array that is difficult to measure reliability. These limitations are referred to as 'dilution
effects' (Wurmbach et al. 2002).
One way to dissect the tissue heterogeneity problem might be to use a simple
biological system, such as a cell line or purified cell populations. Sampling from simple
systems is more likely to represent the expression level for the particular cell i.e.
infected neurons in our study as compare to a complex system where there is a diversity
of cellular substructures and mixed cellularity. Subdissection techniques, such as, laser
capture microdissection of individual cells or tissue substructures are being increasingly
adopted to provide specificity to sampling from complex systems. These approaches
have enormous potential to improve resolution in microarray studies but generally only
limited amount of RNA are obtained from these microdissected samples which are often
too little for conventional labelling strategies.
Recent developments in mRNA amplification techniques are also providing a
solution to this problem (Klur et al. 2004). Reports have shown that neuronal subtypes
could be isolated by combining LCM and gene profiling with cDNA microarray (Luo et
al. 1999) (Wang et al. 2005). It might be a good approach to integrate the technologies
of laser capture microdissection and T7-based RNA amplification with DNA
microarrays. This approach not only could minimise the 'dilution effect' but could
generate information on the viral burden in single VZV infected cells since the ability to
quantify viral load at the level of single cells is essential for understanding many aspects
of latency and reactivation (Sawtell 1997). Individual cell types in the DRG could be
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then studied, as there are differentially expressed genes in the different cell types e.g.,
small versus large neurones or neuronal versus non-neuronal cells. RNA could be
linearly amplified an estimated 106 fold using T7 RNA polymerase which is sufficient
for probe labelling if micorarray experiment is to be carried out.
Some other possible approaches could be implemented to the experimental
design of the microarray study if it would be taken further in the future. Studying the
time dependent changes in transcription after VZV-induced allodynia in the rats might
generate important data since it has been reported that genes show diverse patterns of
regulation in response to nerve injury in neuropathic pain models (Costigan et al. 2002).
If cost permits, replication of the microarray experiment is desirable to obtain the
variation in the gene expression for statistics calculation. It has been suggested that each
microarray experiment should be performed in triplicate to increase data reliability (Lee
et al. 2000).
In order to investigate the functions of latent VZV genes in the development of
allodynia in the rat model, it is necessary to be able to generate mutant viruses that could
be tested in vivo. Although the idea of generating mutant viruses with cosmid DNA
derived from the Oka viruses might not be workable due to their reduced pathogenicity
in the rat model, cloning the VZV genome into a bacterial artificial chromosome (BAC)
might be another alternative to study the function of VZV-encoded genes by
mutagenesis. The genomes of a number of herpesviruses have been cloned into a BAC
(Borst et al. 1999), (Adler et al. 2000), (Zhou et al. 2002). Recently, the complete
genome of VZV pOka strain has been cloned as a BAC and successful reconstitution of
recombinant virus from the full-length VZV BAC genome (Nagaike et al. 2004). This
209
u I > n i i I. 'i • \l r
bacterial genetics method allows the stable maintenance of the viral genome in
Escherichia coli and the introduction of mutations into the genome. This method will
considerably speed up the construction of VZV mutants and allow studies on the
functional role of VZV genes in host-virus interactions. This approach might be adapted
but with cloning of a different VZV strain such as Ellen since this virus was able to
cause the development of allodynia in the rat model.
The work presented in this thesis has provided some insights into the molecular
mechanism that underlie the changes in the behavioural responses in the rat model.
Further work has to be done so that advance in the study of pathogenesis of PHN could
be achieved.
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Appendix 4.1 Present to Absent Gene List in Different Functional Groups
Mock Infected Fold Change Gene Title
Cell adhesion and structure
3.1 2.9 -1.068965517 procollagen, type XI, alpha 1
9.4 4.7 -2 Pleckstrin homology domain containing
10.8 9.4 -1.14893617 protocadherin 3
13 8.8 -1.477272727 Opioid-binding protein/cell adhesion molecule-like
14.5 9.6 -1.510416667 kinesin family member 6
14.5 7.7 -1.883116883 tenascin R
18.1 9.1 -1.989010989 vitamin D receptor
18.9 8.8 -2.147727273 inhibin beta-A
23.7 25 -0.948 inhibin alpha
25.9 21.9 -1.182648402 keratin complex 2, basic, gene 5
27.7 17.2 -1.610465116 slit homolog 1 (Drosophila)
30.4 26.3 -1.155893536 Kinesin light chain 3
40.7 25.2 -1.615079365 procollagen, type II, alpha 1
40.9 55.8 -0.73297491 AE binding protein 1 (predicted)
52.5 42.6 -1.232394366 sushi-repeat-containing protein
Cell cvcle. apoptosis. development
5.8 5.7 -1.01754386 angiotensin II receptor, type 2
7.6 10.4 -0.730769231 Fas-associated factor 1
9.8 9.4 -1.042553191 checkpoint kinase 1 homolog (S. pombe)
10.5 5.3 -1.981132075 Roundabout homolog 1 (Drosophila)
11.3 10.8 -1.046296296 tumor-associated calcium signal transducer 1
11.4 10.7 -1.065420561 Similar to DNA polymerase alpha catalytic subunit
13 9.7 -1.340206186 myosin 5B
14.9 6.7 -2.223880597 B-cell leukemia/lymphoma 2 related protein A1
16.9 15.7 -1.076433121 glypican 2 (cerebroglycan)
19 19.1 -0.994764398 Unc-5 homolog B (C. elegans)
19.4 7 -2.771428571 paraoxonase 1
20.5 15.9 -1.289308176 large (Drosophila) homolog-associated protein 1
24.1 20.5 -1.175609756 Polymerase (DNA-directed), delta 3
25.1 16.8 -1.494047619 polymerase (DNA directed), gamma
27.5 31.2 -0.881410256 G0/G1 switch gene 2 (predicted)
49.8 61.1 -0.815057283 plexin domain containing 2 (predicted)
70 38.3 -1.82767624 calcium/caimodulin-dependent protein kinase II alpha subunit
Siqnal transduction: receptors, kinases, phosphatases. G-proteins
8.3 11.3 -0.734513274 taste receptor, type 2, member 16
8.6 13.3 -0.646616541 wingless-type MMTV integration site 5A
8.6 6.4 -1.34375 angiotensin II type-1 receptor
9 8.5 -1.058823529 protein tyrosine phosphatase, receptor type, Q
9 8.5 -1.058823529 protein tyrosine phosphatase, receptor type, Q
10.2 5.2 -1.961538462 protein phosphatase 1
10.6 17.4 -0.609195402 tensin like C1 domain containing phosphatase
10.9 5 -2.18 thyroid stimulating hormone, beta subunit
11.2 3.3 -3.393939394 membrane-spanning 4-domains, subfamily A
11.5 6.7 -1.71641791 insulin receptor substrate 1
12 12.5 -0.96 Rho guanine nucleotide exchange factor 7
13.8 13.4 -1.029850746 olfactory receptor 1278
14.3 16.7 -0.856287425 growth factor receptor bound protein 7
14.4 12.4 -1.161290323 lectin, galactoside-binding, soluble, 4 (galectin 4)
15.3 10.9 -1.403669725 MAS-related G protein-coupled receptor, member B4
15.6 19.4 -0.804123711 olfactory receptor 1500
15.7 8.4 -1.869047619 membrane-spanning 4-domains
18.5 11.4 -1.622807018 arginine vasopressin receptor 2
19.8 28.5 -0.694736842 thyrotropin releasing hormone receptor
20.6 22.5 -0.915555556 phosphodiesterase 4D
20.6 18.1 -1.138121547 corticotropin releasing hormone receptor 2
23.6 18.4 -1.282608696 apelin, AGTRL1 ligand
26.6 22.2 -1.198198198 protein phosphatase 1
32.9 17.1 -1.923976608 Suppressor of variegation 4-20 homolog 1
37.9 34.6 -1.095375723 gap junction membrane channel protein alpha 4
50 35.9 -1.39275766 Plexin B1 (predicted)
54.1 29.5 -1.833898305 somatostatin receptor 3
65.5 90 -0.727777778 similar to cornichon-like protein (predicted)
74.9 91.9 -0.815016322 preproenkephalin, related sequence
Neural factor
11.5 6.8 -1.691176471 loop tail associated protein (predicted)
21.3 15.7 -1.356687898 synaptonemal complex protein SC65
24.4 15 -1.626666667 solute carrier family 1
61.5 51.5 -1.194174757 huntingtin-associated protein 1
107.5 93 -1.155913978 internexin, alpha
Immune, inflammatory and stress
6.2 1.4 -4.428571429 prostaglandin-endoperoxide synthase 2
12.5 20.5 -0.609756098 interleukin 18
13.5 12.4 -1.088709677 prostaglandin-endoperoxide synthase 1
16.8 15.6 -1.076923077 complement component 3
20.7 28.8 -0.71875 interleukin 2 receptor, beta chain
25.3 33.9 -0.746312684 sequestosome 1
26.5 21.7 -1.221198157 interleukin 2 receptor, gamma
29.4 14.8 -1.986486486 carbonic anhydrase 3
45.6 29 -1.572413793 Lymphocyte antigen 68
Cell cvle
12.4 13.9 -0.892086331 hemogen
12.8 11.6 -1.103448276 epiregulin
15.8 16 -0.9875 cell division cycle 20 homolog (S. cerevisiae)
20.4 5.4 -3.777777778 fibroblast growth factor 7
22.8 33 -0.690909091 myelocytomatosis viral oncogene homolog (avian)
23.6 31.9 -0.739811912 murine thymoma viral (v-akt) oncogene homolog 2
25.9 17.2 -1.505813953 wee 1 homolog (S. pombe) (predicted)
26.4 17.8 -1.483146067 betacellulin
28.2 25.7 -1.097276265 RAD50 homolog (S. cerevisiae)
37.1 32.1 -1.15576324 v-ets erythroblastosis virus E26 oncogene homolog 1
37.5 32.7 -1.146788991 CCA2 protein
40.8 36.2 -1.127071823 brain expressed myelocytomatosis oncogene
Replication, transcription, protein modification, deqradation machinery
7.1 7.3 -0.97260274 AI K-binding cassette, sub-family B (MDR/TAP)
7.6 4.8 -1.583333333 MAD homolog 7 (Drosophila)
9.2 7.4 -1.243243243 epidermal growth factor
9.2 6.6 -1.393939394 paternally expressed 3 (predicted)
9.2 1.3 -7.076923077 similar to KIAA1074 protein (predicted)
9.6 7.5 -1.28 spermatogenesis associated 9 (predicted)
10.9 19.9 -0.547738693 RAR-related orphan receptor alpha (predicted)
11 ' 11 -1 Isoleucine-tRNA synthetase (predicted)
11.1 15.6 -0.711538462 matrix metallopeptidase 3
11.4 13.8 -0.826086957 Double-stranded RNA-binding protein p74
11.9 9.9 -1.202020202 peptidylglycine alpha-amidating monooxygenase
12.1 9.6 -1.260416667 Ubiquitin specific protease 25 (predicted)
13.1 12.3 -1.06504065 Ring finger protein 149 (predicted)
13.2 14.6 -0.904109589 meprin 1 alpha
13.5 17.8 -0.758426966 transcription factor 12
14 9.7 -1.443298969 nuclear receptor subfamily 1, group D, member 2
14.4 21.9 -0.657534247 WD repeat domain 10 (predicted)
14.4 13 -1.107692308 serum amyloid P-component
14.6 16.8 -0.869047619 receptor-interacting serine-threonine kinase 3
14.7 9.2 -1.597826087 Upstream transcription factor 2
15.4 14.8 -1.040540541 DnaJ (Hsp40) homolog, subfamily C
16.5 9.3 -1.774193548 similar to 1500031N24Rik protein (predicted)
16.6 10.5 -1.580952381 thyroid hormone responsive protein
17.4 11.4 -1.526315789 Sp1 transcription factor
17.4 6.1 -2.852459016 Protocadherin 1 (cadherin-like 1) (predicted)
17.9 16.2 -1.104938272 carboxypeptidase X 1 (M14 family) (predicted)
18.9 19.6 -0.964285714 GATA binding protein 4
19.5 8.5 -2.294117647 protein tyrosine phosphatase, non-receptor type 6
19.6 17.2 -1.139534884 ankyrin repeat and SOCS box-containing protein 2
19.6 15.8 -1.240506329 discs, large homolog 4 (Drosophila)
19.8 11.5 -1.72173913 caspase 1
20 10.7 -1.869158879 a disintegrin and metalloprotease domain 2
21.2 24.6 -0.861788618 protein serine kinase H1 (predicted)
21.4 13.7 -1.562043796 Glycogen synthase kinase 3 alpha
21.9 24 -0.9125 mannan-binding lectin serine peptidase 1
22.3 21.4 -1.042056075 amyloid beta (A4) precursor protein-binding
22.6 23.5 -0.961702128 early growth response 3
22.8 22.7 -1.004405286 putative regulation protein GS3
23 16.7 -1.377245509 endothelin 1
23.2 18.7 -1.240641711 upstream binding transcription factor
23.3 21.4 -1.088785047 RNA polymerase 1-2
23.5 27.6 -0.851449275 Rab geranylgeranyl transferase, a subunit
23.5 21.3 -1.103286385 serine/threonine kinase 38 (predicted)
23.7 26 -0.911538462 Ubiquitin-conjugating enzyme E2Q (putative)
24.5 11 -2.227272727 POU domain, class 2, transcription factor 3
25.8 9 -2.866666667 nuclear receptor subfamily 4, group A, member 2
26.2 21.3 -1.230046948 potassium voltage-gated channel
26.8 20.4 -1.31372549 T-box 2 (predicted)
26.8 17.8 -1.505617978 tripartite motif protein 47 (predicted)
29 21.4 -1.355140187 Similar to E430002G05Rik protein (predicted)
29.2 25.1 -1.163346614 signal transducer and activator of transcription 5B
29.5 23.7 -1.244725738 SNF1-like kinase
29.7 40.1 -0.740648379 Copine V (predicted)
30.4 21.6 -1.407407407 peptidyl arginine deiminase, type I
32.8 28 -1.171428571 myeloid/lymphoid or mixed-lineage leukemia
39 38.5 -1.012987013 TAP binding protein
40.3 34.5 -1.168115942 a disintegrin-like and metalloprotease
42.4 33.7 -1.258160237 protein kinase C binding protein 1 (predicted)
43.9 56.8 -0.772887324 signal transducer and activator of transcription 5A
46.6 41.9 -1.112171838 Forkhead box K2 (predicted)
47.7 28.2 -1.691489362 membrane metallo endopeptidase
56.3 36.1 -1.559556787 similar to RIKEN cDNA 1110020A23 (predicted)
56.4 26.8 -2.104477612 ankyrin repeat domain 10 (predicted)
61.1 53.5 -1.142056075 Transcription elongation factor B (Sill)
75.7 73.5 -1.029931973 dual specificity phosphatase 14 (predicted)
80.9 71.1 -1.137834037 tissue specific transplantation antigen P35B
85.3 103.8 -0.82177264 general transcription factor III C 1
Synthesis, transport, biochemical Dathwav
2.8 4.4 -0.636363636 ATPase, Na+/K+ transporting, beta 3 polypeptide
7.1 1.4 -5.071428571 Similar to hypothetical protein CL25084 (predicted)
9.9 5.9 -1.677966102 Solute carrier family 6
11.1 6 -1.85 ATP-binding cassette
11.4 1.4 -8.142857143 solute carrier family 9, member 4
11.7 10.3 -1.13592233 gamma-aminobutyric acid receptor, subunit beta 2
11.9 13.8 -0.862318841 Tetratricopeptide repeat domain 8 (predicted)
12.5 8.5 -1.470588235 gap junction membrane channel protein alpha 1
12.7 8.6 -1.476744186 ataxia, cerebellar, Cayman type (caytaxin)
13.3 6.4 -2.078125 solute carrier family 4
13.5
.
12.8 -1.0546875 Sorting nexin associated golgi protein 1 (predicted)
14 14.2 -0.985915493 solute carrier family 9, member 3
14.4 8.6 -1.674418605 solute carrier family 7
14.7 9 -1.633333333 potassium voltage gated channel
16 13.4 -1.194029851 potassium channel, subfamily K, member 15
16.9 9.6 -1.760416667 ATP-binding cassette
17.5 17.1 -1.023391813 chloride channel 2
17.5 9.4 -1.861702128 sorting nexin associated golgi protein 1 (predicted)
17.8 25.8 -0.689922481 solute carrier family 12
18.4 17.1 -1.076023392 solute carrier family 26 (sulfate transporter)
20.1 9.6 -2.09375 ATP-binding cassette, sub-family C (CFTR/MRP)
20.3 29.1 -0.697594502 ATPase, Ca++ transporting, plasma membrane 2
22.7 13.4 -1.694029851 potassium inwardly-rectifying channel
23.7 18.5 -1.281081081 potassium inwardly-rectifying channel
25.1 12 -2.091666667 glutamate receptor, ionotropic, kainate 2
27.1 22.9 -1.183406114 potassium inwardly-rectifying channel
28.1 21.3 -1.319248826 cadherin 17
30 22.4 -1.339285714 potassium intermediate/small conductance calcium-activated channel
34.2 26.5 -1.290566038 activin A receptor, type 1
34.2 24 -1.425 glutamate receptor, ionotropic, kainate 5
35.4 52.8 -0.670454545 potassium inwardly-rectifying channel
40.1 27 -1.485185185 potassium inwardly-rectifying channel
56.7 46.8 -1.211538462 insulin-like growth factor 2 receptor
58.1 50.3 -1.155069583 potassium voltage gated channel
Miscellaneous
3.5 2 -1.75 glutamate oxaloacetate transaminase 2
6.2 7.4 -0.837837838 dimethylglycine dehydrogenase precursor
7.8 8.1 -0.962962963 Cytochrome P450 IIA1
8.4 9.6 -0.875 leptin receptor
8.5 3.4 -2.5 arylacetamide deacetylase (esterase)
9.2 7.4 -1.243243243 epidermal growth factor
9.3 9.9 -0.939393939 Similar to helicase-like protein NHL isoform 2
9.5 10.6 -0.896226415 FMS-like tyrosine kinase 1
9.8 9 -1.088888889 solute carrier family 2 (facilitated glucose transporter)
10.2 11.7 -0.871794872 Similar to KIAA1161 protein (predicted)
10.4 15.2 -0.684210526 hematopoietically expressed homeobox
10.7 13.9 -0.769784173 similar to RIKEN cDNA 1700073K01 (predicted)
11.5 5.9 -1.949152542 solute carrier family 6 (neurotransmitter transporter)
12.5 9.5 -1.315789474 paired box gene 6
12.6 22.5 -0.56 desmin
12.8 12.3 -1.040650407 troponin T3, skeletal, fast
12.9 4.5 -2.866666667 cytochrome P450, family 2, subfamily c, polypeptide 7
13.5 11.7 -1.153846154 Coagulation factor XIII, A1 subunit
13.6 13 -1.046153846 KH-type splicing regulatory protein
13.8 8.1 -1.703703704 solute carrier family 34 (sodium phosphate)
14.2 9.8 -1.448979592 20 alpha-hydroxysteroid dehydrogenase
14.4 10.6 -1.358490566 triadin
14.5 1.9 -7.631578947 nucleoporin 133 (predicted)
15.9 14.8 -1.074324324 dopa decarboxylase
16 13.2 -1.212121212 cytochrome P450, family 4
16.7 12.9 -1.294573643 regenerating islet-derived 3 alpha
16.8 17.7 -0.949152542 neuraminidase 3
16.8 4.5 -3.733333333 zinc finger, FYVE domain containing 20 (predicted)
17.2 17.7 -0.971751412 thyroglobulin
17.5 23 -0.760869565 tropomodulin 4 (predicted)
18.7 9.1 -2.054945055 phosphoribosyl pyrophosphate synthetase 2
18.8 15.7 -1.197452229 Similar to flavoprotein oxidoreductase MICAL2
19.2 21.5 -0.893023256 exostoses (multiple)-like 3
20.6 32.3 -0.637770898 polycystic kidney disease 1 homolog
21.1 15.6 -1.352564103 fructose-1,6-bisphosphatase 2
21.3 22.9 -0.930131004 ATP-binding cassette, sub-family B (MDR/TAP)
21.7 19.4 -1.118556701 cytosolic acyl-CoA thioesterase 1
22.2 15.3 -1.450980392 Similar to PS1D protein
22.8 7.3 r3.123287671 insulin receptor
24.8 14.3 -1.734265734 kynureninase (L-kynurenine hydrolase)
27.6 28.1 -0.982206406 3-hydroxybutyrate dehydrogenase
27.6 10.9 -2.532110092 phospholipase A2, group X
30.5 16.6 -1.837349398 similar to 2610033H07Rik protein (predicted)
32.1 24.9 -1.289156627 CUG triplet repeat,RNA-binding protein 2
32.2 23.1 -1.393939394 intersectin 1
32.3 33.3 -0.96996997 SH3-domain GRB2-like 1
34.3 24.1 -1.423236515 Synaptonemal complex protein 3
35.1 20.2 -1.737623762 activating transcription factor 3
36.9 23.2 -1.590517241 RNA binding motif protein 7 (predicted)
37.1 40 -0.9275 similar to RIKEN cDNA 0610042E07 (predicted)
37.7 45.5 -0.828571429 spermatogenesis associated 2
37.8 29.6 -1.277027027 N-deacetylase/N-sulfotransferase
38.2 22.1 -1.728506787 B7 homlog 3
38.5 37.5 -1.026666667 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase
39.6 34.4 -1.151162791 Cdc42 guanine nucleotide exchange factor (GEF) 9
40 30.5 -1.31147541 phosphorylase kinase alpha 1
40.2 50.3 -0.799204771 phosphoenolpyruvate carboxykinase 2
42.9 18 -2.383333333 folate receptor 1 (adult)
43.4 35.7 -1.215686275 SECIS binding protein 2
43.8 41.8 -1.04784689 Best5 protein
44.9 30.5 -1.472131148 trimethyllysine hydroxylase, epsilon
45.2 44.5 -1.015730337 protein phosphatase 1
48.3 47.8 -1.010460251 dynein, axonemal, light chain 4 (predicted)
48.4 36.9 -1.311653117 cystathionine beta synthase
50.1 48.7 -1.028747433 low density lipoprotein receptor-related protein 1
58.2 36.9 -1.577235772 creatine kinase, muscle
68 41 -1.658536585 ABO blood group (transferase A)
81.3 62.9 -1.292527822 Lysosomal phospholipase A2
91 51.1 -1.780821918 dentatorubral pallidoluysian atrophy
Appendix 4.2 Absent to Present Gene List in Different Functional Groups
Mock Infect Fold Change Gene Title









nephrosis 1 homolog, nephrin (human)
keratin complex 1, acidic, gene 19
dynein, cytoplasmic, light intermediate chain 1
epithelial V-like antigen (predicted)
opioid-binding protein
LOC498010
scavenger receptor class B, member 1
breast cancer anti-estrogen resistance 1
Signal transduction: receptors, kinases, phosphatases. G-proteins
5.3 13.1 2.471698113 glutamate receptor, metabotropic 8
9.4 15.8 1.680851064 rhodopsin
9.9 12.6 1.272727273 phosphodiesterase 11A
12.6 10.9 0.865079365 gastrin releasing peptide receptor
13.1 15.7 1.198473282 olfactory receptor 857 (predicted)
15.1 20.4 1.350993377 somatostatin receptor 5
15.3 18.4 1.202614379 angiotensin II receptor, type 1 (AT1A)
19.8 22.6 1.141414141 5-hydroxytryptamine (serotonin) receptor 4
21 17 0.80952381 prostaglandin F receptor
21.7 23 1.059907834 inositol 1,4,5-trisphosphate 3-kinase A
22.1 24 1.085972851 smoothened homolog (Drosophila)
33.8 22.4 0.662721893 regulator of G-protein signaling 12
41.2 54.8 1.330097087 protein tyrosine phosphatase
41.8 50.4 1.205741627 guanine nucleotide binding protein
103.8 129.4 1.246628131 phosphatidylinositol 3-kinase














gamma-aminobutyric acid (GABA) receptor
Lactalbumin, alpha
Cell cycle, development, apoptosis. transcription factors
7.7 15.4 2 RAS guanyl releasing protein 2
8.4 21.5 2.55952381 aurora kinase B
10.1 12.3 1.217821782 Bcl2-like 1
13.2 13.9 1.053030303 pro-platelet basic protein
14 13 0.928571429 protein kinase, cGMP-dependent, type II
20.5 28.4 1.385365854 phosphatidylinositol 3-kinase
25.1 30.9 1.231075697 cell division cycle 20 homolog
25.2 34 1 349206349 biregional cell adhesion molecule-related
27.6 37.8 1.369565217 TNFRSFIA-associated via death domain
36.1 51 1.412742382 histone deacetylase 7
37.2 46 1.23655914 Murine thymoma viral (v-akt) oncogene
Replication, transcription, protein modification
5 13.4 2.68 clock homolog (mouse)
5.1 8.6 1.68627451 SMAD, mothers against DPP homolog 5
6.1 17.4 2.852459016 forkhead box E1
6.3 13.8 2.19047619 PHD finger protein 7 (predicted)
7.6 23.7 3.118421053 zinc finger protein 535 (predicted)
8.5 13.3 1.564705882 camello-like 3
8.8 12.9 1.465909091 Similar to Myosin light chain kinase 2
10.5 16.6 1.580952381 Actin related protein 2/3 complex
11.1 12 1.081081081 nuclear receptor subfamily 0, group B
11.9 13 1.092436975 transcription factor 7, T-cell specific
12.5 13.5 1.08 Ribophorin II
12.6 12.1 0.96031746 transient receptor protein 6
12.8 16.7 1.3046875 calcium/calmodulin-dependent protein kinase IV
15.9 26.2 1.647798742 Janus kinase 3
18 25.7 1.427777778 protein phosphatase 1F
18.1 18.8 1.038674033 polymerase (DNA directed), alpha 2
19.8 19.7 0.994949495 cell division cycle 34 homolog
20.8 22.9 1.100961538 protein tyrosine phosphatase
22.5 18.5 0.822222222 Mitogen activated protein kinase 2
27.2 31.7 1.165441176 transcription elongation factor A (Sll)
29.6 26.6 0.898648649 secreted frizzled-related protein 4
30.4 31 1.019736842 ATPase family, AAA domain containing 3A
34.7 46.8 1.34870317 Leucyl-tRNA synthetase, mitochondrial
35.2 51.2 1.454545455 transmembrane 4 superfamily member 7
36 47.6 1.322222222 Fas death domain-associated protein
39.5 53.1 1.344303797 nucleoporin 54
41.6 54.9 1.319711538 heparanase
42.8 34.1 0.796728972 forkhead box D4
49.5 44.9 0.907070707 protein tyrosine phosphatase
49.6 37 0.745967742 TATA element modulatory factor 1
62.8 68.4 1.089171975 myeloid ecotropic viral integration site-related gene 2
68.2 42.3 0.620234604 glucocorticoid modulatory element binding protein 2
68.2 42.3 0.620234604 glucocorticoid modulatory element binding protein 2
Synthesis, transport and biochemical pathways
5.2 10.2 1.961538462 cation channel, sperm associated 2
5.5 13.8 2.509090909 KH-type splicing regulatory protein
5.7 5.9 1.035087719 potassium voltage gated channel
11.3 16.4 1.451327434 hephaestin
12.7 12.3 0.968503937 potassium voltage gated channel
13 20.1 1.546153846 gamma-aminobutyric acid (GABA-A) receptor
13.8 10.4 0.753623188 syntaxin 17
15.6 12.5 0.801282051 glutamate receptor, ionotropic
16.8 17.2 1.023809524 aquaporin 6
19.9 29.4 1.477386935 Solute carrier family 14 (urea transporter)
23.6 36.6 1.550847458 Solute carrier family 6
23.7 34.9 1.47257384 potassium channel, subfamily K
23.8 28 1.176470588 solute carrier family 31 (copper transporters)
33.3 34.3 1.03003003 Solute carrier family 22
33.8 26.1 0.772189349 glutamate receptor, ionotropic, 2
38.8 38.5 0.992268041 ATP-binding cassette







































surfactant, pulmonary-associated protein A1
cytochrome P450, subfamily 2G
phosphorylase kinase gamma 1
enolase 3, beta
Similar to RN49018 (predicted)
FtsJ homolog 2 (E. coli) (predicted)
growth hormone receptor
RAS-related C3 botulinum substrate 2
cytochrome b-245, beta polypeptide
fibromodulin







THO complex 3 (predicted)
fatty acid desaturase 2
RNA, U3 small nucleolar interacting protein 2
carnitine palmitoyltransferase 2
